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To identify novel coding association signals and facilitate characterization of mechanisms 
influencing glycemic traits and type 2 diabetes risk, we analyzed 109,215 variants derived from 
exome array genotyping together with an additional 390,225 variants from exome sequence in up 
to 39,339 normoglycemic individuals from five ancestry groups. We identified a novel 
association between the coding variant (p.Pro50Thr) in AKT2 and fasting insulin, a gene in 
which rare fully penetrant mutations are causal for monogenic glycemic disorders. The low-
frequency allele is associated with a 12% increase in fasting plasma insulin (FI) levels. This 
variant is present at 1.1% frequency in Finns but virtually absent in individuals from other 
ancestries. Carriers of the FI-increasing allele had increased 2-hour insulin values, decreased 
insulin sensitivity, and increased risk of type 2 diabetes (odds ratio=1.05). In cellular studies, the 
AKT2-Thr50 protein exhibited a partial loss of function. We extend the allelic spectrum for 
coding variants in AKT2 associated with disorders of glucose homeostasis and demonstrate 










 The increasing prevalence of type 2 diabetes is a global health crisis, making it critical to 
promote development of more efficient strategies for prevention and treatment. Individuals with 
type 2 diabetes display both pancreatic beta-cell dysfunction and insulin resistance . Genetic 
studies of surrogate measures of these glycemic traits can identify variants that influence these 
central features of type 2 diabetes (2) highlighting potential pathways for therapeutic 
manipulation. Comprehensive surveys of the influence of common genetic variants on fasting 
plasma glucose (FG) and fasting plasma insulin (FI) have highlighted defects in pathways 
involved in glucose metabolism, and insulin processing, secretion, and action (3). Recent studies 
have identified type 2 diabetes-associated alleles that are common in one population but rare or 
absent in others (4-6). These associations were observed either due to an increase in frequency of 
older alleles based on population dynamics and demography (5), or the emergence of population-
specific alleles (4; 6).  
 We set out to identify and characterize low-frequency allele (minor allele frequency 
[MAF]<5%) glycemic trait associations by meta-analysis of exome sequence and exome array 
genotype data in a multi-ancestry sample. We also performed in vitro functional studies of 
protein expression, localization and activity to understand the consequences of our novel 
findings. 
METHODS 
Genetic association studies 
Study Samples 
 The Genetics of Type 2 Diabetes (GoT2D) study and Type 2 Diabetes Genetic 
Exploration by Next-generation sequencing in multi-Ethnic Samples (T2D-GENES) study were 
initially designed to evaluate the contribution of coding variants to type 2 diabetes risk (7). We 






performed a discovery association analysis to find novel coding variants associated with fasting 
glycemic traits in 14 studies from GoT2D that contributed exome array information on 33,231 
non-diabetic individuals of European ancestry. Further discovery analysis was performed with 
GoT2D and T2D-GENES studies with exome sequence data (average 80x coverage) in five 
ancestral groups comprised of 12,940 individuals (6,504 with type 2 diabetes, 6,436 without) 
with measured FG or FI levels available in 2,144 European, 508 South Asian, 1,104 East Asian, 
844 Hispanic, and 508 African American non-diabetic individuals. We performed a replication 
analysis and an assessment of allele frequency distributions in 5,747 individuals from four 
Finnish cohorts: Cardiovascular Risk in Young Finns Study (YFS) (8), Helsinki Birth Cohort 
(HBCS) (9), Health 2000 GenMets Study (GenMets) (10), and National FINRISK Study 1997 
and 2002 (FR) (11). We also assessed the allele frequencies of novel findings in 46,658 
individuals from CHARGE studies with available exome array data (12), although none of the 
studies passed our QC filter of a minor allele count greater than 5 for inclusion in our replication 
analysis. See Supplementary Table 1 for study details, sample characteristics, ascertainment 
criteria, and detailed genotype calling and quality control procedures for each cohort. The 
relevant institutional review boards, conducted according to the Declaration of Helsinki, 
approved all human research and all participants provided written informed consent. A detailed 
description of ethical permissions is provided in the Supplementary Materials. 
Phenotypes 
 For the discovery and replication analysis, we excluded individuals from the analysis if 
they had a diagnosis of type 2 diabetes, were currently receiving oral or injected diabetes 
treatment, had FG measures ≥ 7mmol/L, had 2-hour post-load glucose (2hrG) measures ≥ 
11.1mmol/L, or had HbA1c measures ≥ 6.5% (48mmol/mol). Additional exclusions occurring at 






the study level included pregnancy, non-fasting at time of exam, type 1 diabetes, or impaired 
glucose tolerance. See Supplementary Table 1A for details. Within each study, we adjusted FG 
and log transformed FI levels for age, sex, body mass index (BMI), and additional study specific 
covariates. We applied rank-based inverse-normal transformations to study- or ancestry-specific 
residuals to obtain satisfactory asymptotic properties of the exome-wide association tests. 
 We tested for genetic associations with type 2 diabetes, hypertension, and other related 
quantitative traits in the Finnish discovery and replication cohorts. We analyzed lipid levels (total 
cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol 
(LDL), and triglycerides (TG)), blood pressure (systolic (SBP) and diastolic (DBP) blood 
pressures and hypertension (HTN)), height, BMI, central adiposity measures (waist-to-hip ratio 
(WHR), waist circumference, hip circumference), adiponectin level, 2-hour insulin level, and 
Matsuda index, which is known to correlate with whole-body insulin sensitivity as measured by 
the hyperinsulinemic euglycemic clamp (r=0.7, P<1.0×10
-4
) (13). For quantitative traits and 
HTN, we adjusted for age, sex, BMI (for glycemic, blood pressure, and central adiposity traits), 
stratified by type 2 diabetes status and sex (for central adiposity measures) within study. We 
adjusted LDL and total cholesterol for use of lipid-lowering medication, by dividing total 
cholesterol by 0.8 if on lipid-lowering medication, prior to calculating LDL using the Friedewald 
equation (14). SBP and DBP were adjusted for use of blood pressure-lowering medication by 
adding 15 mmHg to SBP and 10 mmHg to DBP measurements if an individual reported taking 
blood pressure-lowering medication (15). The Matsuda Index was log transformed and analyzed 
in non-diabetic individuals only. After adjusting for covariates, traits were inverse-normalized 
within strata. In addition to studying these metabolic outcomes, we used international 
classification of diseases (ICD) codes to query electronic medical records in the METSIM and 






FINRISK 1997 and 2002 cohorts (in all individuals regardless of type 2 diabetes status) and 
categorized affection status for lipodystrophy, polycystic ovary disease, and ovarian or breast 
cancer. 
Statistical Analysis 
 Discovery Analysis: We performed association analyses within each study for the exome 
array data sets and within ancestry for the exome sequence data sets. We used linear mixed 
models implemented in EMMAX (16) to account for relatedness. Within each study/ancestry, we 
required variants to have a minor allele count (MAC) greater than or equal to five alleles for 
single variant association tests. We meta-analyzed the single variant results from the (European-
ancestry) exome array studies using the inverse variance meta-analysis approach implemented in 
METAL (17) and combined these with the European ancestry exome sequence results. Then, we 
meta-analyzed summary statistics across ancestries. We used P<5×10
-7
 as exome-wide statistical 
significance thresholds for the single variant tests (18). We used the binomial distribution to 
assess enrichment of previously reported associations with FG or FI by calculating a P-value for 
the number of non-significant variants with consistent direction of effects. 
 Gene based association analysis: We performed gene-based association tests using 
variants with MAF <1% (including rare variants with MAC≤5), annotating and aggregating 
variants based on predicted deleteriousness using previously described methods (7). Briefly, we 
defined four different variant groupings: “PTV-only”, containing only variants predicted to 
severely impair protein function,  “PTV+missense”, containing PTV and NS variants with MAF 
<1%, “PTV+NSstrict” composed of PTV and NS variants predicted damaging by five algorithms 
(SIFT, LRT, MutationTaster, polyphen2 HDIV, and polyphen2 HVAR), and “PTV+NSbroad” 
composed of PTV and NS variants with MAF<1% and predicted damaging by at least one 






prediction algorithm above. We used the sequence kernel association test (SKAT) (19) and a 
frequency-weighted burden test to conduct exome array meta-analyses in an unrelated subset of 
individuals using RareMETAL (20). We conducted exome sequence gene-based analyses within 
ancestry using a linear mixed model to account for relatedness and combined results across 
ancestries with MetaSKAT (21), which accounts for heterogeneous effects. We further combined 
gene-based results from exome array and exome sequences using Stouffer’s method with equal 
weights. For gene-based tests, we considered P<2.5×10
-6 
as exome-wide significant, 
corresponding to Bonferroni correction for 20,000 genes in the genome (18). 
 Replication Analysis: The AKT2 p.Pro50Thr variant was observed at sufficient frequency 
in the independent Finnish cohorts to perform single-variant association test of association with 
FI. We tested association in SNPTEST (22) (v.2.4.0) in each study with the same additive linear 
model used in the discovery analysis. Covariate adjustments for FI levels were sex, age, and ten 
principal components (PCs), and models were run with and without adjustment for BMI.  
 Estimate of effect on raw FI level and variance explained: To characterize the association 
between AKT2 p.Pro50Thr and FI, we examined full regression models with raw FI in three 
studies (FUSION, METSIM, and YFS). We estimated the raw effect on log-transformed FI 
levels with a fixed-effects meta-analysis. The variance in log-transformed FI explained by AKT2 
p.Pro50Thr was estimated by a weighted average of the narrow-sense heritability of AKT2 
p.Pro50Thr seen in these three studies. 
 Population genetics and constraint: We used the Exome Aggregation Consortium 
(ExAC) for constraint metrics and allele frequencies (23). We obtained sequence alignments for 
AKT proteins and mRNAs in 100 vertebrates from the UCSC Genome Browser (24), used 






Shannon’s entropy (normalized K=21) as a conservation score (25) and plotted the sequence 
logos in R using the RWebLogo library (26). 
 Associations with other traits: We conducted association tests for traits other than FI and 
FG within studies for both discovery studies as well as the independent Finnish studies used for 
replication. P-values for type 2 diabetes and HTN came from EMMAX (16) or the Wald test 
from logistic regression (Finnish replication data sets) and meta-analyzed using an N weighted 
meta-analysis (17). Odds ratios (OR) were obtained from logistic regression adjusting for age, 
sex, with and without BMI, and PCs and meta-analyzed using an inverse variance meta-analysis. 
Trait distributions and phenotype clustering:  We examined distributions of traits among 
AKT2 missense allele carriers (p.Pro50Thr, p.Arg208Lys, and p.Arg467Trp) in the T2D-GENES 
exome sequencing data set. We used non-parametric rank based methods (kruskal.wallis and 
permKS functions in R) on both the inverse-normalized covariate-adjusted traits used in the 
genetic association studies and normalized raw trait values (scale function in R). We clustered 
AKT2 missense allele carriers on scaled trait values (pheatmap function in R). 
In vitro functional studies 
 Plasmids and cell lines: The generation of the AKT2 allelic series was initiated by the 
production of pDONR223-AKT2 through PCR of the human AKT2 open reading frame with the 
integration of terminal attR sites using primers (see below). HeLa, HuH7, and 293T cells were 
obtained at The Broad Institute and maintained in 10% FBS DMEM, 100U/ml penicillin and 
100µg/ml streptomycin, and documented mycoplasma-free. HeLa and HuH7 cells were starved 
for 18 hours and stimulated for 15 minutes with 100nM insulin for activation analyses. 
Primers for functional work: The generation of the AKT2 allelic series was initiated by the 
production of pDONR223- AKT2 through PCR of the human AKT2 open reading frame with the 






integration of terminal attR sites using primers FWD: 5’ -
GGGGACAAGTTTGTACAAAAAAGTTGGCACCATGAATGAGGTGTCTGTCATC -3’ 
REV: 5’- GGGGACCACTTTGTACAAGAAAGTTGGCAACTCGCGGATGCTG -3’, and 
subsequent Gateway BP reaction into pDONR223 obtained from The Broad Institute Genetics 
Perturbation Platform. Site-directed mutagenesis was then performed to generate AKT2.E17K 
(AKT2.Lys17), AKT2.P50T (AKT2.Thr50), AKT2.R208K (AKT2.Lys208), AKT2.R274H 
(AKT2.His274), AKT2.R467W (AKT2.Trp467) with the following primers: AKT2.E17K: 
FWD: 5'- GGCTCCACAAGCGTGGTAAATACATCAAGACCTGG -3' REV: 5'- 
CCAGGTCTTGATGTATTTACCACGCTTGTGGAGCC -3'; AKT2.P50T: FWD: 5'- 
AGGCCCCTGATCAGACTCTAACCCCCTTAAAC -3' REV: 5'- 
GTTTAAGGGGGTTAGAGTCTGATCAGGGGCCT -3'; AKT2.R208K: FWD: 5'- 
GTCCTCCAGAACACCAAGCACCCGTTCC -3' REV: 5'- 
GGAACGGGTGCTTGGTGTTCTGGAGGAC -3'; AKT2.R274H: FWD: 5'- 
GGGACGTGGTATACCACGACATCAAGCTGGA -3'REV3'REV: 5'- 
TCCAGCTTGATGTCGTGGTATACCACGTCCC -3'; AKT2.R467W: FWD: 5'- 
GGAGCTGGACCAGTGGACCCACTTCCC -3' REV: 5'- 
GGGAAGTGGGTCCACTGGTCCAGCTCC -3'. C-terminal, V5-tagged lentiviral pLX304-
AKT2.E17K, pLX304-AKT2.P50T, pLX304- AKT2.R208K, pLX304-AKT2.R274H, and 
pLX304- AKT2.R467W were each generated by subsequent Gateway LR reactions with 
pDONR223-AKT2.E17K, pDONR223-AKT2.P50T, pDONR223-AKT2.R208K, pDONR223-
AKT2.R274H, and pDONR223-AKT2.R467W, respectively, and pLX304 obtained from The 
Broad Institute Genetics Perturbation Platform. Control plasmid pLX304- empty vector was 
additionally acquired from The Broad Institute Genetics Perturbation Platform. 






 Antibodies: Anti-Akt (#4685), anti-phospho-Akt S473 (#4060), anti-phospho-Akt T308 
(#9275), anti-β Actin (#4970), anti-GSK3β (#9315), anti-phospho-GSK3β (#9336), anti-GST 
(#2625), and anti-V5 (#13202) were purchased from Cell Signaling Technologies (product 
numbers listed for each). Horseradish peroxidase-conjugated anti-rabbit and anti-mouse 
immunoglobulin G (IgG) antibodies were purchased from Millipore. 
 3D modeling: The 3D structure of AKT2 with the full allelic series was predicted using 
IntFOLD (27) and visualized in PyMOL (28). 
 In vitro kinase assays: We isolated V5-AKT2, V5-AKT2.Lys17, V5-AKT2.Thr50, V5-
AKT2.Lys208, V5-AKT2.His274, and V5-AKT2.Trp467 variants from lentivirally infected and 
5µg/mL blasticidin selected HeLa cell lysate with V5 agarose beads (SIGMA) and incubated 
with 150ng GST-GSK3β substrate peptide (Cell Signaling Technologies) and 250mM cold ATP 
in kinase assay buffer (Cell Signaling Technologies) for 35 minutes at 30°C. 
 Proliferation assay: We cultured lentiviral pLX304 V5-AKT2 variants and control empty 
vector infected and 5µg/mL blasticidin selected HuH7 cells in 24 well plate for 72 hours in 10% 
FBS /phenol red-free DMEM for 72 hours. We added WST-1 (Takara Clontech) to each well at 
the manufacture recommended 1:10 ratio and incubated for 4 hours at 37°C prior to absorbance 
measurement at 450nm with BioTek Synergy H4 plate reader. 
 Immunoblots: We washed cells with phosphate buffered saline and lysed in EBC buffer 
(120mM NaCl, 50mM TRIS-HCl (pH7.4), 50nM calyculin, cOmplete protease inhibitor cocktail 
(Roche), 20mM sodium fluoride, 1mM sodium pyrophosphate, 2mM ethylene glycol tetraacetic 
acid, 2mM ethylenediaminetetraacetic acid, and 0.5% NP-40) for 20 minutes on ice. To preclear 
cell lysates, we centrifuged at 12,700 rmp at 4°C for 15 minutes. We measured protein 
concentration with Pierce BCA protein assay kit using a BioTek Synergy H4 plate reader. We 






resolved lysates on BioRad any kD mini-PROTEAN TGX polyacrylamide gels by SDS-PAGE 
and transferred by electrophoresis to nitrocellulose membrane (Life Technologies) at 100V for 
70 minutes. We blocked membranes in 5% nonfat dry milk/ TBST (10mM Tris-HCl, 150mM 
NaCl, 0.2% Tween 20) buffer pH 7.6 for 30 minutes. We incubated blots with indicated antibody 
overnight at 4°C. The membrane was then washed in TBST, three times at 15 minute intervals, 
before 1 hour secondary horseradish peroxidase-conjugated antibody incubation at room 
temperature. We again washed nitrocellulose membranes in TBST, three times for 15 minutes, 
prior to enhanced chemiluminescent substrate detection (Pierce). 
Statistical analysis 
 The quantified results of the in vitro kinase and proliferation assays were normalized to 
internal control values for each replicate. We used generalized linear models of the quantified 
assay results to assess effects of variants within and across replicate rounds, allowing for 
interaction by replicate. The graphical representation was produced using functions in the effects 
(v 3.0-3) package in R. 
Gene Expression Studies 
Study samples 
 GTEx: We compared the expression pattern of AKT2 to the two other members of the 
AKT gene family, AKT1 and AKT3, using multi-tissue RNA sequencing (RNA-seq) data from the 
pilot phase of the GTEx project (dbGaP accession number: phs000424.v3.p1) in 44 tissues with 
data from more than one individual. Detailed procedures for sample collection, RNA extraction, 
RNA-seq, and gene and transcript quantifications have been previously described (29). 
EuroBATs: Samples from photo protected subcutaneous adipose tissue from 766 twins were 
extracted (130 unrelated individuals, 131 monozygotic and 187 dizygotic twin pairs) and 






processed as previously described (30; 31). METSIM: Subcutaneous fat biopsy samples were 
obtained from a sample of 770 participants from the METSIM study and processed as previously 
described (32). 
Phenotypes 
 We studied the association of age, body mass index (BMI) and fasting insulin levels with 
gene expression levels and with expression-associated SNPs (eQTLs) in the AKT2 region. Age 
and sex were available for the GTEx study samples. In additional to age and BMI, fasting insulin 
level was measured at the same time point as the fat biopsies in the EuroBATs sample data, 
following a previously described protocol (33). Baseline age, BMI and fasting insulin levels 
were used for the METSIM study participants (34)  
Statistical analysis 
 The comparison of expression levels of AKT2 versus AKT1, and AKT2 versus AKT3 was 
performed using log2-transformed reads per kilobase per million mapped reads (RPKMs). The 
percent increase in AKT2 expression was calculated with the following formula: 2^log-fold-
change (AKT2 vs AKT1). We studied BMI, age, and fasting insulin (not available in GTEx data) 
associations with AKT2 expression using linear mixed models as implemented in the lme4 
package in R. The gene expression RPKM values were inverse variance rank normalized for 
these analyses. Covariates included study-specific fixed and random effects (see Supplementary 
Note 4 for additional details on each cohort), using sex, BMI and age as additional fixed effects 
as appropriate. The expression quantitative trait loci (eQTL) analysis was performed on single 
nucleotide polymorphisms (SNPs) within a 1 Mb of AKT2 using linear mixed models to assess 
the association of the SNPs with the inverse normalized RPKM expression values. 
RESULTS 






Genetic association studies 
 We tested the association of FI and FG with 390,225 variants from exome sequence data  
(GoT2D and T2D-GENES studies) and 109,215 variants derived from exome array genotyping 
(GoT2D studies) (7) (individual study λGC<1.06; Supplementary Figure S1). We examined 
variants that had been previously associated with FG and FI (3; 18). Of 28 FG and 14 FI loci 
with the reported SNPs or close proxies in our data set, 13 FG and four FI showed directionally 
consistent significant associations. Among the remaining GWAS loci not significant in our data, 
we observed directionally consistent associations in 14/15 FG and 9/10 FI loci (Penrichment =5×10
-4 
for FG and 0.01 for FI) (Supplementary Note 1; Supplementary Table 2). 
 In addition, we identified a novel significant single variant association between 
rs184042322 and FI (MAF=1.2%, P=1.2×10
-7
), a coding variant in AKT2 (V-AKT Murine 
Thymoma Viral Oncogene Homolog 2) where amino acid Pro50 is substituted with a threonine 
(NP_001617.1:p.Pro50Thr) (Figure 1; Supplementary Figure S1). The same allele drove a 
significant FI signal for AKT2 in gene-based analysis (P=6.1×10
-7
), in which we discovered two 
additional significant gene-based associations between GIMAP8 and FG (PPTV=2.3×10
-6
), and 
between NDUFAF1 and FI (PPTV+NSBroad=9.2×10
-7
) (Supplementary Figure S2; Supplementary 
Table 2D). 
 In an effort to replicate the single variant association of AKT2 Pro50Thr with FI, we 
aggregated the allele frequency estimates of AKT2 Pro50Thr in our data with data from the 
CHARGE consortium and the four Finnish studies. In ExAC, rs184042322 is multi-allelic 
(p.Pro50Thr and p.Pro50Ala) but Pro50Ala is observed only twice in the Latino population 
sample and not seen in our exome sequencing data, which includes 1,021 individuals of Hispanic 
ancestry. AKT2 Pro50Thr was observed at a much higher frequency in Finnish individuals 






(MAF=1.1%) than other European (MAF=0.2%), African American (MAF=0.01%), Asian 
(MAF<0.01%), or Hispanic (MAF<0.01%) individuals (Figure 1). We replicated the association 
between FI and AKT2 Pro50Thr by meta-analysis of the association in the four Finnish studies 
(P=5.4×10
-4
, N=5,747) with the discovery studies (Pcombined=9.98×10
-10
, N=25,316). We 
observed no evidence of effect-size heterogeneity between studies (PHeterogeneity=0.76). The minor 
T allele was associated with a 12% (95% CI=7%-18%) increase in FI levels in the discovery and 
replication studies, a per allele effect of 10.4pmol/L (95% CI=6.6-14.3pmol/L).  
 The serine/threonine protein kinases AKT1, AKT2, and AKT3 are conserved across all 
vertebrates (Figure 2). Pro50 and the seven preceding residues in the pleckstrin homology (PH) 
domain appear to be specific for the AKT2 isoform. Population genetic studies show a strong 
intolerance to missense and loss of function variation in AKT2 (Supplementary Note 2; 
Supplementary Figure S3; Supplementary Figure S4; Supplementary Table 3). Notably, in ExAC 
data, AKT2 contains fewer missense variants than expected (the missense constraint metric, 
Z=3.5, is in the 94
th
 percentile of all genes) and extreme constraint against loss-of-function (LoF) 
variation (estimated probability of being LoF intolerant (pLI)=1). 
 AKT2 is a primary transducer of phosphoinositide 3-kinase (PI3K) signaling downstream 
of the insulin receptor and is responsible for mediating the physiological effects of insulin in 
tissues including liver, skeletal muscle, and adipose. Akt2 null mice are characterized by 
hyperglycemia and hyperinsulinemia, and some develop diabetes (35; 36). In humans, highly 
penetrant rare alleles in AKT2 cause familial partial lipodystrophy and hypoinsulinemic 
hypoglycemia with hemihypertrophy (Glu17Lys) (37; 38) and a syndrome featuring severe 
insulin resistance, hyperinsulinemia, and diabetes mellitus (Arg274His) (39). Additional rare 






alleles have been observed in individuals with severe insulin resistance (Arg208Lys and 
Arg467Trp) but no variant has been associated with glycemic traits at the population level (40).  
 Given the spectrum of diseases and traits associated with AKT2 (41), we hypothesized 
that AKT2 Pro50Thr would be associated with features of metabolic syndrome or lipodystrophy. 
In quantitative trait analysis in the initial discovery and replication cohorts, we did observe a 
constellation of features indicative of a milder ‘lipodystrophy-like phenotype’ associated with 
the rare allele: associations with increased 2-hour insulin values (effect=0.2 SD of log-
transformed 2-hour insulin, 95% CI=0.1-0.4; P=7.9×10
-8
, N=14,150), lower insulin sensitivity 
(effect=-0.3 SD of the log-transformed Matsuda index, 95% CI=-0.5 to -0.2, P=1.2×10
-6
, 
N=8,566), and increased risk of type 2 diabetes (odds ratio (OR)=1.05 95% CI=1.0-1.1, 
P=8.1×10
-5 
; 9,783 type 2 diabetes cases; 22,662 controls), with no effects on fasting glucose, 
postprandial glucose, or fasting lipid levels (P≥0.01; Supplementary Table 4). In the T2D-
GENES exome sequencing data where FG and FI levels were available in diabetic individuals, 
we observed one individual who was homozygous for the P50T allele with FI and FG levels in 
the 99.8th and 98.8th percentiles, respectively. There was a significant difference in trait 
distributions by P50T genotype (FI P=0.002; FG P=0.02; Supplementary Figure S5; 
Supplementary Table 4). Next, we used electronic health records available in the Finnish 
METSIM and FINRISK cohorts to characterize the impact of AKT2 Pro50Thr on disease risk. 
We found no evidence for association with any cancer, polycystic ovary disease, or acanthosis 
nigricans (Supplementary Table 5); however, these tests are underpowered due to the low 
number of cases and potential for misclassification. Nor did we find evidence for enrichment of 
low-frequency associations in any AKT2 related pathways or genes implicated in monogenic 






forms of glycemic disease (Supplementary Note 3; Supplementary Table 6; Supplementary 
Table 7; Supplementary Figure S6; Supplementary Figure S7). 
In vitro functional studies 
 To understand the functional consequences of the AKT2 Pro50Thr variant on the protein, 
we investigated protein expression, activation, kinase activity, and downstream effector 
phosphorylation. 
 First, we used in silico classifiers that predict potential functional consequences of alleles 
on protein function. Two of the five classifiers predicted AKT2 Pro50Thr to be deleterious 
(Supplementary Table 3). Second, we used 3D models of AKT2 viewed in the PyMol software, 
which predicted that the Pro50Thr variant causes a change in the conformations of the lipid 
binding PH domain (Figure 3, Supplementary Figure S8). We hypothesized that the variant 
protein is inefficiently recruited to the plasma membrane thereby impacting AKT2 
phosphorylation and downstream activity.  
 To assess the molecular and cellular consequence of the AKT2 Thr50 variant on protein 
function, we performed a comparative analysis of AKT2-Thr50 with inactivating and activating 
alleles implicated in monogenic disorders of insulin signaling. Analysis of AKT2-Thr50 
expression showed that while AKT2 protein levels remained unchanged, there was a partial loss 
of AKT2-Thr50 phosphorylation at its activation sites (Thr308 and Ser473) in HeLa cells, 
suggesting impaired AKT2 signaling (Figure 3; Supplementary Figure S9). Similar effects were 
observed in human liver derived HuH7 cells (Supplementary Figure S10). AKT2-Thr50 also 
showed a reduced ability to phosphorylate its downstream target glycogen synthase kinase 3 beta 
(GSK3β). These defects in AKT2-Thr50 activity were confirmed through an in vitro kinase 
assay (P<0.01) (Figure 3). AKT2-Thr50 showed a similar decrease in kinase function to the 






lipodystrophy-causing AKT2-His274 variant. Using a four-hour time course analysis of AKT2 
activity, we verified a reduction in both maximally phosphorylated Thr308 and Ser473 in AKT2-
Thr50 (Supplementary Figure S11). To understand how this loss of activity could manifest as a 
defect in a known cellular function of AKT2 (42), we determined the impact of AKT2-Thr50 on 
cell proliferation in HuH7 cells. While the addition of AKT2 stimulated hepatocyte proliferation, 
the response to AKT2-Thr50 was reduced (effect=-1.2, P<1.0×10
-3
) (Figure 3C; Supplementary 
Figure S12).  
Gene expression studies 
We queried RNA sequencing data from the Genotype Tissue Expression (GTEx) Project 
and found that, in agreement with previous studies (43), AKT2 is highly and ubiquitously 
expressed across all tissues (44 tissue types, 3-156 individuals/tissue). Notably the AKT2 
Pro50Thr containing exon is expressed in all tissues and individuals (Supplementary Figure 
S13), suggesting that the PH domain is important to AKT2 function (44). Of the three AKT 
homologs, AKT2 had 1.4-fold higher expression in skeletal muscle than AKT1 (P=1.5×10
-19
) and 
11-fold higher expression than AKT3 (P=7.8×10
-91
). Skeletal muscle was the only tested tissue 
displaying such pronounced AKT2 enrichment (Figure 2; Supplementary Note 4; Supplementary 
Figure S14; Supplementary Table 8).  
Motivated by the age-related loss of adipose tissue in Akt2 null mice (35; 36) and the 
growth and lipodystrophy phenotypes in carriers of fully-penetrant alleles (37-40), we examined 
associations of expression levels of AKT2 with BMI, FI, and age in the three adipose tissue data 
sets (Supplementary Table 9). We found an association between lower BMI levels and higher 





) and also observed that higher AKT2 expression was associated with lower 






log-transformed FI (EuroBATS, effect=-0.04 SD, P=1.1×10
-3
, METSIM, effect=-0.4 SD, 
P=3.3×10
-11
). We next tested for gene expression quantitative trait loci (eQTL) and found an 
eQTL in the 5’UTR of AKT2 (rs11880261; MAF=35%; r
2
=0.002, D’=0.47 in the Finnish 1000 





; GTEx P=0.08) (Supplementary Figure S15). 
No association was detected between rs11880261 and FI levels, suggesting that the common 
variant eQTL does not drive the initial FI association (Supplementary Note 4; Supplementary 
Table 10). 
Discussion 
Meta-analyses of exome sequence and array genotyping data in up to 38,339 
normoglycemic individuals enabled the discovery, characterization, and functional validation of 
a FI association with a low-frequency AKT2 coding variant. Rare, penetrant variants in genes 
encoding components of the insulin signaling pathway, including AKT2, cause monogenic but 
heterogeneous glycemic disorders (45). In parallel, common alleles in or near many of these 
genes impact FI levels —the AKT2 Pro50Thr association shows an effect 5 to 10 times larger 
than those of these previous published associations (3). This discovery expands both the known 
genetic architecture of glucose homeostasis and the allelic spectrum for AKT2 coding 
variants associated with glucose homeostasis into the low-frequency range, and highlights the 
effects of both locus and allelic heterogeneity (Figure 4).  
 Individuals of Finnish ancestry drove the AKT2 Pro50Thr association signal. This 
demonstrates the value of association studies in different ancestries where frequencies of rare 
alleles may increase due to selective pressure or stochastic changes from population bottlenecks 
and genetic drift. The allele associated with increased FI most likely rose to a higher frequency 






due to genetic drift and exists within the spectrum of rare and low-frequency variation observed 
in Finland, the excess of which facilitates the study of complex trait associations (46). 
While the AKT2 Pro50Thr allele shows a strong effect on all of the insulin measures and 
modest increased type 2 diabetes risk (OR=1.05) we see no effect on any of the glucose 
measures in individuals without diabetes. Due to the effects of both type 2 diabetes and its 
treatment on glucose homeostasis, we have not tested genetic associations of FG and FI in 
individuals with type 2 diabetes, although we observed a diabetic individual homozygous for 
P50T with extreme FI and FG levels.  The mechanism for such heterogeneous effects is unclear 
and detailed in vivo physiological studies are needed. 
 We leveraged similar findings to generate hypotheses for future work on AKT2 and 
downstream targets to further illuminate tissue-specific mechanisms. All reported carriers of the 
lipodystrophy causing AKT2 Arg274His allele are hyperinsulinemic, and three of the four 
carriers have diabetes mellitus (39). These observations are similar to the ones made for TBC1D4 
(which encodes a protein that acts as a substrate immediately downstream of AKT2 in the PI3K 
pathway). In TBC1D4 a population specific, protein-truncating variant (Arg684Ter) is associated 
with increased type 2 diabetes risk (OR = 10.3), increased postprandial glucose and insulin 
levels, and a modest decrease in FI and FG levels (6) (Figure 4). Another stop codon allele in 
TBC1D4, Arg363Ter that is rare (not observed in ExAC) has been reported with a modest 
elevation in FI levels but extreme postprandial hyperinsulinemia and acanthosis nigricans (47). 
siRNA-mediated gene knock-down of AKT2 in human primary myotubes completely abolishes 
insulin action on glucose uptake and glycogen synthesis (48), which highlights the importance of 
an intact AKT2-TBC1D4 signaling pathway in the regulation of insulin sensitivity in humans. 
TBC1D4 is ubiquitously expressed with adipose and skeletal muscle tissue ranking among the 






tissues with highest expression in GTEx. TBC1D4 Arg363Ter seems to have an effect in 
adipocytes (47), while Arg684Ter falls in an exon that is exclusively expressed in skeletal and 
heart muscle (6; 49). This is a likely cause of the TBC1D4 Arg684Ter tissue specificity, which 
appears to differ from the other TBC1D4 Arg363Ter variant as well as the AKT2 variants. 
The phenotypes exhibited by carriers of rare, penetrant AKT2 alleles reflect differential 
AKT2 activation with kinetically inactivating variants resulting in hyperinsulinemia and 
lipodystrophy while kinetically activating variants lead to hypoglycemia (37-39). The decrease 
of cellular proliferation we observe demonstrates that the downstream signaling changes caused 
by AKT2-Thr50 are sufficient in hepatocytes to impair AKT2 function at the cellular level while 
maintaining varying portions of regulatory capacity. Along with the observed association with 
increased fasting insulin levels in human populations, these results support AKT2 Pro50Thr as a 
partial loss-of-function variant. The inactivating AKT2 Pro50Thr variant contrasts with the 
known activating AKT2 Glu17Lys mutation and showcases bidirectional effects within the PH 
domain of AKT2. While the Pro50 residue is conserved in AKT2 throughout all vertebrates, the 
variant lies within the PH domain that is not conserved between AKT isoforms (Figure 2). These 
residues, harboring the Pro50 variant, may functionally distinguish AKT2 from AKT1 and 
AKT3. Although AKT isoforms are activated in the same mechanism within the PI3K pathway 
downstream of insulin, the Akt2
-/-
 mouse is the only knockout of the gene family to be 
characterized by insulin resistance and diabetes (35; 50-52). A deeper understanding of what 
makes the AKT2 isoform distinct could offer potential sites for therapeutic intervention and 
enable more targeted approaches to disease prevention.  
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Figure 1. AKT2 Pro50Thr association with fasting insulin levels. (a) For each study, the 
square represents the estimate of the additive genetic effect for the association of the AKT2 
Pro50Thr allele with log-transformed fasting insulin (FI) levels and the horizontal line gives the 
corresponding 95% confidence interval of the estimate. Inverse-variance meta-analyses were 
performed for All Discovery Studies, All Replication Studies, and All Studies Combined. The 
vertical dashed lines indicate the 95% confidence interval for the estimate obtained in the meta-
analysis of All Studies Combined. (b) Minor allele frequency for each available region and 
ancestry. Across countries the world, the MAF ranges from 0% to 1.1%. The relative sample 
sizes (N) for each region/ancestry are displayed with the blue circles and the relative minor allele 
frequencies of AKT2 Pro50Thr are displayed with the purple circles, with the size of the circles 
showing comparative differences. Within Finland (inset), where the MAF ranges from 0.9% to 
1.7%, birthplace and study center data were used to show the allele distribution across the 
country. 
a
 FINRISK 2007; 
b
 FIN-D2D 2007; 
c
 FINRISK 1997 and 2002 
 
Figure 2. Expression and conservation properties. (a) Amino acid alignment and conservation 
of the three AKT proteins in vertebrates. The x axis gives the amino acid position and the height 
of the lines shows the conservation score across 100 vertebrate genome alignments. The 
functional domains are the pleckstrin homology (PH) domain (blue) and the kinase domain 
(green). The position of AKT2 Pro50Thr is shown in red while the locations of the other AKT2 
disease-causing mutations (37-40) are shown in orange: Glu17Lys, Arg208Lys, Arg274His, and 
Arg467Trp. (b) WebLogo plots of amino acids 35-60 are shown for AKT2, AKT1, and AKT3 
contrasting the homology of the three isoforms. The height of letters gives the relative frequency 
of different amino acids across the 100 vertebrate species, with the colors showing amino acids 
with similar charge. (c) Expression of AKT1, AKT2, and AKT3 in eight insulin-sensitive tissues 
using RNA sequencing data from the GTEx consortium. 
 
Figure 3. Functional properties of AKT2-Thr50 (a) Predicted protein structure of AKT2. 
Domain and variants are highlighted as in Figure 2. The relative spatial positioning of the AKT2-
Pro50 residue is magnified within the inset. (b) HeLa cells were infected with lentiviral V5-
AKT2, V5-AKT2-Lys17, V5-AKT2-Thr50, V5-AKT2-Lys208, V5-AKT2-His274, V5-AKT2-
Trp467, starved for 18 hours (white bar), and stimulated for 20 minutes with 100nm insulin (grey 
bar). V5-tagged AKT2 was isolated from cell lysates with anti-V5 agarose beads and incubated 
with GSK3β-GST peptide in an in vitro kinase (IVK) assay. Quantification of phosphorylated 
substrate peptide (pGSK3β) relative to total peptide (GST-GSK3β) is shown at the inset. 
Immunoblots and quantification shown are representative of three independent replicates. Linear 
model (LM) statistical analyses across all three independent replicates are available in 
Supplementary Figure S9. The IVK was immunoblotted (IB) with the indicated antibodies. (c) 
HuH7 cells were infected with lentiviral V5-AKT2, V5-AKT2-Thr50, or control pLX304. At 72 






hours relative cellular proliferation was determined with WST-1 assay of HuH7 cells. Error bars 




Figure 4. Genetic architecture of rare, low frequency, and common variants associated 
with FI levels. In this plot, the absolute values of the percent change in fasting insulin level due 
to rare monogenic mutations (diamonds) and common genetic variants (circles) are plotted 
against the minor allele frequency of the variant. The extremely rare monogenic mutations 
(above the dashed line to the left of the x axis) were observed in 2 to 18 individuals (3; 37-40; 
47; 53; 54) with the height of the point indicating the percent change in fasting insulin levels of 
mutation carriers from 40 pmol/L, an estimate of population mean fasting insulin level. 
Mutations in INSR and AKT2 p.Arg274His cause compensatory hyperinsulinemia, individuals 
with TBC1D4 p.Arg363Ter show normal fasting insulin levels but postprandial 
hyperinsulinemia, and mutations in PTEN cause enhanced insulin sensitivity providing 
protection against type 2 diabetes. For common variants, the percent change in fasting insulin 
levels per insulin-increasing allele is plotted above the solid horizontal axis. These observations 
are from sequencing (6) and array-based GWAS (3). For several genes, the effects from rare 
mutations can be compared to the effects of common variants in or near the gene: PPARG (blue), 
TBC1D4 (green), PTEN (orange), and AKT2 (red). 
a 
Donohue syndrome: Biallelic loss-of-
function mutations in INSR (54). 
b
 Rabson-Mendenhall syndrome: Biallelic loss-of-function 
mutations in INSR (54). 
c
 Post-pubertal severe IR: Heterozygous or homozygous loss-of-function 
mutations in INSR (54). 
d
 Loss of function PTEN mutations cause Cowden Syndrome in which 
carriers exhibit a lowered fasting insulin level (mean=29 pmol/l) compared to matched controls 
(3). 
e 
Carriers with the AKT2 p.Glu17Lys mutation were described with hypoinsulinemic 
hypoketotic hypoglycemia and hemihypertrophy with undetectable serum insulin (37; 38). 
 




AKT2 Pro50Thr association with fasting insulin levels. (A) For each study, the square represents the 
estimate of the additive genetic effect for the association of the AKT2 Pro50Thr allele with log-transformed 
fasting insulin (FI) levels and the horizontal line gives the corresponding 95% confidence interval of the 
estimate. Inverse-variance meta-analyses were performed for All Discovery Studies, All Replication Studies, 
and All Studies Combined. The vertical dashed lines indicate the 95% confidence interval for the estimate 
obtained in the meta-analysis of All Studies Combined. (B) Minor allele frequency for each available region 
and ancestry. Across countries the world, the MAF ranges from 0% to 1.1%. The relative sample sizes (N) 
for each region/ancestry are displayed with the blue circles and the relative minor allele frequencies of AKT2 
Pro50Thr are displayed with the purple circles, with the size of the circles showing comparative differences. 
Within Finland (inset), where the MAF ranges from 0.9% to 1.7%, birthplace and study center data were 
used to show the allele distribution across the country. a FINRISK 2007; b FIN-D2D 2007; c FINRISK 1997 
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Expression and conservation properties. (A) Amino‐acid alignment and conservation of the three AKT 
proteins in vertebrates. The x axis gives the amino acid position and the height of the lines shows the 
conservation score across 100 vertebrate genome alignments. The functional domains are the pleckstrin 
homology (PH) domain (blue) and the kinase domain (green). The position of AKT2 Pro50Thr is shown in red 
while the locations of the other AKT2 disease-causing mutations (34-37) are shown in orange: Glu17Lys, 
Arg208Lys, Arg274His, and Arg467Trp. (b) WebLogo plots of amino acids 35-60 are shown for AKT2, AKT1, 
and AKT3 contrasting the homology of the three isoforms. The height of letters gives the relative frequency 
of different amino acids across the 100 vertebrate species, with the colors showing amino acids with similar 
charge. (c) Expression of AKT1, AKT2, and AKT3 in eight insulin-sensitive tissues using RNA sequencing data 
from the GTEx consortium.  
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Functional properties of AKT2-Thr50 (A) Predicted protein structure of AKT2. Domain and variants are 
highlighted as in Figure 2. The relative spatial positioning of the AKT2-Pro50 residue is magnified within the 
inset. (B) HeLa cells were infected with lentiviral V5-AKT2, V5-AKT2-Lys17, V5-AKT2-Thr50, V5-AKT2-
Lys208, V5-AKT2-His274, V5-AKT2-Trp467, starved for 18 hours (white bar), and stimulated for 20 minutes 
with 100nm insulin (grey bar). V5-tagged AKT2 was isolated from cell lysates with anti-V5 agarose beads 
and incubated with GSK3β-GST peptide in an in vitro kinase (IVK) assay. Quantification of phosphorylated 
substrate peptide (pGSK3β) relative to total peptide (GST-GSK3β) is shown at the inset. Immunoblots and 
quantification shown are representative of three independent replicates. Linear model (LM) statistical 
analyses across all three independent replicates are available in Supplementary Figure 9. The IVK was 
immunoblotted (IB) with the indicated antibodies. (C) HuH7 cells were infected with lentiviral V5-AKT2, V5-
AKT2-Thr50, or control pLX304. At 72 hours relative cellular proliferation was determined with WST-1 assay 
of HuH7 cells. Error bars represent the standard deviation (SD). *** P=4.5×10-5.  
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Genetic architecture of rare, low frequency, and common variants associated with FI levels. In 
this plot, the absolute values of the percent change in fasting insulin level due to rare monogenic mutations 
(diamonds) and common genetic variants (circles) are plotted against the minor allele frequency of the 
variant. The extremely rare monogenic mutations (above the dashed line to the left of the x axis) were 
observed in 2 to 18 individuals (3; 34-37; 44; 50; 51) with the height of the point indicating the percent 
change in fasting insulin levels of mutation carriers from 40 pmol/L, an estimate of population mean fasting 
insulin level. Mutations in INSR and AKT2 p.Arg274His cause compensatory hyperinsulinemia, individuals 
with TBC1D4 p.Arg363Ter show normal fasting insulin levels but postprandial hyperinsulinemia, and 
mutations in PTEN cause enhanced insulin sensitivity providing protection against type 2 diabetes. For 
common variants, the percent change in fasting insulin levels per insulin-increasing allele is plotted above 
the solid horizontal axis. These observations are from sequencing (6) and array-based GWAS (3). For 
several genes, the effects from rare mutations can be compared to the effects of common variants in or 
near the gene: PPARG (blue), TBC1D4 (green), PTEN (orange), and AKT2 (red). a Donohue syndrome: 
Biallelic loss-of-function mutations in INSR (51). b Rabson-Mendenhall syndrome: Biallelic loss-of-function 
mutations in INSR (51). c Post-pubertal severe IR: Heterozygous or homozygous loss-of-function mutations 
in INSR (51). d Loss of function PTEN mutations cause Cowden Syndrome in which carriers exhibit a lowered 
fasting insulin level (mean=29 pmol/l) compared to matched controls (3). e Carriers with the AKT2 
p.Glu17Lys mutation were described with hypoinsulinemic hypoketotic hypoglycemia and hemihypertrophy 
with undetectable serum insulin (34; 35).  
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Supplementary Notes  
SUPPLEMENTARY NOTE 1: SUMMARY OF ASSOCIATION RESULTS AT KNOWN AND NOVEL LOCI. 
The exome-wide single variant association results are displayed in Supplementary Table 2. We first partitioned the significant (P <5 
× 10
-7
) and suggestive (P <5 × 10
-6
) single variant association results into two sets: variants in previously reported associated regions 
(Supplementary Table 2A) and variants with potentially novel association signals (Supplementary Table 2B).  
Of the 57 loci with common variants associated with FG or FI in multiple ancestries (1-13), twenty-one regions contained significant 
or suggestive association signals in our analysis. Of the seven regions harboring significant associations with non-synonymous 
variants, five (GCKR, G6PC2, SLC30A8, PCSK1, and GLP1R) were described previously by our group (13), where, when possible, 
conditional analyses and functional experiments are utilized to illuminate functional transcripts. In the MADD locus, a missense 
variant ACP2 p.Arg29Gln showed significant association with FG levels (P = 1.91 x 10
-7
, MAF = 38%). This variant is in low LD (r
2 
= 0.138) with the reported variant, rs7944584 (P = 2.62 x 10
-11
, MAF = 39%), but after conditioning on rs7944584 the association was 
not significant (P = 0.003). An additional association with a low-frequency variant was observed at the MTNR1B locus. A variant 
upstream of MTNR1B, rs7950811, (effect = 0.057; P = 6.8 x 10
-11
), has a MAF of 4.5% and in low LD with the index SNP, 
rs10830963 (r
2
 = 0.002), in 1000 Genomes data (14). After conditioning on the index SNP, the association of rs7950811 with FG 
remained significant (P = 3.07 x 10
-7
). For FI, five regions contained significant or suggestive association signals. All of the insulin-
associated variants were common with MAF > 25%. Two of these regions, the GCKR and GRB14/COBLL1 loci, harbor significant 
missense variants and were previously described (13). 
Association results at previously reported variants from genome-wide association studies are presented in Supplementary Table 2C. 
Of the 68 previously published common variant associations with FG and FI, we were able to carry out association tests at 36 FG and 
16 FI variants. Thirty of the FG association loci showed P < 0.05, with 100 % having a consistent direction of effect. Thirteen FI 
associated loci had P < 0.05, with 100% demonstrating a consistent direction of effect. 
Potentially novel association signals 
We observed five and seven variants passing suggestive level of significance for FI and FG, respectively (Supplementary Table 2B). 
As this analysis focused on coding variation, we took the three coding variants forward to a replication analysis in four independent 
Finnish studies (N = 5,747) (15-18). The AKT2 p.Pro50Thr variant in AKT2 was present and well-imputed in the 1000 Genomes 
reference panel (imputation score: 0.886 to 0.957). The correlation between imputed and directly genotyped genotypes was high (r
2
 > 
0.88), and the association of this variant with FI levels replicated, (Preplication = 0.00054, N = 5,747) resulting in a combined (discovery 
and replication) sample P value of 9.98 × 10
-10
 (Supplementary Table 2E). MMEL1 p.Glu323Gln, which has a MAF of only 0.2% 
(seven minor allele carriers in the HBCS subset), was poorly imputed and not tested for association (imputation score: 0.718 to 0.945, 
r
2
 = 0.57). TP53BP1 p.Thr1278Ile was not observed in the studies. 
Summary of exome-wide significant gene based association results 
The suggestive and significant gene based association signals from each ancestry group in the exome sequencing data and the exome 
chip data, as well as combined results, are displayed in Supplementary Table 2D. The AKT2 gene based association with FI is 
described in the main text. 
In gene-based tests using the PTV+NSbroad mask, NDUFAF1 was significantly associated with FI levels (PBurden = 1.10 × 10
-6
). This 
association was driven by a single missense variant (p.His309Asp, rs199599633, P = 9.3 × 10
-5
, N = 1,673) that was not associated 
with FI levels in exome array data (P = 0.018, N = 19,569). NADH dehydrogenase (ubiquinone) complex I, assembly factor 1, or 
NDUFAF1, encodes for a complex I assembly factor protein, which is part of the first step of the respiratory chain. Mutations in both 
copies of this gene are reported to cause mitochondrial complex I deficiency, which manifests as cardioenphalomypathy or fatal 
hypertrophic cardiomyopathy while heterozygous parents were reported as healthy(19; 20).  
Additionally, a third gene, GIMAP8, was associated with FG levels in the PTV-only mask (PBurden = 2.30 × 10
-6
). This association was 
driven by singleton and doubleton variants. This gene encodes a GTPase of the immunity-associated protein family (21) 
SUPPLEMENTARY NOTE 2: POPULATION GENETICS AND CONSTRAINT  
We studied the population genetics properties of AKT2 and AKT2 p.Pro50Thr by cataloguing details of all the protein altering variants 
observed in the T2D-GENES exome sequence data (N=12,940). We phased variants in proteins or genes (including non-coding 
variants) using SHAPEIT (22) and calculated population statistics and diversity indices with Arlequin (v 3.5) (23), grouped by country 
of origin. We built the haplotype network using the pegas and igraph libraries in R. dN/dS for Human-Chimpanzee alignments were 
extracted from ENSEMBL database (24). We computed the “within-human” dN/dS with codeml (PAML) (25) using hg19 sequence as 
reference and alternative sequence containing all the observed segregating sites. The Mcdonald-Kreitman test (26) for AKT2 was 
computed in Bioperl (Bio::PopGen::Statistics) using AKT3 (hg19) as an outgroup. 
 
There was modest heterogeneity across regions of Finland, with North Karelia (MAF=1.7%) different (0.001<pairwise FST<0.003; 
P<0.01) from all other tested regions, except Central Finland (MAF=1.3%, pairwise FST=0.0004, P=0.08). These geographical 
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differences in Pro50Thr allele frequency are consistent with long-term drift (27) with no evidence of selection pressure differences at 
AKT2 across Finland (dN/dSFinland=0.1; 0.08<dN/dSEuropean<0.4). 
 
In the complete GoT2D and T2D-GENES exome sequence data of 12,940 individuals (6,504 with type 2 diabetes), AKT2 displayed 
some evidence of purifying selection (dN/dS<0.01 comparing human and chimpanzee) (Supplementary Figure S3; Supplementary 
Figure S4). We observed 36 non-synonymous variants in AKT2 (35 with a MAC≤5 and Pro50Thr with MAC=61) (Supplementary 
Table 3). No other protein-altering variants had frequency greater than 0.3% in the 60,706 individuals (including 6,347 from the 
GoT2D and T2D-GENES studies) in the Exome Aggregation Consortium (ExAC) data. 
SUPPLEMENTARY NOTE 3: PATHWAY ANALYSES 
We used biological knowledge to test for enrichment of signal in pathways. Pathways and networks were selected from MSigDB (28), 
which includes Gene Ontology, pathways from KEGG, Ingenuity, Reactome, and Biocarta; and the manually curated monogenic 
pathways previously considered. We carried out a two-stage enrichment analysis: step one calculates gene aggregation scores using a 
function of single variant statistics; and step two calculates gene set scores using a function of aggregation scores from each gene in 
the set. In step one, we make use of a range of gene aggregation functions, including the minimum p-value (or maximum Bayes’ 
factor) for single-variant association (within ancestry or trans-ethnic) in the gene (with correction for the number of variants in the 
gene). In step two, we apply a pre-ranked GSEA method (28), which consists of a sensitive-improved Kolmogorov-Smirnov (random 
bridge) statistic, and which provides better correction of the null distribution for highly correlated gene sets (as we see for our hand 
curated gene sets). Additionally, we performed a biologically enhanced pathway analyses with DEPICT (29), an integrative tool that 
we used to highlight enriched pathways and identify tissues/cell types where genes from associated loci are highly expressed. 
Gene set definitions: We assembled pre-defined, hand-curated lists to create four gene sets: “Monogenic All” (N = 81), including any 
gene with reported mutations that result in a disease or syndrome leading to either increased prevalence of diabetes or changes in 
glycemic traits. We further prioritized two subsets of genes, “Monogenic Glucose” (N = 41) and “Monogenic Insulin” (N = 37) 
including any gene with mutations leading to changes in respective glycemic traits as a primary feature. The list contains genes 
identified before September 2013. The fourth gene set, “Insulin Receptor Signaling,” was created using Ingenuity Pathway Analysis 
(IPA) tools (30) by merging the insulin receptor signaling, IGF-1 signaling, and PI3K/AKT signaling pathways and adding all 
downstream phosphylated substrates of AKT. 
Association Analysis: SKAT and burden tests were performed after aggregating functional variants (according to the previously 
described criteria) across all the genes in each gene set. Conditional analyses were performed using features implemented in 
RareMETALS (31; 32). 
Enrichment of association signals: Empirical enrichment for the number of gene based tests with P < 0.001 and the number of single 
variant tests with P < 0.001 in each gene set was determined by first counting the number of tests below the threshold. For a particular 
gene set, let Nobserved denote the number of tests with P < 0.001. A pool of similar genes was assigned to each gene in the gene set, 
according to the quartile of exon length and quintiles of the number of the nonsynonymous and synonymous variants in the gene. For 
each gene set, 1,000 matched gene sets were created. An empirical distribution of Ni (the number of tests with P < 0.001 in matched 
set i) was constructed for each of the matched sets. The empirical enrichment P-value was calculated by observing the proportion of 
matched sets with Ni ≥ Nobserved. 
Additional traits related to insulin resistance: We examined the single variant association of fasting adiponectin level (log-
transformed, age, sex and BMI adjusted, and inverse-normalized), 2 hour glucose level (age, sex and BMI-adjusted, and inverse-
normalized) and 2 hour insulin level (log-transformed, age, sex and BMI adjusted, and inverse-normalized) in these pathways using 
exome array data when available from the discovery cohorts (D2D2007, DPS, DRSEXTRA, FINRISK, FUSION, Health2008, 
Inter99, METSIM, ULSAM). 
Summary of Results 
To further assess the evidence of enriched signals in biologically related genes, we looked for enrichment across pathways using both 
hand curated and publically available pathways. This was conducted using GSEA (28; 33). While no gene-set was significant after 
multiple testing correction, there is enrichment for several pathways, including adipocytokine signaling, glucose transport, galactose 
metabolism, glycolysis and gluconeogenesis, and starch and sucrose metabolism pathways, all of which include both G6PC2 and 
G6PC. While the G6PC2 association with FG has previously been described (13), we note that G6PC mutations result in glycogen 
storage disorders (34).  
Since AKT2 lies in the insulin receptor signaling pathway and AKT2 mutations are a known cause of both familial lipodystophy, 
severe insulin resistance and hypoglycemia (35-38) we next explored whether there was an enrichment of rare and low frequency 
variants in these gene sets (“Monogenic Genes,” and “Insulin Receptor Signaling Genes”) [Supplementary Table 6A]. First, we 
tested for global enrichment by aggregating all variants predicted to be deleterious using the annotation masks previously described 
for gene based testing (PTV-only, PTV+NSstrict, PTV+NSbroad, PTV+Missense). We found a significant enrichment of deleterious 
variants (protein truncating, splice site and non-synonymous) in the monogenic genes (P = 2 × 10
-4
) in exome array data 
[Supplementary Table 6B] but no such enrichment in an analysis of the exome sequencing data set (P = 0.87) [Supplementary 
Table 6C]. Conditional analyses demonstrated that in addition to AKT2 p.Pro50Thr (P conditional on AKT2 p.Pro50Thr = 0.0017), 
seven additional top ranked variants contribute to this signal (P conditional on AKT2 p.Pro50Thr, CFTR p.Asp1270Asn, INSR 
p.Val1012Met, ZMPSTE24 p.Arg178His, ZFP57 p.Arg178His, CFTR splice donor variant rs78756941 and PCNT p.Glu1785Lys 
jointly = 0.0104) [Supplementary Table S6D,E]. No other novel associations were detected with the other gene sets and variant 
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masks, although when comparing the effects of the burden tests across the four variant aggregation categories, we observed a positive 
trend of effect as we examined the category containing the least predicted deleterious (PTV+missense) to the most predicted 
deleterious (PTV-only), although the confidence intervals widen as the number of included variants decrease [Supplementary Fig. 6]. 
To find specific genes harboring an enrichment of association with either FG or FI levels, we next focused on association results from 
the monogenic genes, testing each set for empirical enrichment. We found that a gene implicated in congenital generalized 
lipodystrophy, CAV1 (39), showed enrichment of association with FG levels when considering the set of glucose-specific monogenic 
genes from the exome sequencing analysis (enrichment P = 0.03; CAV1 P = 1.9 × 10
-4
 with protein truncating and low-frequency 
missense variants and P = 7.0 × 10
-4
 with protein truncating and predicted deleterious variants). Mutations in CAV1 are characterized 
by extreme insulin resistance and lipodystrophy (39) but in our data no association of CAV1 variants with FI levels was observed. We 
also observed a borderline enrichment for fasting insulin level with a gene-based burden test in the insulin receptor signaling pathway 
(enrichment P = 0.06; (PTGS2 burden P = 1.1 × 10
-4 
with protein truncating and low-frequency missense variants; [Supplementary 
Fig. 7, Supplementary Table S7A,B]. 
We further examined the association of three quantitative traits related to insulin resistance: fasting adiponectin level, and 2 hour 
glucose and 2 hour insulin levels after an oral glucose tolerance test. Besides a nominally significance Other than the AKT2 
p.Pro50Thr allele association with 2 hour insulin level (Effect = 26% increase, 95% confidence interval = 16% - 38%, P = 7.86 × 10
-
8
), no other associations were observed [Supplementary Fig. 7C]. 
SUPPLEMENTARY NOTE 4: EXPRESSION PROFILE OF AKT2 
GTEx 
We compared the expression pattern of AKT2 to the two other members of the AKT gene family, AKT1 and AKT3, using multi-tissue 
RNA sequencing (RNA-seq) data from the pilot phase of the GTEx project. Detailed procedures for sample collection, RNA 
extraction, RNA-seq, and gene and transcript quantifications have been previously described (40). Briefly, in the pilot phase, a total of 
9,365 tissue samples targeting more than 30 distinct human tissues were collected from 237 post-mortem donors. RNA was extracted, 
and 1,749 unique samples that passed QC (RIN value of 6.0 or higher and at least 1µg of total RNA), were selected for RNA-seq. Non 
strand-specific RNA sequencing after poly-A selection was performed using Illumina TruSeq RNA Sample Preparation protocol on 
the Illumina HiSeq 2000, and aligned with Tophat (v 1.4.1) (41) to UCSC hg19. Gencode (v 12) (42) was used as a transcriptome 
model for the alignment, and gene and isoform quantifications. Gene and exon level expression was quantified using RNA-SeQC (43) 
and the Flux Capacitor (v 1.2.3, http://flux.sammeth.net) was used in the quantification of the expression of several transcriptional 
elements including gene transcript, splice junctions and introns. In total, 44 tissues had data from more than one individual and were 
used in the analyses. 
 
Genotyping and imputation: Samples were genotyped on the Illumina HumanOmni5-4v1_B SNP array and imputed to the 1,000 
Genomes Phase 1 reference (an updated data freeze version from 19 April 2012, release v3) using IMPUTE2 (44; 45) as described 
(40). 
 
Age and BMI associations: We studied BMI and age associations using a linear mixed model as implemented in the lmer function in 
the lme4 R package (46). Sex, age, BMI, and three PCs were included in the model as fixed covariates and the date of sequencing and 
the date of nucleic acid isolation as random covariates. The gene expression RPKM values were inverse variance rank normalized for 
these analyses. 
 
eQTL analysis: The cis-eQTL for AKT2 in subcutaneous adipose tissue was extracted from the eQTL data generated during the pilot 
phase of the GTEx project. The methods have been previously described in detail (47). Briefly, the association of common (MAF ≥ 
5%) SNPs with gene expression levels was studied using a linear model in MatrixEQTL (48) including sex, three genotyping PCs, and 
15 expression PEER factors (49) as covariates. The cis-window was defined as one megabase (Mb) up- and down-stream of the 
transcription start site of each transcript. Prior to the eQTL analysis the RPKM values were inverse normalized across genes within 
each tissue and transformed into a standard normal based on rank.  
EuroBATs 
EuroBATs RNA-seq samples: Samples from photo protected subcutaneous adipose tissue from 766 twins were extracted (131 
monozygotic twin pairs, 187 dizygotic twin pairs and 130 unrelated individuals) and processed as previously described (50; 51). In 
brief, samples were prepared for sequencing with the Illumina TruSeq sample preparation kit (Illumina, San Diego, CA) according to 
manufacturer’s instructions and were sequenced on a HiSeq2000 machine. Afterwards, the 49-bp sequenced paired-end reads were 
mapped to the GRCh37reference genome (52) with BWA v0.5.9 (53). We use genes defined in the GENCODE 10 annotation (42), 
removing genes with more than 10% zero read count. RPKM values were root mean transformed.  
 
Genotyping and imputation: Samples were genotyped on a combination of the HumanHap300, HumanHap610Q, 1M‐Duo, and 
1.2MDuo 1M Illumnia arrays, as described in Grundberg et. al (54). Samples were imputed into the 1000 Genomes Phase 1 reference 
panel (data freeze, 10/11/2010) (6)
 
using IMPUTE2 (44; 45) and filtered (removing variants with MAF<1%, IMPUTE info 
value<0.8). Samples with both genotypes and expression values (N=720) were used in the subsequent analyses. 
 
Gene-age, gene-BMI, and insulin associations: We used inverse normalized RPKM values to assess the effects of age and BMI on 
gene expression. We fit linear mixed models using R (55) with the lmer function in the lme4 package (46). Confounding factors in all 
Page 49 of 91 Diabetes
models included fixed effects (primer insert size, GC content mean) and random effects (primer index, date of sequencing, family 
relationship and zygosity). In addition to the adjusting for these fixed and random covariates, the analysis of age also adjusted for BMI 
and the analysis of BMI was adjusted for age. The P values to assess significance for age and BMI effects were calculated from the 
Chi-square distribution with 1 degree of freedom using likelihood ratio as the test statistic. FI was measured at the same time point as 
the fat biopsies, following a previously described protocol (56). Natural log transformed FI were adjusted for age or for age and BMI 
and the residuals were inverse rank normalized. FI-SNP and FI-AKT2 association was tested with a linear model using the lm function 
in R. 
 
eQTL analysis: We ran the eQTL analysis on residuals from a mixed model including the first 20 PCs as fixed effects and family 
relationship and zygosity as random effects. SNP-expression association was performed with a t-test statistic using the NP-GWAS 
software. We assessed statistical significance through 100,000 permutations. 
METSIM 
METSIM RNA samples: Subcutaneous fat biopsy samples were obtained from a sample of the participants of the baseline METSIM 
study. Total RNA was isolated from these samples using Qiagen miRNeasy Kit according to the manufacturer’s instructions. RNA 
integrity number values were assessed with the Agilent Bioanalyzer 2100. High-quality samples (RNA integrity number>7.0) were 
used for transcriptional profiling with the Affymetrix Human Genome U219 Array. Genome Studio software (2010.v3) was used to 
obtain fluorescent intensities. 
 
eQTL analysis and gene-age, gene-BMI and insulin associations: The SNP-gene associations were studied for all SNP within 1 Mb 
of a given gene. The RNA normalized expression data were adjusted for 35 PEER factors and inverse normal transformed PEER 
processed residuals were for used eQTL mapping (57). Linear mixed model EMMAX (58) accounts for sample relatedness and was 
implemented in EPACTS (http://genome.sph.umich.edu/wiki/EPACTS). The sample size for eQTL-mapping was N=770. BMI and 
age associations, as well as FI associations (with and without adjustment for BMI) were studied using the mixed linear model 
implemented in lme4 (46) in R. The fixed covariates including age and BMI were used as random covariates. Association between the 
SNPs associated with AKT2 expression (eSNPs) and FI was tested with a linear model using the lm() function in R. The natural log 
transformed FI levels were adjusted for age and BMI and the residuals were inverse rank normalized. All analyses using expression 
data were conducted in 770 METSIM individuals, while for the tests of eSNP and FI association the sample size for analysis was 
10,081. 
Expression Profile of AKT2 
To gain further insights into the tissues relevant for AKT2 function we explored gene and transcript expression patterns of AKT2 
(ENSG00000105221) from multiple (N = 44) human tissues using RNA sequencing (RNA-seq) data from the Genotype Tissue 
Expression (GTEx) Project (47). 
In the GTEx data AKT2 is ubiquitously expressed [Supplementary Fig. 13A,B]; the gene is present in all the available tissues 
(median expression across individuals RPKM(59) (reads per kb per million reads) > 7 in all tissues, [Supplementary Table 8] and in 
all individuals, in agreement with previous studies examining AKT2 expression via RT-PCR, Western blot, and Northern Blot analysis 
(60-63), and documented essential role of AKT isoforms in biological processes throughout the body (64). No enrichment of AKT2 
expression is present in insulin sensitive tissues (i.e. pancreas, skeletal muscle, adipose tissue (both subcutaneous and visceral), liver 
and kidney cortex) via RNA sequencing as proposed in mouse and rat models, however, this is consistent with previous examination 
of AKT2 mRNA in human tissues (61-63; 65). This GTEx RNA sequencing data does not address insulin-sensitive tissue enrichment 
seen at the level of AKT2 protein, yet in general mRNA levels correlate with protein abundance (66-68).  
AKT2 has multiple alternatively spliced transcripts, yet little is known of their specific roles, and therefore we investigated which of 
the transcripts are the most abundant and which tissues these are active in Gencode version 12 used in the gene and transcript 
annotations lists 28 AKT2 transcripts and 17 of these transcripts are expressed (mean RPKM > 1) in at least one of the studied tissues 
[Supplementary Fig. 13C,D]. However, majority of the expression appears to be due to three AKT2 transcripts: AKT2-004 (processed 
transcript) and AKT2-001 (protein-coding) that span the full length of the gene, and AKT2-008 (protein-coding), which does not 
include the downstream exons. Together these three transcripts constitute on average 44% (range 18-65%) of AKT2 expression in the 
GTEx tissues. The two longer AKT2 transcripts, AKT2-004 and AKT2-001, follow similar expression pattern to the gene, while the 
shorter one, AKT2-008, shows more specific pattern of expression being most expressed in uterus, kidney cortex and esophagus 
mucosa. 
The exon containing the p.Pro50Thr variant is included in 14 out of 28 expressed transcripts (all the 28 AKT2 transcripts are expressed 
at a detectable level in at least one individual in at least one tissue), including in all the three most highly expressed transcripts 
[Supplementary Fig. 13D]. The expression profile of the exon containing p.Pro50Thr is similar to the whole AKT2 gene with the 
tissues showing highest AKT2 expression generally having the higher levels of expression of the exon containing p.Pro50Thr 
[Supplementary Fig. 13B]. Notably, the exon is expressed in all tissues and all individuals, further suggesting that the exon likely 
encodes part of the protein integral for its function. 
Similarly to AKT2, the two other members of the AKT gene family, AKT1 and AKT3, are expressed in all the tissues available in the 
GTEx data with the exception of rather low expression of AKT3 in liver and whole blood. Of the three genes, AKT1 is generally the 
most and AKT3 the least abundant in all tissues. AKT2 is the most highly expressed of the three homologs (P < 0.05 for all 
comparisons using one-sided paired Student’s t-test and log2 transformed expression values) only in skeletal muscle, pituitary and 
cerebellum/cerebellar hemisphere, with the higher AKT2 expression being most pronounced in skeletal muscle [Supplementary Fig. 
14]. 
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AKT2 expression in adipose tissue and association with FI 
To assess whether Pro50Thr was associated with AKT2 expression, we tested for gene expression quantitative trait loci (eQTL) in 
available adipose tissue data. We found an eQTL in the 5’UTR of AKT2 (rs11880261; MAF=35%) with the common allele associated 
with lower AKT2 expression levels (Supplementary Figure 15; Supplementary Table 9). For Pro50Thr, we found the rare allele 
was associated with lower AKT2 expression in adipose tissue (METSIM effect=-1.0 SD; P=8.9×10
-4
, EAF=0.8%). The rare Pro50Thr 
coding allele (T) sits on the same haplotype as the common allele of rs11880261 (C, r
2
=0.002, D’=0.5 in the 1000 Genomes Finnish 





). No association was detected between rs11880261 and FI levels (METSIM 
P=0.30, N=10,081; EuroBATS P=0.80, N=710), suggesting that the common variant eQTL does not drive the initial FI association. 
 
Mendelian randomization analysis 
 
To elaborate the potential causality behind the association between AKT2 expression and fasting insulin association, we applied a 
Mendelian randomization based approach using the discovered eQTL SNPs as instrumental variables (IV) following a similar 
procedure as described recently (69). The association data for the SNP-gene, gene-FI, and SNP-FI analyses from EuroBATS and 
METSIM were first combined in a fixed-effects inverse-variance-weighted meta-analysis. We derived the IV estimator by taking the 
ratio of the regression coefficients from the SNP-FI and SNP-AKT2 analyses, estimating standard error using the delta method. We 
used a Z test to determine the significance of the IV estimator and the difference between the IV estimator and the observational 
estimator. Power for this analysis was calculated using an online MR calculator (http://cnsgenomics.com/shiny/mRnd/) with the 
following values as input: sample size = 2091, alpha = 0.05, beta_xy =[0.01-0.1], beta_OLS = 0.05, R2_xz = 0.025, sigma_x = 
sigma_y = 1 (70). 
 
Mendelian randomization with rs11880261 as an instrumental variable for AKT2 expression failed to show a causal relationship 
between AKT2 expression and FI (P=0.41) (Supplementary Table 10). However, power for the Mendelian randomization analysis is 
not sufficient to conclude there is no effect. Our instrument (rs11880261) explains about 2.5% of the variance in AKT2, but the 
observational association between AKT2 expression and FI is also weak. Depending on the estimate of the causal effect of AKT2 
expression to FI, the power with the sample size of 2,091 can be as low as 5%. 
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SUPPLEMENTARY FIGURE S1 
A. Fasting Plasma Glucose * 
  
B. Fasting Insulin 
  
Manhattan and QQ plots for exome-wide association analysis with FG (A) and FI levels (B). On the Manhattan plots, variants 
within regions of known association are colored in dark blue, and variants outside those regions are colored in gray. The red horizontal 
line represents the exome-wide significance threshold for single variant associations (P<2.5×10-7). * For readability, the FG Manhattan 
plot is truncated at –log10(P) = 20, although variants in the G6PC2 region on chromosome 2 have –log10(P values) > 20. 
SUPPLEMENTARY FIGURE S2 
 
QQ plots from the gene based association tests for FI and FG. Two tests were applied, SKAT (left column) and Burden (right 
column) to four annotation masks (PTV, PTV+NSBroad, PTV+NSStrict, PTV+Missense). A. FI with variants in exome sequencing data set. 
B. FG with variants in exome sequencing data set. C. FI with variants in exome chip data set. The point deviating from the diagonal is 
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SUPPLEMENTARY FIGURE S3 
 
 
Population structure and diversity indices of AKT2 protein in the exome sequencing data set. Each pie represents the frequency 
of different haplotypes, estimated from phased exome sequencing data in the five continental ancestries (grouped by study or country 
of origin). Significance of Tajima’s D and F-statistics (global FST, FIS, FIT, and pairwise FST (gray line), and within population FIS) are 
indicated with asterisk: * P-value < 0.05; ** P-value < 0.01; *** P-value < 0.001. 
 
S: Number of segregating sites; Na: expected number of alleles; Pi (π): Mean number of pairwise differences; Theta (θ): Watterson’s θ 
estimate; dN/ds: ratio of non-synonymous nucleotide substitutions per non-synonymous site (dN) and number of synonymous 
nucleotide substitutions per synonymous site (dS); MK: McDonald-Kreitman test.  
 
African-American: AJ – Jackson Heart Study, AW – Wake Forest School of Medicine Study; East-Asian: EK – Korea Association 
Research Project, ES – Singapore Diabetes Cohort Study and Singapore Prospective Study Program; European: UA – Ashkenazi (US, 
Israel), UB – UKT2D Consortium (UK), UF (Finland) – Metabolic Syndrome in Men Study (METSIM), Finland-United States 
Investigation of NIDDM Genetics (FUSION) Study, Malmo-Botnia Study, UG (Germany) – KORA-gen (Germany), US (Sweden) – 
Malmo-Botnia Study; Hispanic: HA – San Antonio Family Heart Study, San Antonio Family Diabetes/ Gallbladder Study, Veterans 
Administration Genetic Epidemiology Study, and the Investigation of Nephropathy and Diabetes Study family component, HS – Starr 
County, Texas; South-Asian: SL – London Life Sciences Population Study, SS – Singapore Indian Eye Study. 
	  
Page 57 of 91 Diabetes
SUPPLEMENTARY FIGURES PAGE 3 OF 15 
SUPPLEMENTARY FIGURE S4 
 
AKT family conservation compared to other genes. The dN/dS ratio is calculated by comparing homologous coding sequences 
between human and chimpanzee. It shows the degree to which selection is acting on a gene: ratio<1 points to negative 
selection/purifying selection, i.e. evolutionary pressure to conserve the sequence in ancestral state, ratio>1 to positive selection, and 
ratio=1 to neutral evolution. Three AKT homologs are highly conserved when compared to the set of “Insulin monogenic” genes (37 
genes), to which AKT2 belongs, and two other gene sets: 1,002 anatomical structure development genes (“conserved”), and 132 sexual 
reproduction genes (“fast evolving”).  
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SUPPLEMENTARY FIGURE S5A 
 
 
Trait values among AKT2 variant carriers. Profile of the inverse normalized, adjusted metabolic trait values (top plot) and scaled 
(normalized by overall mean and standard deviation) raw trait values (bottom plot) of carriers of three AKT2 variants: AKT2 p.Pro50Thr, 
AKT2 p.Arg208Lys and AKT2 p.Arg467Trp from the T2D-GENES whole exome sequencing data set.  Points on the graph are observed 
trait values for heterozygous (black) and homozygous (red) carriers of the variants, split by type 2 diabetes status. Trait abbreviations: 
HBA1C- glycated hemoglobin, FAST_INS- fasting insulin, FAST_GLU- fasting plasma glucose, TG- triglycerides, CHOL- total 
cholesterol, LDL-C, low-density lipoprotein cholesterol, HDL-C- high-density lipoprotein cholesterol, BMI- body mass index, WHR- waist 
to hip ratio, WASITC- waist circumference, HIPC- hip circumference, DBP- diastolic blood pressure, SBP- systolic blood pressure. 
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HbA1c, Fasting Glucose and Fasting Insulin distributions in T2D-GENES exome sequence data subset of Finnish cohorts 
(Botnia, FUSION, and METSIM). Scaled (normalized by overall mean and standard deviation) trait distributions are displayed by 
genotype group and type 2 diabetes status.  
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SUPPLEMENTARY FIGURE S5C 
 
Phenotype clustering of AKT2 missense variant carriers in the T2D-GENES whole exome sequencing dataset on seven 
metabolic traits: all missense carriers (A), carriers of AKT2 p.Pro50Ala variant (B), and carriers of the other variants (C), (see 
Supplementary Table 3). The row labels indicate the variant carried by an individual. P50Talleles: the number of Ala alleles carried; 
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SUPPLEMENTARY FIGURE S6 
 
 
The trend in the estimate of the effect size of the global gene burden test for the four variant aggregation categories. The effect 






Monogenic enrichment in single variant association tests. Single variant association results from the FG and FI association 
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SUPPLEMENTARY FIGURE S7B 
 
Pathway enrichment in gene-based tests. Gene burden association results from the fasting glucose and fasting insulin analysis for 
variants in the PTV+Missense mask in the monogenic gene sets (top) and the insulin receptor signaling genes (bottom). 
 
SUPPLEMENTARY FIGURE S7C 
 
Pathway associations in traits related to insulin resistance. Single variant association results for three traits related to insulin 
resistance: fasting adiponectin levels, 2 hour glucose level and 2 hour insulin level after an oral glucose tolerance test. The variants in 
these plots are in the PTV+Missense annotation category, with results from variants in the monogenic gene sets (top) and the insulin 
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SUPPLEMENTARY FIGURE S8 
 
Predicted structure change in AKT2 due to AKT2 p.Pro50Thr. The left plot shows the predicted structure of wild-type AKT2. The 
right plot shows the predicted structure of AKT2.Thr50. 
 
SUPPLEMENTARY FIGURE S9 
 
In vitro kinase (IVK) assay. A. Results of a generalized linear 
model (GLM) applied on rescaled raw data. The relative 
substrate phosphorylation values were generated by dividing 
each value in each round of analysis with the value for non-
stimulated, serum-starved AKT2. A first GLM (“Round” model) 
was analyzed including the Round as variable; the three 
independent rounds were not significant: we used them as 
replicate in the Full model. The plots represent the GLM 
estimates (and 95% CI) in the Full model for the two significant 
interactions: B. Assay:Insulin. C. Assay:Variants. For the 
Glycogen Synthase Kinase 3 b (GSK3b), the different AKT2 
variants show significant relative phosphorylation (pairwise 
comparison p-values from contrast analysis reported in inset 
table). For GST-GSK3 peptide, none of the AKT2 variants 
showed different relative phosphorylation values. * P < 0.05, ** 
P < 0.01, *** P < 0.001. DF: degrees of freedom, F: statistic 








Round 2 2.73% 1.228 0.300
Assay 1 8.42% 7.572 0.008
Insulin7induction 1 12.38% 11.125 0.001
Round:Assay 2 1.60% 0.718 0.492
Round:Insulin 2 4.52% 2.033 0.140
Assay:Insulin 1 3.34% 2.999 0.088





Assay 1 8.42% 14.71 3.12E;04
Insulin7induction 1 12.38% 21.61 1.98E;05
Variants 5 23.52% 8.21 6.49E;06
Assay:Insulin 1 3.34% 5.83 1.90E;02
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Phosphorylation of AKT2 activation sites in HuH7 liver 
cells (A) HuH7 cells cells were infected with lentiviral control, 
V5-AKT2, V5-AKT2-Lys17, V5-AKT2-Thr50, V5-AKT2-Lys208, 
V5-AKT2-His274, V5-AKT2-Trp467, blasticidin selected and 
starved for 18 hr (white bar), and stimulated for 20 min with 
100nm insulin (grey bar). V5-tagged AKT2 was isolated from 
cell lysates with anti-V5 agarose beads and immunoblots (IB) 
were probed with indicated antibodies. (B) Phosphorylated 
AKT2 Thr308 and Ser473 were quantified and normalized to 
total by V5-AKT2. (C) Linear model for the statistical analysis 
of quantified pAKT2. The “Round” model tests for significant 
differences between the three rounds of analysis. The Full 
model examines significance of assay (V5, pAKT2 T308 and 
pAKT2 S473) and variants (AKT2, AKT2.Lys17, AKT2.Thr50, 
AKT2.Lys208, AKT2.His274 and AKT2.Trp467) and their 
interactions. * P < 0.05, ** P < 0.01, *** P < 0.001. DF: degrees 
of freedom, F: statistic testing the importance of the grouping 
term, Pr(>F): P value of the F statistic. 


































































Round 2 1.86% 0.903 0.409
Assay 2 1.04% 0.504 0.606
Insulin8induction 1 2.00% 1.941 0.167
Round:Assay 4 0.20% 0.049 0.995
Round:Insulin 2 0.11% 0.055 0.946
Assay:Insulin 2 1.37% 0.664 0.517





Assay 2 1.04% 1.96 1.47E901
Variants 5 46.52% 35.13 2.20E916
Insulin8induction 1 2.00% 7.56 7.28E903
Assay:Variant 10 26.02% 9.83 8.39E911














V5 pAkt2 T308pAkt2 S473
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Time-course analysis of AKT2 phosphorylation (A) HeLa cells were infected with lentiviral V5-AKT2, V5-AKT2-Thr50, or control 
pLX304, blasticidin selected and starved for 18 hours and then stimulated for 0, 2, 60, and 240 minutes with 100nm insulin. V5-tagged 
AKT2 was isolated from cell lysates with anti-V5 agarose beads. Immunoprecipitated (IP) V5-AKT2 and whole cell lysates (WCL) were 
immunoblotted (IB) with the indicated antibodies.  Immunoblots are representative of three independent replicates. (B) Quantification of 
the three replicates of indicated immunoblots relative to total V5-AKT2. (C) Linear Model (LM) statistical analysis across all three 
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SUPPLEMENTARY FIGURE S12 
 
Proliferation assay. A. Results of a generalized linear model (GLM) applied on rescaled raw data (absorbance value) to test for 
significant difference in proliferation between the three rounds of analysis, the three variants and an interaction between round and 
variants. The rescaling was performed by dividing all the values in each round by the average absorbance in controls. The plots 
represent the GLM estimates (and 95% CI) for the B. Round:Variant interaction and individual variables: C. Round and D. Variants. * P 
< 0.05, ** P < 0.01, *** P < 0.001. DF: degrees of freedom, F: statistic testing the importance of the grouping term, Pr(>F): P value of 





Round 2 33.41% 1186.3 2.20E016
Variants 2 28.95% 1028.2 2.20E016
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AKT2 expression in human tissues. A. Boxplot displaying the level and distribution of AKT2 gene expression (in reads per kilobase 
per million mapped reads, RPKM) in 44 human tissues available in the GTEx RNA-seq data. B. Box plot of the expression (in RNA-seq 
reads) of the AKT2 exon of affected by the p.Pro50Thr variant. Read counts are not normalized by the total number of reads per 
sample, resulting in larger variance in the expression within each tissue. C. Heat map of expression patterns of the 28 AKT2 transcripts 
in the GTEx tissues, as annotated in Gencode version 12. Intensity of color in each cell represents the expression of the transcript in 
that tissue; white indicating no expression, and red indicating higher expression. D. Visualization of the transcript structure of AKT2 
(Gencode v12). The affected exon, highlighted with the red dashed line, is included in the majority of the AKT2 transcripts and in all the 
three most highly expressed transcripts. The tissues are presented in the same order across panels A-C, and colored similarly in panels 
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SUPPLEMENTARY FIGURE S14
 
Expression of the AKT gene family across human tissues. Each cluster of three boxplots represents the expression of AKT1 (left), 
AKT2 (middle) and AKT3 (right) in each tissue. AKT2 is the isoform with the highest expression (P-value < 0.05) in BRNCHA (Brain – 
Cerebellum), BRNCHB (Brain - Cerebellar Hemisphere), MSCLSK (Muscle – Skeletal) and PTTARY (Pituitary). Tissue abbreviations 
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AKT2 Pro50Thr G/T 0.0083 -0.980 8.9E-04 -0.754 8.4E-03 
Lead eSNP 
rs8104727 T/C 0.647 -0.403 3.6E-14 -0.391 1.9E-13 
 
Expression analysis with common eQTL SNP and AKT2 p.Pro50Thr. Top left plot: The regional association plot of variants in the 
AKT2 region testing association with AKT2 expression. The SNP showing the most significant signal in this plot, rs8104727, is a proxy 
for rs11880261 (r2 = 1, D’ = 1 in the 1000 Genomes phase 3 Finnish sample). Top right plot: observed AKT2 expression levels for the 
two AKT2 p.Pro50Thr genotypes observed in the METSIM cohort. Bottom table: eQTL statistics and reciprocal conditional analysis with 
the two SNPs: rs8104727and AKT2 p.Pro50Thr. The “Beta conditional” and “P conditional” columns highlight the associations with 
AKT2 expression after conditioning on the other SNP.	
P50T (chr19:40762860) 
METSIM lead eQTL SNP rs8104727 
(chr19:40760188) 
Regional association with AKT2 expression in METSIM 
(n=770) 
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Supplementary Tables 
SUPPLEMENTARY TABLE 1 . 
Details and characteristics of studies included in the analysis.  
Supplementary Table 1A: Study details including references, ascertainment, sample QC, variant QC and association covariates.  
Stage Ancestry Study Citation(s) PubMed ID(s) Sample Ascertainment 
Genotypin








[Finnish] FIN-D2D 2007 
Kotronen, A. et al. Non-alcoholic and alcoholic fatty liver 
disease - two diseases of affluence associated with the 
metabolic syndrome and type 2 diabetes: the FIN-D2D 
survey. BMC Public Health. 2010 May 10;10:237. 
20459722 
- Population-based survey 
- Glucose tolerance classified according to WHO 1999 criteria 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 
mmol/l or 2-h plasma glucose concentration ≥11.1 mmol/l) 
cases excluded 
- Further excluded individuals with HbA1c ≥6.5% according to 






- call rate ≤99% 
- heterozygosity >median + 
3*IQR 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers 
- sex discrepancy 
- contamination score >10% 
≥95% 
- exclude 101 indels with different allele mapping 
across the two sites 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate. If the call rate is the same, 
arbitrarily take the one with that comes first in the 
file 
- call rate <95% 




files + Zcall 
- age, age2, sex, 
BMI for EMMAX-
analysis 
- age, age2, sex, 
BMI, PC1, PC2, 






The Finnish Diabetes 
Prevention Study (DPS) 
Tuomilehto, J. et al. Prevention of type 2 diabetes 
mellitus by changes in lifestyle among subjects with 
impaired glucose tolerance. N Engl J Med. 2001 May 
3;344(18):1343-50. 
11333990 
- Randomised controlled trial 
- All subjects were impaired glucose tolerant at baseline, from 
mean of two OGTTs using WHO 1985 criteria 
- Excluded individuals with fasting plasma glucose ≥7.0 
mmol/l or 2-h plasma glucose concentration ≥11.1 mmol/l or  






- call rate ≤99% 
- heterozygosity >median + 
3*IQR 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers 
- sex discrepancy 
- contamination score >10% 
≥95% 
- exclude 101 indels with different allele mapping 
across the two sites 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate. If the call rate is the same, 
arbitrarily take the one with that comes first in the 
file 
- call rate <95% 





trained on using 
study samples + 
manual review 
of clusterplots 
- age, age2, sex, 
BMI for EMMAX-
analysis 
- age, age2, sex, 
BMI, PC1, PC2, 






The Dose Responses to 
Exercise Training (DR's 
EXTRA) Study 
Kouki, R. et al. Diet, fitness and metabolic syndrome--the 
DR's EXTRA study. Nutr Metab Cardiovasc Dis. 2012 
Jul;22(7):553-60. 
21186108 
- Randomised controlled trial 
- Glucose tolerance classified according to WHO 1999 criteria 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 
mmol/l or 2-h plasma glucose concentration ≥11.1 mmol/l or 





- call rate ≤99% 
- heterozygosity >median + 
3*IQR 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers 
- sex discrepancy 
- contamination score >10% 
≥95% 
- exclude 101 indels with different allele mapping 
across the two sites 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate. If the call rate is the same, 
arbitrarily take the one with that comes first in the 
file 
- call rate <95% 




files + Zcall 
- age, age2, sex, 
BMI for EMMAX-
analysis 
- age, age2, sex, 
BMI, PC1, PC2, 






National FINRISK 2007 
Study (FINRISK 2007) 
Vartiainen, E. et al. Thirty-five-year trends in 
cardiovascular risk factors in Finland. Int J Epidemiol. 
2010 Apr;39(2):504-18. 
19959603 
- T2D case control study 
- Glucose tolerance classified according to WHO 1999 criteria 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 






- call rate ≤99% 
- heterozygosity >median + 
3*IQR 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers 
- sex discrepancy 
- contamination score >10% 
≥95% 
- exclude 101 indels with different allele mapping 
across the two sites 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate. If the call rate is the same, 
arbitrarily take the one with that comes first in the 
file 
- call rate <95% 




files + Zcall 
- age, age2, sex, 
BMI for EMMAX-
analysis 
- age, age2, sex, 
BMI, PC1, PC2, 







Investigation of NIDDM 
Genetics (FUSION) Study 
Valle, T. et al. Mapping genes for NIDDM. Design of the 
Finland-United States Investigation of NIDDM Genetics 
(FUSION) Study. Diabetes Care. 1998 Jun;21(6):949-58.; 
Scott, L.J., et al. A genome-wide association study of 
type 2 diabetes in Finns detects multiple susceptibility 
variants. Science. 2007 Jun 1;316(5829):1341-5. 
9614613; 
17463248 
- T2D case control study 
- Glucose tolerance classified according to WHO 1999 criteria 
- T2D (fasting plasma glucose concentration ≥7.0 mmol/l or 2-
h plasma glucose concentration ≥11.1 mmol/l, by report of 
diabetes medication use, or based on medical record review), 






- call rate ≤99% 
- heterozygosity >median + 
3*IQR 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers 
- sex discrepancy 
- contamination score >10% 
≥95% 
- exclude 101 indels with different allele mapping 
across the two sites 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate. If the call rate is the same, 
arbitrarily take the one with that comes first in the 
file 
- call rate <95% 




files + Zcall 
- age, age2, sex, 
BMI, study origin 
for EMMAX-
analysis 
- age, age2, sex, 
BMI, study origin, 
PC1, PC2, PC3, 






Metabolic Syndrome in 
Men Study (METSIM) 
Stancáková, A. et al. Changes in insulin sensitivity and 
insulin release in relation to glycemia and glucose 
tolerance in 6,414 Finnish men. Diabetes. 2009 
May;58(5):1212-21. 
19223598 
- Population-based cross-sectional study 
- Glucose tolerance classified according to WHO 1997 criteria 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 
mmol/l or 2-h plasma glucose concentration ≥11.1 mmol/l) 
cases excluded 
- Further excluded individuals with HbA1c ≥6.5% according to 
ADA 2012 criteria for T2D 
HumanExo
me-12v1_A >99% 
- call rate ≤99% 
- heterozygosity >median + 
3*IQR 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers 
- sex discrepancy 
- contamination score >10% 
≥95% 
- exclude 101 indels with different allele mapping 
across the two sites 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate. If the call rate is the same, 
arbitrarily take the one with that comes first in the 
file 
- call rate <95% 





trained on using 
study samples + 
manual review 
of clusterplots 
- age, age2, BMI 
for EMMAX-
analysis 
- age, age2, BMI, 
PC1, PC2, PC3, 






Thuesen, B.H. et al. Cohort Profile: The Health2006 
cohort, Research Centre for Prevention and Health. Int J 
Epidemiol. 2013 Apr 24. 
23615486 
- Population-based cohort 
- Glucose tolerance classified according to WHO 1999 criteria 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 





- call rate <98% 
- heterozygosity  
- sex discrepancy 
- discordance with previous 
genotypes 
≥95% 
- exclude duplicated variants, keeping the one 
with higher call rate.  
- call rate <95% 
- HWE <10-4 




files + Zcall 
- age, age2, BMI for 
EMMAX-analysis 








Jørgensen, T. et al. A randomized non-pharmacological 
intervention study for prevention of ischaemic 
heart disease: baseline results Inter99. Eur J Cardiovasc 
Prev Rehabil. 2003 Oct;10(5):377-86. 
14663300 
- Population-based cohort 
- Glucose tolerance classified according to WHO 1999 criteria 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 






- call rate <98% 
- heterozygosity  
- sex discrepancy 
- discordance with previous 
genotypes 
≥95% 
- exclude duplicated variants, keeping the one 
with higher call rate.  
- call rate <95% 
- HWE <10-4 




files + Zcall 
- age, age2, BMI for 
EMMAX-analysis 







[Danish] Vejle Biobank 
Albrechtsen, A. et al. Exome sequencing-driven 
discovery of coding polymorphisms associated with 
common metabolic phenotypes. Diabetologia. 2013 
Feb;56(2):298-310. 
23160641 
- Controls from T2D case-control 
- Glucose tolerance classified according to WHO 1999 criteria 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 






- call rate <98% 
- heterozygosity  
- sex discrepancy 
- discordance with previous 
genotypes 
≥95% 
- exclude duplicated variants, keeping the one 
with higher call rate.  
- call rate <95% 
- HWE <10-4 




files + Zcall 
- age, age2, BMI for 
EMMAX-analysis 








Genetics of Diabetes 




Morris, A.D. et al. The diabetes audit and research in 
Tayside Scotland (DARTS) study: electronic record 
linkage to create a diabetes register. DARTS/MEMO 





- Population-based cohort 
- T2D cases, sample with fasting plasma glucose 






- call rate ≤99% 
- heterozygosity 4SD of mean 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers, or non-European 
reported ancestry 
- sex discrepancy 
>99% 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate.  
- call rate <98% for GenCall and <99% for zCall 
- exact HWE <10-4 





files + Zcall 
- age, age2, sex, 
and BMI for 
EMMAX-analysis 
- age, age2, sex, 







[UK] Twins UK 
Moayyeri A, Hammond CJ, Hart DJ, Spector TD. The UK 
Adult Twin Registry (TwinsUK Resource). Twin Res Hum 
Genet. 2013 Feb;16(1):144-9.  
23088889 
 
- Unrelated samples selected as controls from the Twins UK 
study 
- T1D and T2D cases and samples with recorded family 
history of diabetes, or if either twin was ever recorded as 
impaired glucose tolerant (defined as fasting plasma glucose 







- call rate ≤99% 
- heterozygosity 4SD of mean 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers, or non-European 
reported ancestry 
- sex discrepancy 
>99% 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate.  
- call rate <98% for GenCall and <99% for zCall 
- exact HWE <10-4 





files + Zcall 
- age, age2, sex, 
and BMI for 
EMMAX-analysis 
- age, age2, sex, 
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[UK] Oxford BioBank (OBB) http://www.oxfordbiobank.org.uk/ NA 
- T2D cases (on diabetic treatment or fasting glucose  ≥7 





- call rate ≤99% 
- heterozygosity 4SD of mean 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers, or non-European 
reported ancestry 
- sex discrepancy 
>99% 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate.  
- call rate <98% for GenCall and <99% for zCall 
- exact HWE <10-4 





files + Zcall 
- age, age2, sex, 
and BMI for 
EMMAX-analysis 
- age, age2, sex, 










the Vasculature in 
Uppsala Seniors (PIVUS) 
Lind, L. et al. A comparison of three different methods to 
evaluate endothelium-dependent vasodilation in the 
elderly: the Prospective Investigation of the Vasculature 
in Uppsala Seniors (PIVUS) study. Arterioscler Thromb 
Vasc Biol. 2005 Nov;25(11):2368-75. 
16141402 
- Population-based cohort 
- T1D, T2D cases or fasting plasma glucose concentration ≥7 






- call rate ≤99% 
- heterozygosity 4SD of mean 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers 
- sex discrepancy 
>99% 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate.  
- call rate <98% for GenCall and <99% for zCall 
- exact HWE <10-4 





files + Zcall 
- age, age2, sex, 
and BMI for 
EMMAX-analysis 
- age, age2, sex, 









Study of Adult Men 
(ULSAM) 
Hedstrand, H. A study of middle-aged men with particular 
reference to risk factors for cardiovascular disease. Ups J 
Med Sci Suppl. 1975;19:1-61. 
1216390 
- Population-based cohort 
- T1D, T2D cases or fasting plasma glucose concentration ≥7 





- call rate ≤99% 
- heterozygosity 4SD of mean 
- technical duplicates with lower 
call rate 
- Non-European population 
outliers 
- sex discrepancy 
>99% 
- exclude variants that had chromosome or 
position or allele mismatch 
- exclude duplicated variants, keeping the one 
with higher call rate.  
- call rate <98% for GenCall and <99% for zCall 
- exact HWE <10-4 





files + Zcall 
- age, age2, and 
BMI for EMMAX-
analysis 
- age, age2, sex, 









and Prevention of 
Diabetes (PPP)-Botnia 
study 
Isomaa, B. et al. A family history of diabetes is associated 
with reduced physical fitness in the Prevalence, 
Prediction and Prevention of Diabetes (PPP)-Botnia 
study. Diabetologia. 2010 Aug;53(8):1709-13.  
20454776 
- Population-based cohort  
- T1D, T2D cases or fasting plasma glucose concentration ≥7 






-call rate ≤99% 
- heterozygosity 4SD of mean 
- gender discordance 
- GWAS discordance 
- genotyping platform fingerprint 
discordance 
- population outliers 
>99% 
- genotyping cluster checks within batches, 
outliers removed. 
- exact HWE <10-4 
Birdseed with 
cluster filter 
- age, age2, and 
BMI for EMMAX-
analysis 
- age, age2, sex, 
BMI, PC1, PC2, 






American Jackson Heart Study (AJ) 
Taylor, H. A. et al. Toward resolution of cardiovascular 
health disparities in African Americans: design and 
methods of the Jackson Heart Study. Ethn Dis 15, S6–4 
(2005) 
16320381 
- No T2D by ADA 2004 definition, fasting plasma glucose 
<100 mg/dl, and HbA1c <6% at each of two exams 
- Controls were matched to cases in a two-stage approach: 
1. Strong matches (greedy algorithm): age > 50, sex match, 
BMI within 1 unit, and age within 5 years (N=457 matched 
pairs) 
2. Closest available matches: sex match and BMI > 25; for 
females, BMI within 5 units and age within 20 years; for 













- poor quality 
samples removed 













(VSQR) for SNVs, 
and hard filtering 
for INDELs after 
genotype calling 
with GATK 
- using autosomal 
variants that 
passed extended 
QC and with 
MAF>1% in all 





each pair of 




ethnic r2<0.05) and 
constructed axes 









duplicates on the 
basis of IBS, and 
excluded the 
sample from each 





- sequence reads from all 
exome sequenced samples 
processed  jointly and aligned 
to the reference genome (hg19) 
with Picard 
(http://picard.sourceforge.net) 
- polymorphic sites and 
genotypes called with GATK 
(https://www.broadinstitute.org/
gatk/) 
- poor quality samples and 
variants removed on the basis 
of multiple metrics: array 
genotype concordance (where 
available), mean heterozygosity 
and homozygosity, high 
singleton counts for samples, 
Variant Quality Score 
Recalibration (VSQR) for SNVs, 
and hard filtering for INDELs.   
-  within each ancestry group 
(African-American, East-Asian, 
European, Hispanic, and 
South-Asian), extended QC 
further excluded variants on the 
basis of call rate (<90% in any 
study in ancestry group), 
deviation from Hardy-Weinberg 
equilibrium (exact p<10-6, 
females only for X 
chromosome, in any study in 
ancestry group) or differential 
call rate between T2D cases 
and controls (p<10-4, all 
studies combined across 
ancestry group) 
'- within each 
study, age, sex, 








Wake Forest School of 
Medicine Study (AW) 
Palmer, N. D. et al. A genome-wide association search 
for type 2 diabetes genes in African Americans. PLoS 
One 7:e29202. (2012) 
22238593 
- No current diagnosis of diabetes or renal disease 







Research Project (EK) 
Cho, Y. S. et al. A large-scale genome-wide association 
study of Asian populations uncovers genetic factors 
inﬂuencing eight quantitative traits. Nat. Genet. 41, 527–
534 (2009) 
19396169 
- No past history of diabetes  
- No anti-diabetic medication 
- Fasting plasma glucose <5.6 mmol/l and plasma glucose 2 
hours after ingestion of 75g oral glucose load <7.8 mmol/l at 
both baseline and follow up timepoints 







Cohort Study and 
Singapore Prospective 
Study Program (ES) 
Sim, X. et al. Transferability of type 2 diabetes implicated 
loci in multi-ethnic cohorts from Southeast Asia. PLoS 
Genet. 7(4), e1001363 (2011) 
21490949 
- Fasting blood glucose <6 mmol/l   
- No personal history of diabetes  
- No anti-diabetic medication 







Atzmon, G. et al. Lipoprotein genotype and conserved 
pathway for exceptional longevity in humans. PLoS Biol. 
4(4), e113 (2006); Atzmon, G. et al. Evolution in health 
and medicine Sackler colloquium: Genetic variation in 
human telomerase is associated with telomere length in 
Ashkenazi centenarians. Proc Natl Acad Sci U S A. 107 
(Suppl 1), 1710-1717 (2010); Permutt, M.A. et al. A 
genome scan for type 2 diabetes susceptibility loci in a 
genetically isolated population. Diabetes 50(3), 681-685 
(2001); Blech et al. Predicting diabetic nephropathy using 







- Fasting blood glucose <7 mmol/l  
- No personal history of diabetes 





Metabolic Syndrome in 
Men Study (METSIM) 
Stancakova, A. et al. Changes in insulin sensitivity and 
insulin release in relation to glycemia and glucose 
tolerance in 6,414 Finnish men. Diabetes 58, 1212–1221 
(2009) 
19223598 
- Normal glucose tolerance at baseline and follow-up visits 
- Prioritized samples with no family history of diabetes and 
meeting strict NGT criteria: fasting glucose <5.6 mmol/l and 2 
hour post-challenge glucose <7.8 mmol/l 
- Additional samples selected with fasting glucose <6.1 mmol/l 
and 2 hour post-challenge glucose <7.8 mmol/l 
- Unrelated samples 






Investigation of NIDDM 
Genetics (FUSION) Study 
 
Valle, T. et al. Mapping genes for NIDDM. Design of the 
Finland-United States Investigation of NIDDM Genetics 
(FUSION) Study. Diabetes Care 21(6), 949-958 (1998); 
Scott, L. et al. A genome-wide association study of type 2 
diabetes in Finns detects multiple susceptibility variants. 





- Unrelated controls with normal glucose tolerance (NGT) 
based on WHO (1999) definitions: fasting plasma glucose 
<6.1 mM and 2 hour postload glucose during an OGTT <7.8 
mM 
- Frequency matched to cases by birth province; BMI 
≥18.5kg/m2; age ≤80 
- Within each birth province, prioritized samples from stage 2 





Wichmann, H. E., Gieger, C. and Illig, T. KORA-gen–
resource for population genetics, controls and a broad 
spectrum of disease phenotypes. Gesundheitswesen 67 
Suppl 1, 26–30 (2005) 
16032514 
- Controls selected from KORA F4 
- All controls are normal glucose tolerant: fasting glucose level 
<6.1 mmol/l and two hour glucose level after oral glucose 
tolerance test <7.8 mmol/l 
- Controls are either >60 years of age with BMI >32 or over 65 




[UK] UKT2D Consortium 
Wellcome Trust Case Control Consortium. Genome-wide 
association study of 14,000 cases of seven common 
diseases and 3,000 shared controls. Nature 447, 661–78 
(2007); Voight, B.F. et al. Twelve type 2 diabetes 
susceptibility loci identiﬁed through large-scale 
association analysis. Nat. Genet. 42, 579–589 (2010); 
Spector, T.D. and Williams, F.M. The UK Adult Twin 





- Unrelated samples selected as controls from the Twins UK 
study 
- A twin pair was considered for selection if there was no 
recorded family history of diabetes, neither twin was ever 
recorded as impaired glucose tolerant (defined as fasting 
glucose >6.1mmol/L in any reading), there were available 
quantitative trait and genetic (GWAs) data, and no evidence 
of admixture in MDS analysis of GWAs data 
- From set of qualifying twin pairs, the best control twin was 
selected from each pair with the lowest ratio of fasting glucose 
level to BMI across all readings, and further prioritization of 
the qualifying unrelated samples involved selecting samples 
that had the lowest fasting glucose to (BMI * age) ratios 
- Top two principal components were used to perform 
pairwise sample matching between cases and possible 
controls, and the best control for each case was selected 
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Malmo-Botnia Study  
Groop, L. et al. Metabolic consequences of a family 
history of NIDDM (the Botnia study): evidence for sex-
speciﬁc parental effects. Diabetes 45, 1585–93 (1996); 
Lindholm, E., Agardh, E., Tuomi, T., Groop, L. & Agardh, 
C. D. Classifying diabetes according to the new WHO 
clinical stages. Eur. J. of Epid. 17, 983–9 (2001); Parker, 
A. et al. A gene conferring susceptibility to type 2 
diabetes in conjunction with obesity is located on 
chromosome 18p11. Diabetes 50, 675–80 (2001); 
Berglund G. et al. The Malmo Diet and Cancer Study. 
Design and feasibility. J Intern Med. Jan;233(1):45-51 
(1993). Berglund, G. et al. Long-term outcome of the 
Malmo Preventive Project: Mortality and cardiovascular 
morbidity. J. of Intern. Med. 247, 19–29 (2000); 
Lyssenko, V. et al. Clinical risk factors, DNA variants, and 
the development of type 2 diabetes. NEJM 359, 2220–32 
(2008); Isomaa, B. et al. A family history of 
diabetes is associated with reduced physical fitness in 
the Prevalence, 
Prediction and Prevention of Diabetes (PPP)-Botnia 
study. Diabetologia. Aug;53(8):1709-13 (2010); Bøg-
Hansen, E. et al. Risk 
factor clustering in patients with hypertension and non-
insulin-dependent 
diabetes mellitus. The Skaraborg Hypertension Project. J 









- Controls selected from the extreme of a liability score 
distribution, based upon gender, age and BMI at last follow-up 
visit; only BMI and gender used to construct scores for Malmö 
study 
- Eligible controls limited to individuals above 35 years of age 
at follow-up and with a BMI between 20 and 40 
- To match for ethnicity, equal numbers of controls were 
selected from the Botnia and Malmö studies 
Discovery 
[ExomeSeq] Hispanic 
San Antonio Family Heart 




Epidemiology Study, and 
the Investigation of 
Nephropathy and 
Diabetes Study family 
component (HA) 
Mitchell, B. D. et al. Genetic and environmental 
contributions to cardiovascular risk factors in Mexican 
Americans. The San Antonio Family Heart Study. 
Circulation 94, 2159–2170 (1996); Hunt, K. J. et al. 
Genome-wide linkage analyses of type 2 diabetes in 
Mexican Americans: the San Antonio Family 
Diabetes/Gallbladder Study. Diabetes 54, 2655–2662 
(2005); Coletta, D. K. et al. Genome-wide linkage scan 
for genes inﬂuencing plasma triglyceride levels in the 
Veterans Administration Genetic Epidemiology Study. 
Diabetes 58, 279–284 (2009); Knowler, W. C. et al. The 
Family Investigation of Nephropathy and Diabetes 






- Fasting glucose <126 mg/dl at each visit 
- If OGTT performed, 2 hour glucose must be <200mg/dl 
- No self-reported antidiabetic therapy at any visit, including 
oral agents or insulin prescribed as a result of physician-
diagnosed diabetes 
- Prioritize samples with strict NGT with no family history first, 
then NGT in two visits, followed by oldest age    
Discovery 
[ExomeSeq] Hispanic Starr County, Texas (HS) 
Hanis, C. L. et al. Diabetes among Mexican Americans in 
Starr County, Texas. Am. J. Epidemiol. 118, 659–672 
(1983); Below JE, et al. Genome-wide association and 
meta-analysis in populations from Starr County, Texas 
and Mexico City identify type 2 diabetes susceptibility loci 
and enrichment for eQTLs in top signals. Diabetologia 
54, 2047-2055 (2011) 
6637993 
21573907 
- Controls ascertained from epidemiologically represented 
sample of individuals in Starr County, TX 
- Individuals with known diagnosis of diabetes excluded 
- Impaired glucose tolerant and impaired fasting glucose 
controls retained due to the age difference between cases 
and controls (controls are younger on average) and to allow 






London Life Sciences 
Population Study (SL) 
Chambers, J.C. et al. Genome-wide association study 
identifies variants in TMPRSS6 associated with 
hemoglobin levels. Nat. Genet. 41, 1170-1172 (2009); 
Chambers, J.C. et al. Common genetic variation near 
melatonin receptor MTNR1B contributes to raised plasma 
glucose and increased risk of type 2 diabetes among 
Indian Asians and European Caucasians. Diabetes 58, 
2703-2708 (2009); van der Harst, P. et al. Seventy-five 
genetic loci influencing the human red blood cell. Nature 




- No previous history of diabetes 
- No anti-diabetic medication 






Singapore Indian Eye 
Study (SS) 
Sim, X. et al. Transferability of type 2 diabetes implicated 
loci in multi-ethnic cohorts from Southeast Asia. PLoS 
Genet. 7(4), e1001363 (2011) 
21490949 
- HbA1c <6% 
- No personal history of diabetes 
- Not taking antidiabetes medication 





The Cardiovascular Risk 
in Young Finns Study 
(YFS) 
Raitakari, O.T.  et al. Cohort profile: the cardiovascular 
risk in Young Finns Study. Int. J. Epidemiol., 37, 1220–
1226 (2008) 
18263651 
- Population-based survey 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 
mmol/l or on diabetes medication) cases excluded 




670K array  
≥95% 
- excessive heterozygosity 
- closely related individuals 
- sex discrepancy 





Helsinki Birth Cohort 
Study (HBCS) 
Eriksson, J.G.  Epidemiology, genes and the 
environment: lessons learned from the Helsinki Birth 
Cohort Study. J. Intern. Med., 261, 418–425 (2007) 
17444881 
- Birth cohort 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 




670K array  
≥95% 
- excessive heterozygosity 
- closely related individuals 
- sex discrepancy 





The Health 2000 GenMets 
Study (GenMets) 
Perttila, J. et al. OSBPL10, a novel candidate gene for 
high triglyceride trait in dyslipidemic Finnish subjects, 
regulates cellular lipid metabolism. J. Mol. Med., 87, 825–
835 (2009) 
19554302 
- Population-based survey 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 
mmol/l or on diabetes medication) cases excluded 
Illumina 
610K array  ≥95% 
- excessive heterozygosity 
- closely related individuals 
- sex discrepancy 





The National FINRISK 
Study 1997 and 2002 
(FINRISK 1997 and 2002) 
Vartiainen E. et al. Thirty-five-year trends in 
cardiovascular risk factors in Finland. Int J Epidemiol., 39, 
504-518  (2010) 
19959603 
- Population-based survey 
- T1D and T2D (fasting plasma glucose concentration ≥7.0 
mmol/l or on diabetes medication) cases excluded 






- excessive heterozygosity 
- closely related individuals 
- sex discrepancy 
≥95% - call rate <95% See methods - age,  sex, BMI, PCs 1-10 
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 Ancestry European [Finnish] European [Finnish] European [Finnish] European [Finnish] European [Finnish] European [Finnish] European [Danish] 
European 
[Danish] European [Danish] European [UK] European [UK] European [UK] European [Swedish] European [Finnish] 
 Study FIN-D2D 2007 
The Finnish Diabetes 
Prevention Study 
(DPS) 
The Dose Responses 
to Exercise Training 
(DR's EXTRA) Study 
National FINRISK 2007 
Study (FINRISK 2007) 
Finland-United States 
Investigation of NIDDM 
Genetics (FUSION) 
Study 
Metabolic Syndrome in 
Men  
(METSIM) 
Health2006 Inter99 Vejle Biobank 
Genetics of Diabetes 
Audit and Research 
Tayside (GoDARTS) 
Twins UK Oxford BioBank (OBB) Pivus and Ulsam 
Prevalence, Prediction 
and Prevention of 
Diabetes (PPP)-Botnia 
study 
Single variant analysis 
(relateds) # available 2132 328 622 549 1414 6599 3371 5546 439 802 701 4513 1859 4533 
 
Mean fasting glucose 
(SD), mmol/l F: 5.79 (0.45) F: 5.86 (0.59) F: 5.45 (0.47) F: 5.58 (0.30) F: 5.22 (0.46) F: 0 (0) F: 5.31 (0.52) F: 5.28 (0.47) F: 5.07 (0.32) F: 4.81 (0.45) F: 4.71 (0.59) F: 5.11 (0.41) F: 4.96 (0.56) F: 5.24 (0.54) 
  M: 6.04 (0.43) M: 5.93 (0.54) M: 5.68 (0.48) M: 5.71 (0.27) M: 5.37 (0.49) M: 5.72 (0.48) M: 5.58 (0.51) M: 5.58 (0.48) M: 5.19 (0.3) M: 4.98 (0.48) M: 4.88 (0.64) M: 5.41 (0.45) M: 5.26 (0.58) M: 5.29 (0.56) 
 # Females (%) 1154 (54.13) 224 (68.29) 448 (72.03) 328 (59.74) 653 (46.18) 0 (0.00) 1459 (43.3) 2626 (47.3) 147 (33.5) 369 (46.01) 582 (83.02) 2474 (54.82) 444 (23.88) 2448 (0.54) 
 Mean age (SD), years F: 58.76 (8.23) F: 55.06 (7.19) F: 66.29 (5.22) F: 63.97 (7.53) F: 62.65 (7.70) F: 0 (0) F: 47.89 (12.32) F: 45.45 (7.91) F: 55 (12.5) F: 57.07 (11.09) F: 44.13 (12.98) F: 41.57 (5.98) F: 70.26 (0.15) F: 48.73 (15.67) 
  M: 59.49 (8.44) M: 56.10 (7.16) M: 67.90 (6.38) M: 65.64 (6.49) M: 60.40 (8.11) M: 57.40 (7.24) M: 48.77 (12.14) M: 45.83 (7.82) M: 62.36 (10.21) M: 58.95 (10.80) M: 45.18 (12.06) M: 42.04 (5.62) M: 70.72 (0.67) M: 48.43 (15.56) 
 Mean BMI (SD), kg/m
2 F: 27.00 (4.96) F: 31.78 (4.88) F: 27.23 (4.66) F: 30.08 (4.91) F: 26.52 (4.24) F: 0 (0) F: 25.11 (4.7) F: 25.46 (4.77) F: 21.75 (1.92) F: 26.61 (4.78) F: 23.75 (4.01) F: 25.44 (4.80) F: 26.92 (4.70) F: 25.85 (4.66) 
  M: 26.81 (3.74) M: 29.54 (3.46) M: 27.25 (3.59) M: 28.59 (3.85) M: 26.56 (3.49) M: 26.89 (3.83) M: 26.37 (3.84) M: 26.58 (3.86) M: 23.05 (1.47) M: 27.59 (4.05) M: 23.81 (3.85) M: 26.61 (4.00) M: 26.17 (3.37) M: 26.66 (3.75) 
 # available (with BMI) 2128 328 622 549 1414 6597 3369 5542 439 801 701 4513 1857 4532 
 
Mean fasting glucose 
(SD), mmol/l F: 5.79 (0.45) F: 5.86 (0.59) F: 5.45 (0.47) F: 5.58 (0.30) F: 5.22 (0.46) F: 0 (0) F: 5.31 (0.52) F: 5.28 (0.47) F: 5.07 (0.32) F: 4.81 (0.45) F: 4.71 (0.59) F: 5.11 (0.41) F: 4.96 (0.56) F: 5.24 (0.54) 
  M: 6.04 (0.42) M: 5.93 (0.54) M: 5.68 (0.48) M: 5.71 (0.27) M: 5.37 (0.49) M: 5.72 (0.48) M: 5.58 (0.51) M: 5.58 (0.48) M: 5.19 (0.3) M: 4.98 (0.48) M: 4.88 (0.64) M: 5.41 (0.45) M: 5.26 (0.58) M: 5.29 (0.56) 
 # Females (%) 1152 (54.14) 224 (68.29) 448 (72.03) 328 (59.74) 653 (46.18) 0 (0.00) 1459 (43.3) 2625 (47.4) 147 (33.5) 368 (45.94) 582 (83.02) 2474 (54.82) 444 (23.91) 2447 (0.54) 
 Mean age (SD), years F: 58.77 (8.23) F: 55.06 (7.19) F: 66.29 (5.22) F: 63.97 (7.53) F: 62.65 (7.70) F: 0 (0) F: 47.9 (12.31) F: 45.46 (7.91) F: 55 (12.5) F: 57.04 (11.09) F: 44.13 (12.98) F: 41.57 (5.98) F: 70.26 (0.15) F: 48.73 (15.67) 
  M: 59.47 (8.43) M: 56.10 (7.16) M: 67.90 (6.38) M: 65.64 (6.49) M: 60.40 (8.11) M: 57.40 (7.24) M: 48.77 (12.14) M: 45.84 (7.82) M: 62.36 (10.21) M: 58.95 (10.80) M: 45.18 (12.06) M: 42.04 (5.62) M: 70.72 (0.67) M: 48.43 (15.56) 
 Mean BMI (SD), kg/m
2 F: 27.00 (4.96) F: 31.78 (4.88) F: 27.23 (4.66) F: 30.08 (4.91) F: 26.52 (4.24) F: 0 (0) F: 25.11 (4.7) F: 25.46 (4.77) F: 21.75 (1.92) F: 26.68 (4.78) F: 23.75 (4.01) F: 25.44 (4.80) F: 26.92 (4.70) F: 25.85 (4.66) 
  M: 26.81 (3.74) M: 29.54 (3.46) M: 27.25 (3.59) M: 28.59 (3.85) M: 26.56 (3.49) M: 26.89 (3.83) M: 26.37 (3.84) M: 26.58 (3.86) M: 23.05 (1.47) M: 27.59 (4.05) M: 23.81 (3.85) M: 26.61 (4.00) M: 26.21 (3.37) M: 26.66 (3.75) 
 # available 2111 306 657 548 1342 6596 3370 5337 0 244 0 4136 1853 4492 
 
Mean fasting insulin 
(SD), pmol/l F: 40.90 (20.63) F: 82.99 (41.26) F: 41.66 (25.96) F: 40.74 (21.64) F: 52.18 (33.05) F: 0 (0) F: 37.98 (24.96) F: 38.73 (25.22) NA F: 64.15 (31.44) NA F: 94.71 (39.61) F: 58.00 (35.62) F: 8.46 (6.6) 
  M: 43.84 (26.76) M: 84.39 (42.06) M: 44.82 (32.97) M: 37.02 (19.73) M: 49.27 (30.38) M: 50.70 (36.47) M: 40.78 (28.24) M: 42.59 (27.82) NA M: 80.97 (55.91) NA M: 105.54 (51.97) M: 77.45 (45.29) M: 9.16 (7.5) 
 # Females (%) 1141 (54.05) 214 (69.93) 472 (71.84) 327 (59.67) 632 (47.09) 0 (0.00) 1458 (43.3) 2538 (47.6) NA 127 (52.05) NA 2240 (54.16) 445 (24.02) 2426 (0.54) 
 Mean age (SD), years F: 58.75 (8.23) F: 54.98 (7.09) F: 66.33 (5.21) F: 64.02 (7.48) F: 62.71 (7.80) F: 0 (0) F: 47.89 (12.32) F: 45.4 (7.92) NA F: 56.40 (10.82) NA F: 41.65 (5.99) F: 70.26 (0.15) F: 48.69 (15.68) 
  M: 59.49 (8.46) M: 55.77 (7.27) M: 67.89 (6.34) M: 65.64 (6.49) M: 60.70 (8.11) M: 57.40 (7.24) M: 48.78 (12.14) M: 45.82 (7.8) NA M: 60.04 (9.25) NA M: 42.11 (5.63) M: 70.72 (0.67) M: 48.39 (15.53) 
 Mean BMI (SD), kg/m
2 F: 27.01 (4.97) F: 31.92 (4.89) F: 27.19 (4.66) F: 30.05 (4.89) F: 26.52 (4.23) F: 0 (0) F: 25.11 (4.7) F: 25.5 (4.79) NA F: 25.66 (4.29) NA F: 25.46 (4.75) F: 26.92 (4.69) F: 25.85 (4.66) 
  M: 26.79 (3.73) M: 29.64 (3.47) M: 27.10 (3.58) M: 28.59 (3.85) M: 26.51 (3.42) M: 26.89 (3.83) M: 26.37 (3.83) M: 26.58 (3.87) NA M: 27.36 (3.02) NA M: 26.58 (3.97) M: 26.18 (3.38) M: 26.67 (3.759) 
 # available (with BMI) 2107 306 657 548 1342 6594 3368 5333 0 244 NA 4136 1851 4491 
 
Mean fasting insulin 
(SD), pmol/l F: 40.91 (20.65) F: 82.99 (41.26) F: 41.66 (25.96) F: 40.74 (21.64) F: 52.18 (33.05) F: 0 (0) F: 37.96 (24.96) F: 38.7 (25.2) NA F: 64.15 (31.44) NA F: 94.71 (39.61) F: 58.00 (35.62) F: 8.46 (6.6) 
  M: 43.79 (26.74) M: 84.39 (42.06) M: 44.82 (32.97) M: 37.02 (19.73) M: 49.27 (30.38) M: 50.70 (36.47) M: 40.78 (28.24) M: 42.6 (27.82) NA M: 80.97 (55.91) NA M: 105.54 (51.97) M: 77.40 (45.19) M: 9.16 (7.5) 
 # Females (%) 1139 (54.06) 214 (69.93) 472 (71.84) 327 (59.67) 632 (47.09) 0 (0.00) 1458 (43.3) 2537 (47.6) NA 127 (52.05) NA 2240 (54.16) 445 (24.04) 2425 (0.54) 
 Mean age (SD), years F: 58.77 (8.23) F: 54.98 (7.09) F: 66.33 (5.21) F: 64.02 (7.48) F: 62.71 (7.80) F: 0 (0) F: 47.9 (12.31) F: 45.41 (7.92) NA F: 56.40 (10.82) NA F: 41.65 (5.99) F: 70.26 (0.15) F: 48.69 (15.69) 
  M: 59.47 (8.45) M: 55.77 (7.27) M: 67.89 (6.34) M: 65.64 (6.49) M: 60.70 (8.11) M: 57.40 (7.24) M: 48.78 (12.14) M: 45.82 (7.8) NA M: 60.04 (9.25) NA M: 42.11 (5.63) M: 70.72 (0.67) M: 48.39 (15.53) 
 Mean BMI (SD), kg/m
2 F: 27.01 (4.97) F: 31.92 (4.89) F: 27.19 (4.66) F: 30.05 (4.89) F: 26.52 (4.23) F: 0 (0) F: 25.11 (4.7) F: 25.5 (4.79) NA F: 25.66 (4.29) NA F: 25.46 (4.75) F: 26.92 (4.69) F: 25.85 (4.66) 
  M: 26.79 (3.73) M: 29.64 (3.47) M: 27.10 (3.58) M: 28.59 (3.85) M: 26.51 (3.42) M: 26.89 (3.83) M: 26.37 (3.83) M: 26.58 (3.87) NA M: 27.36 (3.02) NA M: 26.58 (3.97) M: 26.22 (3.38) M: 26.67 (3.759) 
Gene-level analysis 
(unrelateds) # available 2132 328 622 549 1414 6599 3159 5481 431 801 697 4442 1804 4206 
 
Mean fasting glucose 
(SD), mmol/l F: 5.79 (0.45) F: 5.86 (0.59) F: 5.45 (0.47) F: 5.58 (0.30) F: 5.22 (0.46) F: 0 (0) F: 5.31 (0.51) F: 5.28 (0.47) F: 5.08 (0.32) F: 4.81 (0.45) F: 4.71 (0.59) F: 5.11 (0.41) F: 4.96 (0.56) F: 5.24 (0.55) 
  M: 6.04 (0.43) M: 5.93 (0.54) M: 5.68 (0.48) M: 5.71 (0.27) M: 5.37 (0.49) M: 5.72 (0.48) M: 5.58 (0.5) M: 5.58 (0.48) M: 5.19 (0.3) M: 4.98 (0.48) M: 4.87 (0.64) M: 5.41 (0.45) M: 5.26 (0.58) M: 5.29 (0.56) 
 # Females (%) 1154 (54.13) 224 (68.29) 448 (72.03) 328 (59.74) 653 (46.18) 0 (0.00) 1371 (43.4) 2593 (47.3) 145 (33.6) 369 (46.07) 580 (83.21) 2430 (54.71) 437 (24.22) 2302 (0.55) 
 Mean age (SD), years F: 58.76 (8.23) F: 55.06 (7.19) F: 66.29 (5.22) F: 63.97 (7.53) F: 62.65 (7.70) F: 0 (0) F: 48.03 (12.17) F: 45.46 (7.91) F: 55.05 (12.61) F: 57.07 (11.09) F: 44.19 (12.95) F: 41.57 (5.99) F: 70.26 (0.15) F: 48.7 (15.53) 
  M: 59.49 (8.44) M: 56.10 (7.16) M: 67.90 (6.38) M: 65.64 (6.49) M: 60.40 (8.11) M: 57.40 (7.24) M: 48.87 (12.06) M: 45.85 (7.81) M: 62.29 (10.26) M: 58.92 (10.80) M: 45.08 (12.12) M: 42.09 (5.61) M: 70.72 (0.67) M: 48.36 (15.58) 
 Mean BMI (SD), kg/m
2 F: 27.00 (4.96) F: 31.78 (4.88) F: 27.23 (4.66) F: 30.08 (4.91) F: 26.52 (4.24) F: 0 (0) F: 25.13 (4.75) F: 25.47 (4.77) F: 21.73 (1.93) F: 26.61 (4.78) F: 23.76 (4.01) F: 25.43 (4.81) F: 26.93 (4.71) F: 25.87 (4.64) 
  M: 26.81 (3.74) M: 29.54 (3.46) M: 27.25 (3.59) M: 28.59 (3.85) M: 26.56 (3.49) M: 26.89 (3.83) M: 26.36 (3.85) M: 26.58 (3.84) M: 23.03 (1.47) M: 27.60 (4.05) M: 23.79 (3.82) M: 26.60 (4.00) M: 26.18 (3.40) M: 26.59 (3.749) 
 # available (with BMI) 2128 328 622 549 1414 6597 3157 5477 431 800 697 4442 1802 4205 
 
Mean fasting glucose 
(SD), mmol/l F: 5.79 (0.45) F: 5.86 (0.59) F: 5.45 (0.47) F: 5.58 (0.30) F: 5.22 (0.46) F: 0 (0) F: 5.31 (0.51) F: 5.28 (0.47) F: 5.08 (0.32) F: 4.81 (0.45) F: 4.71 (0.59) F: 5.11 (0.41) F: 4.96 (0.56) F: 5.24 (0.55) 
  M: 6.04 (0.42) M: 5.93 (0.54) M: 5.68 (0.48) M: 5.71 (0.27) M: 5.37 (0.49) M: 5.72 (0.48) M: 5.58 (0.5) M: 5.58 (0.48) M: 5.19 (0.3) M: 4.98 (0.48) M: 4.87 (0.64) M: 5.41 (0.45) M: 5.26 (0.58) M: 5.29 (0.56) 
 # Females (%) 1152 (54.14) 224 (68.29) 448 (72.03) 328 (59.74) 653 (46.18) 0 (0.00) 1371 (43.4) 2592 (47.3) 145 (33.6) 368 (46.00) 580 (83.21) 2430 (54.71) 437 (24.25) 2301 (0.55) 
 Mean age (SD), years F: 58.77 (8.23) F: 55.06 (7.19) F: 66.29 (5.22) F: 63.97 (7.53) F: 62.65 (7.70) F: 0 (0) F: 48.04 (12.16) F: 45.47 (7.91) F: 55.05 (12.61) F: 57.04 (11.09) F: 44.19 (12.95) F: 41.57 (5.99) F: 70.26 (0.15) F: 48.69 (15.53) 
  M: 59.47 (8.43) M: 56.10 (7.16) M: 67.90 (6.38) M: 65.64 (6.49) M: 60.40 (8.11) M: 57.40 (7.24) M: 48.87 (12.06) M: 45.85 (7.81) M: 62.29 (10.26) M: 58.92 (10.80) M: 45.08 (12.12) M: 42.09 (5.61) M: 70.72 (0.67) M: 48.36 (15.58) 
 Mean BMI (SD), kg/m
2 F: 27.00 (4.96) F: 31.78 (4.88) F: 27.23 (4.66) F: 30.08 (4.91) F: 26.52 (4.24) F: 0 (0) F: 25.13 (4.75) F: 25.47 (4.77) F: 21.73 (1.93) F: 26.68 (4.78) F: 23.76 (4.01) F: 25.43 (4.81) F: 26.93 (4.71) F: 25.87 (4.64) 
  M: 26.81 (3.74) M: 29.54 (3.46) M: 27.25 (3.59) M: 28.59 (3.85) M: 26.56 (3.49) M: 26.89 (3.83) M: 26.36 (3.85) M: 26.58 (3.84) M: 23.03 (1.47) M: 27.60 (4.05) M: 23.79 (3.82) M: 26.60 (4.00) M: 26.22 (3.40) M: 26.59 (3.749) 
 # available 2111 306 657 548 1342 6596 3158 5272 0 244 0 4075 1799 4171 
 
Mean fasting insulin 
(SD), pmol/l F: 40.90 (20.63) F: 82.99 (41.26) F: 41.66 (25.96) F: 40.74 (21.64) F: 52.18 (33.05) F: 0 (0) F: 37.99 (24.95) F: 38.68 (25.22) NA F: 64.15 (31.44) NA F: 94.69 (39.65) F: 58.06 (35.82) F: 8.42 (6.1) 
  M: 43.84 (26.76) M: 84.39 (42.06) M: 44.82 (32.97) M: 37.02 (19.73) M: 49.27 (30.38) M: 50.70 (36.47) M: 40.9 (28.46) M: 42.59 (27.79) NA M: 80.97 (55.91) NA M: 105.55 (51.87) M: 77.50 (45.65) M: 9.02 (7.1) 
 # Females (%) 1141 (54.05) 214 (69.93) 472 (71.84) 327 (59.67) 632 (47.09) 0 (0.00) 1370 (43.4) 2505 (47.5) NA 127 (52.05) NA 2204 (54.09) 438 (24.35) 2283 (0.55) 
 Mean age (SD), years F: 58.75 (8.23) F: 54.98 (7.09) F: 66.33 (5.21) F: 64.02 (7.48) F: 62.71 (7.80) F: 0 (0) F: 48.03 (12.17) F: 45.41 (7.92) NA F: 56.40 (10.82) NA F: 41.64 (6.00) F: 70.26 (0.15) F: 48.65 (15.54) 
  M: 59.49 (8.46) M: 55.77 (7.27) M: 67.89 (6.34) M: 65.64 (6.49) M: 60.70 (8.11) M: 57.40 (7.24) M: 40.9 (28.46) M: 42.59 (27.79) NA M: 60.04 (9.25) NA M: 42.15 (5.63) M: 70.72 (0.67) M: 48.32 (15.55) 
 Mean BMI (SD), kg/m
2 F: 27.01 (4.97) F: 31.92 (4.89) F: 27.19 (4.66) F: 30.05 (4.89) F: 26.52 (4.23) F: 0 (0) F: 25.13 (4.75) F: 25.51 (4.79) NA F: 25.66 (4.29) NA F: 25.45 (4.77) F: 26.94 (4.71) F: 25.87 (4.64) 
  M: 26.79 (3.73) M: 29.64 (3.47) M: 27.10 (3.58) M: 28.59 (3.85) M: 26.51 (3.42) M: 26.89 (3.83) M: 26.37 (3.85) M: 26.58 (3.85) NA M: 27.36 (3.02) NA M: 26.58 (3.97) M: 26.19 (3.41) M: 26.59 (3.758) 
 # available (with BMI) 2107 306 657 548 1342 6594 3156 5268 0 244 NA 4075 1797 4170 
 
Mean fasting insulin 
(SD), pmol/l F: 40.91 (20.65) F: 82.99 (41.26) F: 41.66 (25.96) F: 40.74 (21.64) F: 52.18 (33.05) F: 0 (0) F: 37.97 (24.96) F: 38.65 (25.2) NA F: 64.15 (31.44) NA F: 94.69 (39.65) F: 58.06 (35.82) F: 8.42 (6.1) 
  M: 43.79 (26.74) M: 84.39 (42.06) M: 44.82 (32.97) M: 37.02 (19.73) M: 49.27 (30.38) M: 50.70 (36.47) M: 40.9 (28.46) M: 42.6 (27.8) NA M: 80.97 (55.91) NA M: 105.55 (51.87) M: 77.45 (45.55) M: 9.02 (7.1) 
 # Females (%) 1139 (54.06) 214 (69.93) 472 (71.84) 327 (59.67) 632 (47.09) 0 (0.00) 1370 (43.4) 2504 (47.5) NA 127 (52.05) NA 2204 (54.09) 438 (24.37) 2282 (0.55) 
 Mean age (SD), years F: 58.77 (8.23) F: 54.98 (7.09) F: 66.33 (5.21) F: 64.02 (7.48) F: 62.71 (7.80) F: 0 (0) F: 37.97 (24.96) F: 38.65 (25.2) NA F: 56.40 (10.82) NA F: 41.64 (6.00) F: 70.26 (0.15) F: 48.65 (15.55) 
  M: 59.47 (8.45) M: 55.77 (7.27) M: 67.89 (6.34) M: 65.64 (6.49) M: 60.70 (8.11) M: 57.40 (7.24) M: 48.87 (12.06) M: 45.83 (7.78) NA M: 60.04 (9.25) NA M: 42.15 (5.63) M: 70.72 (0.67) M: 48.32 (15.55) 
 Mean BMI (SD), kg/m
2 F: 27.01 (4.97) F: 31.92 (4.89) F: 27.19 (4.66) F: 30.05 (4.89) F: 26.52 (4.23) F: 0 (0) F: 25.13 (4.75) F: 25.51 (4.79) NA F: 25.66 (4.29) NA F: 25.45 (4.77) F: 26.94 (4.71) F: 25.87 (4.64) 
  M: 26.79 (3.73) M: 29.64 (3.47) M: 27.10 (3.58) M: 28.59 (3.85) M: 26.51 (3.42) M: 26.89 (3.83) M: 26.37 (3.85) M: 26.58 (3.85) NA M: 27.36 (3.02) NA M: 26.58 (3.97) M: 26.23 (3.41) M: 26.59 (3.758) 
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[Finnish, Swedish] Hispanic Hispanic 
South Asian 




Jackson Heart Study 
(AJ) 
Wake Forest School of 
Medicine Study (AW) 
Korea Association 
Research Project (EK) 
Singapore Diabetes 












KORA-gen UKT2D Consortium Malmo-Botnia Study 
San Antonio Family 






Study, and the 
Investigation of 
Nephropathy and 
Diabetes Study family 
component (HA) 
Starr County, Texas 
(HS) 
London Life Sciences 
Population Study (SL) 
Singapore Indian Eye 
Study (SS) 
Single variant analysis 
(relateds) # available 508 NA 556 549 332 498 476 90 320 442 154 699 508 NA 
 
Mean fasting glucose 
(SD), mmol/l F: 4.83 (0.35) NA F: 4.42 (0.37) F: 4.73 (0.43) F: 4.69 (0.73) F: 0 (0) F: 5.28 (0.39) F: 5.97 (0.38) F: 4.72 (0.47) F: 5.10 (0.38) F: 5.06 (0.56) F: 4.63 (0.45) F: 5.09 (0.42) NA 
  M: 4.84 (0.32) NA M: 4.44 (0.41) M: 4.95 (0.48) M: 4.78 (0.75) M: 5.49 (0.32) M: 5.44 (0.36) M: 6.16 (0.43) M: 4.70 (0.53) M: 5.18 (0.33) M: 5.19 (0.58) M: 4.82 (0.46) M: 5.15 (0.38) NA 
 # Females (%) 321 (63.19) NA 326 (58.63) 335 (61.02) 191 (57.53) 0 (0.00) 214 (44.96) 57 (63.33) 265 (82.81) 194 (43.89) 92 (59.74) 502 (71.82) 80 (15.75) NA 
 Mean age (SD), years F: 55.81 (11.40) NA F: 62.91 (3.52) F: 57.92 (6.45) F: 80.29 (14.74) F: 0 (0) F: 63.78 (7.05) F: 68.95 (5.43) F: 60.93 (10.23) F: 68.04 (8.04) F: 51.89 (14.28) F: 39.12 (9.40) F: 63.51 (8.64) NA 
  M: 56.49 (11.25) NA M: 63.72 (3.60) M: 58.54 (7.61) M: 76.96 (11.68) M: 54.74 (4.54) M: 62.19 (7.29) M: 70.91 (5.79) M: 59.80 (8.99) M: 65.57 (8.08) M: 49.42 (15.24) M: 39.49 (11.10) M: 63.14 (9.32) NA 
 Mean BMI (SD), kg/m
2 F: 32.98 (6.87) NA F: 24.19 (3.14) F: 22.63 (3.41) F: 24.17 (4.27) F: 0 (0) F: 28.49 (4.44) F: 34.65 (3.51) F: 31.04 (6.17) F: 33.70 (4.11) F: 31.60 (7.34) F: 30.42 (6.52) F: 28.26 (4.39) NA 
  M: 30.01 (5.14) NA M: 23.10 (2.83) M: 22.83 (3.20) M: 26.24 (3.71) M: 25.82 (3.15) M: 27.48 (3.35) M: 34.17 (3.42) M: 28.41 (3.71) M: 32.25 (3.85) M: 28.40 (4.54) M: 29.49 (5.32) M: 26.96 (3.35) NA 
 # available (with BMI) 508 NA 556 548 323 498 476 90 315 442 145 699 508 NA 
 
Mean fasting glucose 
(SD), mmol/l F: 4.83 (0.35) NA F: 4.42 (0.37) F: 4.73 (0.43) F: 4.70 (0.72) F: 0 (0) F: 5.28 (0.39) F: 5.97 (0.38) F: 4.73 (0.46) F: 5.10 (0.38) F: 5.05 (0.57) F: 4.63 (0.45) F: 5.09 (0.42) NA 
  M: 4.84 (0.32) NA M: 4.44 (0.41) M: 4.95 (0.48) M: 4.79 (0.76) M: 5.49 (0.32) M: 5.44 (0.36) M: 6.16 (0.43) M: 4.70 (0.53) M: 5.18 (0.33) M: 5.15 (0.56) M: 4.82 (0.46) M: 5.15 (0.38) NA 
 # Females (%) 321 (63.19) NA 326 (58.63) 335 (61.13) 185 (57.28) 0 (0.00) 214 (44.96) 57 (63.33) 260 (82.54) 194 (43.89) 86 (59.31) 502 (71.82) 80 (15.75) NA 
 Mean age (SD), years F: 55.81 (11.40) NA F: 62.91 (3.52) F: 57.92 (6.45) F: 80.33 (14.66) F: 0 (0) F: 63.78 (7.05) F: 68.95 (5.43) F: 61.17 (10.10) F: 68.04 (8.04) F: 52.12 (14.33) F: 39.12 (9.40) F: 63.51 (8.64) NA 
  M: 56.49 (11.25) NA M: 63.72 (3.60) M: 58.63 (7.51) M: 76.51 (11.40) M: 54.74 (4.54) M: 62.19 (7.29) M: 70.91 (5.79) M: 59.80 (8.99) M: 65.57 (8.08) M: 48.71 (14.82) M: 39.49 (11.10) M: 63.14 (9.32) NA 
 Mean BMI (SD), kg/m
2 F: 32.98 (6.87) NA F: 24.19 (3.14) F: 22.63 (3.41) F: 24.17 (4.27) F: 0 (0) F: 28.49 (4.44) F: 34.65 (3.51) F: 31.04 (6.17) F: 33.70 (4.11) F: 31.68 (7.39) F: 30.42 (6.52) F: 28.26 (4.39) NA 
  M: 30.01 (5.14) NA M: 23.10 (2.83) M: 22.83 (3.20) M: 26.24 (3.71) M: 25.82 (3.15) M: 27.48 (3.35) M: 34.17 (3.42) M: 28.41 (3.71) M: 32.25 (3.85) M: 28.28 (4.55) M: 29.49 (5.32) M: 26.96 (3.35) NA 
 # available 507 NA 556 548 117 497 473 90 293 206 154 697 431 NA 
 
Mean fasting insulin 
(SD), pmol/l F: 95.25 (52.59) NA F: 47.68 (35.27) F: 42.55 (26.07) F: 87.65 (57.64) F: 0 (0) F: 52.75 (26.44) F: 48.41 (54.15) F: 64.85 (47.30) F: 62.98 (36.10) F: 109.11 (103.46) F: 40.03 (45.84) F: 59.76 (34.45) NA 
  M: 83.26 (50.58) NA M: 38.44 (29.40) M: 40.54 (32.61) M: 112.94 (51.51) M: 38.32 (22.83) M: 52.86 (29.22) M: 63.71 (38.14) M: 62.60 (85.24) M: 69.28 (43.87) M: 88.95 (52.39) M: 48.72 (51.91) M: 66.27 (41.37) NA 
 # Females (%) 321 (63.31) NA 326 (58.63) 334 (60.95) 62 (52.99) 0 (0.00) 214 (45.24) 57 (63.33) 242 (82.59) 96 (46.60) 92 (59.74) 500 (71.74) 59 (13.69) NA 
 Mean age (SD), years F: 55.81 (11.40) NA F: 62.91 (3.52) F: 57.94 (6.45) F: 81.21 (13.43) F: 0 (0) F: 63.78 (7.05) F: 68.95 (5.43) F: 61.39 (10.26) F: 66.23 (9.38) F: 51.89 (14.28) F: 39.11 (9.41) F: 62.50 (8.31) NA 
  M: 56.47 (11.27) NA M: 63.72 (3.60) M: 58.54 (7.61) M: 76.51 (10.20) M: 54.74 (4.55) M: 62.21 (7.30) M: 70.91 (5.79) M: 59.98 (9.25) M: 63.92 (10.16) M: 49.42 (15.24) M: 39.49 (11.10) M: 62.47 (9.14) NA 
 Mean BMI (SD), kg/m
2 F: 32.98 (6.87) NA F: 24.19 (3.14) F: 22.60 (3.38) F: 24.45 (3.85) F: 0 (0) F: 28.49 (4.44) F: 34.65 (3.51) F: 31.25 (6.27) F: 31.07 (3.74) F: 31.60 (7.34) F: 30.42 (6.53) F: 28.14 (3.95) NA 
  M: 30.02 (5.15) NA M: 23.10 (2.83) M: 22.83 (3.20) M: 27.18 (3.24) M: 25.82 (3.15) M: 27.47 (3.36) M: 34.17 (3.42) M: 28.62 (3.72) M: 29.22 (3.58) M: 28.40 (4.54) M: 29.49 (5.32) M: 26.89 (3.19) NA 
 # available (with BMI) 507 NA 556 547 114 497 473 90 293 206 145 697 431 NA 
 
Mean fasting insulin 
(SD), pmol/l F: 95.25 (52.59) NA F: 47.68 (35.27) F: 42.55 (26.07) F: 86.40 (57.75) F: 0 (0) F: 52.75 (26.44) F: 48.41 (54.15) F: 64.85 (47.30) F: 62.98 (36.10) F: 108.08 (105.91) F: 40.03 (45.84) F: 59.76 (34.45) NA 
  M: 83.26 (50.58) NA M: 38.44 (29.40) M: 39.69 (30.22) M: 112.07 (51.58) M: 38.32 (22.83) M: 52.86 (29.22) M: 63.71 (38.14) M: 62.60 (85.24) M: 69.28 (43.87) M: 89.46 (53.64) M: 48.72 (51.91) M: 66.27 (41.37) NA 
 # Females (%) 321 (63.31) NA 326 (58.63) 334 (61.06) 60 (52.63) 0 (0.00) 214 (45.24) 57 (63.33) 242 (82.59) 96 (46.60) 86 (59.31) 500 (71.74) 59 (13.69) NA 
 Mean age (SD), years F: 55.81 (11.40) NA F: 62.91 (3.52) F: 57.94 (6.45) F: 81.77 (13.22) F: 0 (0) F: 63.78 (7.05) F: 68.95 (5.43) F: 61.39 (10.26) F: 66.23 (9.38) F: 52.12 (14.33) F: 39.11 (9.41) F: 62.50 (8.31) NA 
  M: 56.47 (11.27) NA M: 63.72 (3.60) M: 58.63 (7.51) M: 76.11 (9.85) M: 54.74 (4.55) M: 62.21 (7.30) M: 70.91 (5.79) M: 59.98 (9.25) M: 63.92 (10.16) M: 48.71 (14.82) M: 39.49 (11.10) M: 62.47 (9.14) NA 
 Mean BMI (SD), kg/m
2 F: 32.98 (6.87) NA F: 24.19 (3.14) F: 22.60 (3.38) F: 24.45 (3.85) F: 0 (0) F: 28.49 (4.44) F: 34.65 (3.51) F: 31.25 (6.27) F: 31.07 (3.74) F: 31.68 (7.39) F: 30.42 (6.53) F: 28.14 (3.95) NA 
  M: 30.02 (5.15) NA M: 23.10 (2.83) M: 22.83 (3.20) M: 27.18 (3.24) M: 25.82 (3.15) M: 27.47 (3.36) M: 34.17 (3.42) M: 28.62 (3.72) M: 29.22 (3.58) M: 28.28 (4.55) M: 29.49 (5.32) M: 26.89 (3.19) NA Gene-level analysis 
(unrelateds) # available 483 NA 555 549 332 496 470 90 320 436 154 699 503 NA 
 
Mean fasting glucose 
(SD), mmol/l F: 4.84 (0.35) NA F: 4.42 (0.37) F: 4.73 (0.43) F: 4.69 (0.73) F: 0 (0) F: 5.28 (0.39) F: 5.97 (0.38) F: 4.72 (0.47) F: 5.10 (0.38) F: 5.06 (0.56) F: 4.63 (0.45) F: 5.08 (0.42) NA 
  M: 4.84 (0.33) NA M: 4.44 (0.41) M: 4.95 (0.48) M: 4.78 (0.75) M: 5.50 (0.32) M: 5.45 (0.35) M: 6.16 (0.43) M: 4.70 (0.53) M: 5.18 (0.33) M: 5.19 (0.58) M: 4.82 (0.46) M: 5.15 (0.38) NA 
 # Females (%) 303 (62.73) NA 326 (58.74) 335 (61.02) 191 (57.53) 0 (0.00) 212 (45.11) 57 (63.33) 265 (82.81) 191 (43.81) 92 (59.74) 502 (71.82) 79 (15.71) NA 
 Mean age (SD), years F: 55.64 (11.26) NA F: 62.91 (3.52) F: 57.92 (6.45) F: 80.29 (14.74) F: 0 (0) F: 63.75 (7.08) F: 68.95 (5.43) F: 60.93 (10.23) F: 68.13 (7.81) F: 51.89 (14.28) F: 39.12 (9.40) F: 63.38 (8.62) NA 
  M: 56.63 (11.30) NA M: 63.70 (3.59) M: 58.54 (7.61) M: 76.96 (11.68) M: 54.75 (4.55) M: 62.14 (7.26) M: 70.91 (5.79) M: 59.80 (8.99) M: 65.78 (7.85) M: 49.42 (15.24) M: 39.49 (11.10) M: 63.14 (9.31) NA 
 Mean BMI (SD), kg/m
2 F: 33.03 (6.87) NA F: 24.19 (3.14) F: 22.63 (3.41) F: 24.17 (4.27) F: 0 (0) F: 28.51 (4.45) F: 34.65 (3.51) F: 31.04 (6.17) F: 33.71 (4.11) F: 31.60 (7.34) F: 30.42 (6.52) F: 28.23 (4.41) NA 
  M: 30.06 (5.18) NA M: 23.11 (2.83) M: 22.83 (3.20) M: 26.24 (3.71) M: 25.82 (3.15) M: 27.44 (3.35) M: 34.17 (3.42) M: 28.41 (3.71) M: 32.24 (3.86) M: 28.40 (4.54) M: 29.49 (5.32) M: 26.96 (3.34) NA 
 # available (with BMI) 483 NA 555 548 323 496 470 90 315 436 145 699 503 NA 
 
Mean fasting glucose 
(SD), mmol/l F: 4.84 (0.35) NA F: 4.42 (0.37) F: 4.73 (0.43) F: 4.70 (0.72) F: 0 (0) F: 5.28 (0.39) F: 5.97 (0.38) F: 4.73 (0.46) F: 5.10 (0.38) F: 5.05 (0.57) F: 4.63 (0.45) F: 5.08 (0.42) NA 
  M: 4.84 (0.33) NA M: 4.44 (0.41) M: 4.95 (0.48) M: 4.79 (0.76) M: 5.50 (0.32) M: 5.45 (0.35) M: 6.16 (0.43) M: 4.70 (0.53) M: 5.18 (0.33) M: 5.15 (0.56) M: 4.82 (0.46) M: 5.15 (0.38) NA 
 # Females (%) 303 (62.73) NA 326 (58.74) 335 (61.13) 185 (57.28) 0 (0.00) 212 (45.11) 57 (63.33) 260 (82.54) 191 (43.81) 86 (59.31) 502 (71.82) 79 (15.71) NA 
 Mean age (SD), years F: 55.64 (11.26) NA F: 62.91 (3.52) F: 57.92 (6.45) F: 80.33 (14.66) F: 0 (0) F: 63.75 (7.08) F: 68.95 (5.43) F: 61.17 (10.10) F: 68.13 (7.81) F: 52.12 (14.33) F: 39.12 (9.40) F: 63.38 (8.62) NA 
  M: 56.63 (11.30) NA M: 63.70 (3.59) M: 58.63 (7.51) M: 76.51 (11.40) M: 54.75 (4.55) M: 62.14 (7.26) M: 70.91 (5.79) M: 59.80 (8.99) M: 65.78 (7.85) M: 48.71 (14.82) M: 39.49 (11.10) M: 63.14 (9.31) NA 
 Mean BMI (SD), kg/m
2 F: 33.03 (6.87) NA F: 24.19 (3.14) F: 22.63 (3.41) F: 24.17 (4.27) F: 0 (0) F: 28.51 (4.45) F: 34.65 (3.51) F: 31.04 (6.17) F: 33.71 (4.11) F: 31.68 (7.39) F: 30.42 (6.52) F: 28.23 (4.41) NA 
  M: 30.06 (5.18) NA M: 23.11 (2.83) M: 22.83 (3.20) M: 26.24 (3.71) M: 25.82 (3.15) M: 27.44 (3.35) M: 34.17 (3.42) M: 28.41 (3.71) M: 32.24 (3.86) M: 28.28 (4.55) M: 29.49 (5.32) M: 26.96 (3.34) NA 
 # available 482 NA 555 548 117 495 467 90 293 201 154 697 426 NA 
 
Mean fasting insulin 
(SD), pmol/l F: 96.08 (53.19) NA F: 47.68 (35.27) F: 42.55 (26.07) F: 87.65 (57.64) F: 0 (0) F: 52.75 (26.51) F: 48.41 (54.15) F: 64.85 (47.30) F: 61.64 (35.24) F: 109.11 (103.46) F: 40.03 (45.84) F: 59.96 (34.72) NA 
  M: 83.77 (51.28) NA M: 38.53 (29.43) M: 40.54 (32.61) M: 112.94 (51.51) M: 38.31 (22.83) M: 52.96 (29.30) M: 63.71 (38.14) M: 62.60 (85.24) M: 68.76 (43.75) M: 88.95 (52.39) M: 48.72 (51.91) M: 66.13 (41.51) NA 
 # Females (%) 303 (62.86) NA 326 (58.74) 334 (60.95) 62 (52.99) 0 (0.00) 212 (45.40) 57 (63.33) 242 (82.59) 94 (46.77) 92 (59.74) 500 (71.74) 58 (13.62) NA 
 Mean age (SD), years F: 55.64 (11.26) NA F: 62.91 (3.52) F: 57.94 (6.45) F: 81.21 (13.43) F: 0 (0) F: 63.75 (7.08) F: 68.95 (5.43) F: 61.39 (10.26) F: 66.22 (9.09) F: 51.89 (14.28) F: 39.11 (9.41) F: 62.31 (8.26) NA 
  M: 56.61 (11.33) NA M: 63.70 (3.59) M: 58.54 (7.61) M: 76.51 (10.20) M: 54.76 (4.55) M: 62.16 (7.27) M: 70.91 (5.79) M: 59.98 (9.25) M: 64.34 (9.86) M: 49.42 (15.24) M: 39.49 (11.10) M: 62.47 (9.12) NA 
 Mean BMI (SD), kg/m
2 F: 33.03 (6.87) NA F: 24.19 (3.14) F: 22.60 (3.38) F: 24.45 (3.85) F: 0 (0) F: 28.51 (4.45) F: 34.65 (3.51) F: 31.25 (6.27) F: 31.04 (3.72) F: 31.60 (7.34) F: 30.42 (6.53) F: 28.09 (3.97) NA 
  M: 30.07 (5.20) NA M: 23.11 (2.83) M: 22.83 (3.20) M: 27.18 (3.24) M: 25.82 (3.15) M: 27.43 (3.36) M: 34.17 (3.42) M: 28.62 (3.72) M: 29.11 (3.55) M: 28.40 (4.54) M: 29.49 (5.32) M: 26.88 (3.18) NA 
 # available (with BMI) 482 NA 555 547 114 495 467 90 293 201 145 697 426 NA 
 
Mean fasting insulin 
(SD), pmol/l F: 96.08 (53.19) NA F: 47.68 (35.27) F: 42.55 (26.07) F: 86.40 (57.75) F: 0 (0) F: 52.75 (26.51) F: 48.41 (54.15) F: 64.85 (47.30) F: 61.64 (35.24) F: 108.08 (105.91) F: 40.03 (45.84) F: 59.96 (34.72) NA 
  M: 83.77 (51.28) NA M: 38.53 (29.43) M: 39.69 (30.22) M: 112.07 (51.58) M: 38.31 (22.83) M: 52.96 (29.30) M: 63.71 (38.14) M: 62.60 (85.24) M: 68.76 (43.75) M: 89.46 (53.64) M: 48.72 (51.91) M: 66.13 (41.51) NA 
 # Females (%) 303 (62.86) NA 326 (58.74) 334 (61.06) 60 (52.63) 0 (0.00) 212 (45.40) 57 (63.33) 242 (82.59) 94 (46.77) 86 (59.31) 500 (71.74) 58 (13.62) NA 
 Mean age (SD), years F: 55.64 (11.26) NA F: 62.91 (3.52) F: 57.94 (6.45) F: 81.77 (13.22) F: 0 (0) F: 63.75 (7.08) F: 68.95 (5.43) F: 61.39 (10.26) F: 66.22 (9.09) F: 52.12 (14.33) F: 39.11 (9.41) F: 62.31 (8.26) NA 
  M: 56.61 (11.33) NA M: 63.70 (3.59) M: 58.63 (7.51) M: 76.11 (9.85) M: 54.76 (4.55) M: 62.16 (7.27) M: 70.91 (5.79) M: 59.98 (9.25) M: 64.34 (9.86) M: 48.71 (14.82) M: 39.49 (11.10) M: 62.47 (9.12) NA 
 Mean BMI (SD), kg/m
2 F: 33.03 (6.87) NA F: 24.19 (3.14) F: 22.60 (3.38) F: 24.45 (3.85) F: 0 (0) F: 28.51 (4.45) F: 34.65 (3.51) F: 31.25 (6.27) F: 31.04 (3.72) F: 31.68 (7.39) F: 30.42 (6.53) F: 28.09 (3.97) NA 
  M: 30.07 (5.20) NA M: 23.11 (2.83) M: 22.83 (3.20) M: 27.18 (3.24) M: 25.82 (3.15) M: 27.43 (3.36) M: 34.17 (3.42) M: 28.62 (3.72) M: 29.11 (3.55) M: 28.28 (4.55) M: 29.49 (5.32) M: 26.88 (3.18) NA 
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SUPPLEMENTARY TABLE 2  
Association results from the discovery phase.  
Supplementary Table 2A:  Significant (P < 5 × 10-7) and suggestive (P < 5 × 10-6) single variant association results in previously published regions associated with FI levels or FG 
levels. The published association statistics are shaded in gray.  The association results for each region in our analyses are presented in the non-shaded rows.  
Insulin 
            
GWAS Loci Location rsID Gene Consequence Protein Change ETH Allele Allele Freq Beta estimate 
Standard
Error P value N 
LYPLAL1    rs4846565         G 0.67 0.013   1.8E-09 99014 
 
1:219644224 rs2605100 NA NA NA 1 A 0.31 -0.019 0.0039 4.5E-07 30825 
 
1:219652033 rs2791552 NA NA NA 1 A 0.32 -0.018 0.0039 8.7E-07 30824 
GCKR    rs780094         C 0.62 0.015   3.6E-20 96126 
 
2:27730940 rs1260326 GCKR missense,splice_region p.L446P 5 T 0.39 -0.021 0.0036 2.2E-10 35380 
 
2:27741237 rs780094 GCKR intron NA 1 T 0.37 -0.023 0.0038 6.3E-11 30825 
 
2:27742603 rs780093 GCKR intron NA 1 T 0.37 -0.023 0.0038 5.4E-11 30815 
 
2:27801493 rs1919127 C2orf16 missense p.V685A 5 T 0.73 0.022 0.0047 4.7E-07 26227 
 
2:27801759 rs1919128 C2orf16 missense p.I774V 5 A 0.73 0.021 0.0040 1.9E-08 35381 
 
2:27851918 rs3749147 GPN1 missense p.R12K 5 A 0.25 -0.020 0.0044 5.4E-07 30846 
GRB14    rs10195252        T 0.60 0.017   1.3E-16   
 
2:165540800 rs12328675 COBLL1 downstream_gene NA 1 T 0.89 0.029 0.0058 1.6E-07 30739 
 
2:165551201 rs7607980 COBLL1 missense p.N939D 4 T 0.88 0.031 0.0056 3.1E-09 34278 
 
2:165528876 rs7578326 NA NA NA 1 T 0.38 -0.019 0.0038 4.2E-07 30824 
IRS1    rs2943645         T 0.63 0.019   2.3E-19 99023 
 
2:227020653 rs7578326 NA NA NA 1 A 0.65 0.023 0.0038 5.8E-11 30823 
 
2:227068080 rs2943634 NA NA NA 1 A 0.34 -0.025 0.0038 7.7E-13 30816 
 
2:227093745 rs2943641 NA NA NA 1 T 0.37 -0.028 0.0038 1.4E-15 30825 
 
2:227100698 rs2972146 NA NA NA 1 T 0.63 0.028 0.0038 1.1E-15 30818 
 
2:227105921 rs2943650 NA NA NA 1 T 0.62 0.049 0.0083 3.8E-09 6792 
ANKRD55:MAP3K1  rs459193          G 0.73 0.015   1.1E-12   
 
5:55806751 rs459193 AC022431.2.1 downstream_gene NA 1 A 0.29 -0.019 0.0040 1.5E-06 30825 
GCKR   rs780094         C 0.62 0.03   5.8E-38 118032 
 
2:27424636 rs1395 SLC5A6 missense p.S481F 5 A 0.69 -0.02 0.0036 4.0E-08 38338 
 
2:27550967 rs1049817 GTF3C2 synonymous p.P782P 5 A 0.58 -0.02 0.0033 1.4E-07 38339 
 
2:27711893 rs1260327 IFT172 intron NA 1 A 0.52 -0.02 0.0035 2.9E-09 33231 
 
2:27730940 rs1260326 GCKR missense,splice_region p.L446P 5 T 0.37 -0.03 0.0034 3.1E-18 38338 
 
2:27741237 rs780094 GCKR intron NA 1 T 0.37 -0.03 0.0037 1.4E-18 33231 
 
2:27742603 rs780093 GCKR intron NA 1 T 0.37 -0.03 0.0037 8.0E-18 33221 
 
2:27801493 rs1919127 C2orf16 missense p.V685A 5 T 0.72 0.02 0.0043 2.6E-07 29085 
 
2:27801759 rs1919128 C2orf16 missense p.I774V 5 A 0.72 0.02 0.0037 6.0E-10 38339 
 
2:27851918 rs3749147 GPN1 missense p.R12K 5 A 0.25 -0.02 0.004 7.7E-09 33763 
 
2:28344285 rs12104449 BRE intron NA 1 A 0.11 -0.03 0.0056 2.2E-06 33231 
 
2:27972833 rs4401177 NA NA NA 1 A 0.88 0.02 0.0054 3.7E-06 33200 
G6PC2   rs560887         C 0.70 0.08   8.7E-218 119169 
 
2:169763148 rs560887 G6PC2 intron NA 5 T 0.30 -0.07 0.0036 7.9E-87 38339 
 
2:169763262 rs138726309 G6PC2 missense p.H177Y 1 T 0.01 -0.10 0.0193 7.4E-08 34574 
 
2:169764141 rs2232323 G6PC2 missense p.Y207S 3 A 0.99 0.13 0.0227 1.7E-09 35227 
 
2:169764176 rs492594 G6PC2 missense p.V219L 5 C 0.48 0.02 0.0032 1.4E-08 38339 
 
2:169791438 rs552976 ABCB11 intron NA 1 A 0.35 -0.06 0.0037 5.1E-66 33231 
 
2:169774071 rs563694 NA NA NA 1 A 0.65 0.06 0.0037 4.3E-68 33231 
PCSK1    rs4869272         T 0.69     1.0E-15 13,872 
 
5:95728898 rs6235 PCSK1 missense p.S690T 5 C 0.72 0.02 0.0036 2.1E-09 38339 
 
5:95728974 rs6234 PCSK1 missense p.Q665E 5 C 0.28 -0.02 0.0036 2.0E-09 38339 
 
5:95539448 rs4869272 NA NA NA 1 T 0.68 0.02 0.0038 8.3E-07 33231 
CDKAL1    rs9368222         A 0.28 0.01   1.0E-09 128453 
 
6:20679709 rs7756992 CDKAL1 intron NA 1 A 0.70 -0.02 0.0038 3.9E-06 33219 
GLP1R                         
 
6:39046794 rs10305492 GLP1R missense p.A316T 2 A 0.02 -0.07 0.0139 4.5E-07 36218 
DGKB:TMEM195  rs2191349          T 0.52 0.03   3.0E-44   
 
7:15063833 rs10244051 NA NA NA 1 T 0.51 -0.03 0.0035 1.5E-14 33230 
7:15064309 rs2191349 NA NA NA 1 T 0.49 0.03 0.0035 1.3E-14 33231 
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Glucose             
GWAS Loci Location rsID Gene Consequence Protein Change ETH  Allele Freq Beta estimate 
Standard 
Error P value N 
GCK   rs4607517         A 0.16 0.06   6.5E-92 118500 
 
7:44183187 rs2971681 MYL7 upstream_gene NA 1 A 0.79 -0.02 0.0044 2.8E-07 33231 
 
7:44223721 rs730497 GCK intron NA 1 A 0.14 0.06 0.0052 4.7E-31 33231 
 
7:44229068 rs1799884 GCK upstream_gene NA 1 T 0.13 0.06 0.0064 4.9E-21 24042 
 
7:44231886 rs6975024 GCK upstream_gene NA 1 T 0.86 -0.06 0.0052 2.2E-31 33228 
 
7:44235668 rs4607517 YKT6 upstream_gene NA 1 A 0.14 0.06 0.0052 2.2E-31 33231 
GRB10   rs6943153         T 0.34 0.02   1.6E-12 131795 
 
7:50730452 rs2715094 GRB10 intron NA 1 A 0.69 -0.02 0.0039 6.5E-07 33231 
 
7:50751090 rs10248619 GRB10 intron NA 1 T 0.30 0.02 0.004 8.6E-09 33225 
 
7:50786663 rs2108349 GRB10 intron NA 1 A 0.61 -0.02 0.0037 5.8E-08 33226 
 
7:50791579 rs6943153 GRB10 intron NA 1 T 0.39 0.02 0.0037 6.7E-08 33230 
 
7:50758245 rs933360 NA NA NA 1 T 0.68 -0.02 0.0046 1.3E-06 23984 
PPP1R3B    rs983309         T 0.12 0.03   6.3E-15 127470 
 
8:9183358 rs9987289 NA NA NA 1 A 0.13 0.03 0.0058 3.8E-07 26841 
 
8:9183596 rs4841132 NA NA NA 1 A 0.13 0.03 0.0054 2.0E-07 33231 
 
8:9184691 rs6601299 NA NA NA 1 T 0.14 0.03 0.0055 3.9E-07 28698 
 
8:9185146 rs2126259 NA NA NA 1 T 0.14 0.02 0.0052 3.4E-06 33230 
SLC30A8    rs11558471        A 0.68 0.03   2.6E-11   
 
8:118184783 rs13266634 SLC30A8 missense p.R276W 5 T 0.36 -0.02 0.0034 1.6E-11 38338 
 
8:118185025 rs3802177 SLC30A8 3_prime_UTR NA 1 A 0.36 -0.02 0.0036 2.5E-10 33230 
 
8:118185733 rs11558471 SLC30A8 3_prime_UTR NA 1 A 0.64 0.02 0.0036 2.1E-10 33231 
CDKN2B   rs10811661        T 0.82 0.02   5.6E-18   
 
9:22133284 rs10965250 NA NA NA 1 A 0.15 -0.03 0.0059 7.9E-07 22658 
IKBKAP    rs16913693        T 0.97 0.04   3.5E-11   
 
9:111679940 rs17853166 IKBKAP missense p.S251G 2 T 0.97 0.04 0.0097 3.7E-06 36218 
ADRA2A    rs10885122        G 0.87 0.04   2.9E-16   
 
10:113022555 rs10885117 NA NA NA 1 T 0.91 0.03 0.006 9.5E-07 33211 
TCF7L2    rs7903146         C 0.72 -0.02   2.7E-20 127477 
 
10:114758349 rs7903146 TCF7L2 intron NA 1 T 0.23 0.02 0.0042 4.3E-07 33231 
CRY2    rs11605924        A 0.49 0.02   1.0E-14   
 
11:45878992 rs7945565 CRY2 intron NA 1 A 0.51 0.02 0.0035 1.8E-10 33230 
MADD   rs7944584         A 0.75 0.03   2.0E-18 118741 
 
11:47270255 rs2167079 ACP2 missense p.R29Q 5 T 0.38 0.02 0.0034 1.9E-07 38338 
 
11:47286290 rs7120118 NR1H3 intron NA 1 T 0.63 -0.02 0.0037 2.8E-06 33231 
 
11:47290984 rs1449627 MADD 5_prime_UTR NA 1 T 0.62 -0.02 0.0036 4.6E-06 33231 
 
11:47298360 rs326214 MADD synonymous p.E347E 5 A 0.61 -0.02 0.0033 3.8E-07 38339 
 
11:47336320 rs7944584 MADD intron NA 1 A 0.77 0.03 0.0043 2.6E-11 33231 
 
11:47354787 rs1052373 MYBPC3 synonymous p.E1096E 5 T 0.39 0.02 0.0033 1.1E-06 38337 
FADS1    rs174550         T 0.64 0.02   1.7E-15 118908 
 
11:61557803 rs102275 C11orf10 intron NA 1 T 0.62 0.02 0.0036 1.5E-07 33231 
 
11:61569830 rs174546 FADS1 3_prime_UTR NA 1 T 0.38 -0.02 0.0037 4.1E-07 33231 
 
11:61570783 rs174547 FADS1 intron NA 5 T 0.62 0.02 0.0034 2.1E-09 38339 
 
11:61571478 rs174550 FADS1 intron NA 1 T 0.62 0.02 0.0037 3.4E-07 33230 
 
11:61597972 rs1535 FADS2 intron NA 1 A 0.62 0.02 0.0036 6.1E-07 33230 
 
11:61609750 rs174583 FADS2 intron NA 1 T 0.38 -0.02 0.0036 3.0E-07 33231 
ARAP1    rs11603334        G 0.83 0.02   1.1E-11   
 
11:72432985 rs11603334 ARAP1 5_prime_UTR NA 1 A 0.21 -0.02 0.0044 1.5E-08 33231 
 
11:72433098 rs1552224 ARAP1 5_prime_UTR NA 1 A 0.79 0.02 0.0044 1.2E-08 33230 
MTNR1B    rs10830963        G 0.30 0.08   5.8E-175   
 
11:92708710 rs10830963 MTNR1B intron NA 1 C 0.69 -0.09 0.0038 2.8E-118 33230 
 
11:92651002 rs7950811 NA NA NA 1 A 0.05 0.06 0.0087 6.8E-11 33231 
 
11:92668826 rs3847554 NA NA NA 1 T 0.43 0.06 0.0035 1.6E-62 33231 
 
11:92673828 rs1387153 NA NA NA 1 T 0.30 0.07 0.0038 5.6E-76 33231 
 
11:92691532 rs2166706 NA NA NA 1 T 0.60 -0.06 0.0036 5.5E-57 33231 
 
11:92722761 rs1447352 NA NA NA 1 A 0.53 0.04 0.0035 5.3E-31 33214 
C2CD4B    rs11071657        A 0.63 0.02   3.6E-08   
 
15:62383155 rs4502156 NA NA NA 1 T 0.50 0.02 0.0035 1.4E-10 33231 
 
15:62396389 rs7172432 NA NA NA 1 A 0.51 0.02 0.0035 3.8E-11 33231 
 
15:62404382 rs1436955 NA NA NA 1 T 0.28 -0.02 0.0039 1.0E-06 33231 
FOXA2   rs6113722         G 0.96 0.35   2.5E-11 123665 
 
20:39832628 rs17265513 ZHX3 missense p.N310S 4 T 0.76 -0.02 0.0039 1.4E-07 37233 
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Supplementary Table 2B: Significant (P< 5×10-7) and suggestive (P<5×10-6) single variant association results that are not in previously published regions. 
Results are shown for variants with association P< 5×10-6 that fall outside the regions of previously published genetic associations.  
 
 
Location rsID Gene Consequence Protein Change ETH Allele Allele Freq Effect Standard Error P value N 
Glucose 7:2854547 rs116515234 GNA12 intron NA 1 A 0.98 -0.30 0.07 6.7E-07 508 
 
15:43714320 rs140119148 TP53BP1 missense p.T1278I 1 A 0.002 0.34 0.07 9.0E-07 13286 
 
1:2535397 rs150660153 MMEL1 missense p.E323Q 2 C 1.00 -0.24 0.05 1.1E-06 17659 
 
6:43806609 rs881858 VEGFA NA NA 1 A 0.69 -0.02 0.004 4.1E-06 33231 
 
19:3754020 rs61731066 APBA3 synonymous p.S282S 4 C 0.02 -0.16 0.03 4.1E-06 4004 
 
Location rsID Gene Consequence Protein Change ETH Allele Allele Freq Effect Standard Error P value N 
Insulin 19:40762860 rs184042322 AKT2 missense p.P50T 1 T 0.01 0.12 0.02 1.2E-07 28118 
 
6:43758873 rs6905288 VEGFA downstream gene NA 1 A 0.56 0.02 0.00 4.2E-07 17898 
 
9:116764392 rs143246917 ZNF618 intron NA 1 A 0.99 -0.77 0.14 9.2E-07 507 
 
8:23004629 rs3924519 TNFRSF10D intron NA 5 T 0.56 -0.06 0.01 9.8E-07 4556 
 
6:30414848 rs1362115 HLA-E NA NA 1 T 0.15 -0.02 0.01 1.9E-06 30825 
 
10:116331030 rs3824819 ABLIM1 intron NA 1 T 0.07 -0.28 0.05 2.0E-06 1103 
 
6:30428351 rs2077573 HLA-E NA NA 1 A 0.85 0.02 0.01 2.3E-06 30825 
 
Supplementary Table 2C: Single variant association results at previously published genome-wide association loci. Each row contains a previously reported 
GWAS association with FG level or FI level.  Not all previously published SNPs were available for analysis in the exome array or exome sequencing data (denoted 
with - for our analyses).  
Fasting Glucose   Published WES + ExomeArray 
rsID Gene BMI PHENO Eff /Neff 
Effective 
Freq Effect P N Ancestry CITATION Freq Effect 
Std 
Error P N 
rs340874 PROX1 No FGlu C/T 0.52 0.021 6.6E-12 116882 European Dupuis et al. (Nat Genet 2010) 0.49 0.01 0.00 2.23E-02 33231 
rs560887 G6PC2 No FGlu C/T 0.7 0.075 8.7E-218 119169 European 
Dupuis et al. (Nat Genet 2010); Prokopenko et al. (Nat Genet 2008); 
Sabatti et al. (Nat Genet 2008); Kristiansson et al. (Circ Cardiovasc Genet 
2012); Bouatia et al. (Science 2008) 0.70 0.07 0.00 7.88E-87 38339 
rs1371614 DPYSL5 Yes FGluBMIadj T/C 0.25 0.020/ 0.022 2.3E-12 96496 European Manning et al. (Nat Genet 2012) 
     rs780094 GCKR No FGlu C/T 0.62 0.026 5.6E-38 118032 European Dupuis et al. (Nat Genet 2010); Prokopenko et al. (Nat Genet,  2008) 0.63 0.03 0.00 1.37E-18 33231 
rs3736594 MRPL33 Yes FGluBMIadj A/C 0.27 
 
1.1E-15 96487 European Manning et al. (Nat Genet 2012) - - - - - 
rs895636 SIX3 - SIX2 No FGlu C/T 0.38 0.039 1.0E-12 17617 East Asian Kim et al. (Nat Genet 2011) - - - - - 
rs11715915 AMT No FGlu C/T 0.68 0.012 4.9E-08 131523 European Scott et al. (Nat Genet 2012) 0.63 0.01 0.00 5.34E-02 38337 
rs11708067 ADCY5 No FGlu A/G 0.78 0.027 7.1E-22 118475 European Dupuis et al. (Nat Genet 2010) 0.79 0.02 0.00 1.33E-04 33228 
rs11920090 SLC2A2 No FGlu T/A 0.87 0.025 8.1E-13 119024 European Dupuis et al. (Nat Genet 2010) 0.87 0.02 0.01 4.87E-05 33231 
rs7651090 IGF2BP2 No FGlu G/A 0.3 0.013 1.8E-08 104019 European Scott et al. (Nat Genet 2012) 0.31 0.00 0.00 7.51E-01 33231 
rs7708285 ZBED3 Yes FGluBMIadj G/A 0.27 0.015 1.2E-08 117931 European Scott et al. (Nat Genet 2012) - - - - - 
rs4869272 PCSK1 No FGlu T/C 0.69 0.018 1.0E-15 131872 European Scott et al. (Nat Genet 2012) 0.68 0.02 0.00 8.32E-07 33231 
rs13179048 PCSK1 
 
FGluBMIadj C/A 0.69 0.022/ 0.018 1.6E-10 96496 European Manning et al. (Nat Genet 2012) 0.70 0.01 0.01 2.41E-01 4532 
rs9368222 CDKAL1 No FGlu A/C 0.28 0.014 1.0E-09 128453 European Scott et al. (Nat Genet 2012) - - - - - 
rs17762454 RREB1 Yes FGluBMIadj T/C 0.26 0.014 9.6E-09 123247 European Scott et al. (Nat Genet 2012) - - - - - 
rs1127065 CAMK2B No FGlu G/A 0.49 0.08 8.9E-11 11616 European Kristiansson et al. (Circ Cardiovasc Genet,  2012) 0.59 0.03 0.01 5.20E-04 5108 
rs2191349 DGKB/TMEM195 No FGlu T/G 0.52 0.03 3.0E-44 122743 European Dupuis et al. (Nat Genet 2010) 0.49 0.03 0.00 1.25E-14 33231 
rs6947830 DGKB/TMEM195 No FGlu A/G 0.46 0.1 1.4E-13 11616 European Kristiansson et al. (Circ Cardiovasc Genet,  2012) - - - - - 
rs1799884 GCK No FGlu A/G 0.85 0.063 4.5E-18 14211 East Asian Go et al. (J Hum Genet 2013) 0.13 0.06 0.01 4.94E-21 24042 
rs3757840 GCK No FGlu A/C 0.46 0.1 4.9E-13 11616 European Kristiansson et al. (Circ Cardiovasc Genet,  2012) - - - - - 
rs6975024 GCK No FGlu C/T 0.15 0.061 2.9E-99 103517 European Scott et al. (Nat Genet 2012) 0.14 0.06 0.01 2.25E-31 33228 
rs4607517 GCK No FGlu A/G 0.16 0.062 6.5E-92 118500 European Dupuis et al. (Nat Genet 2010) 0.14 0.06 0.01 2.25E-31 33231 
rs6943153 GRB10 No FGlu T/C 0.34 0.015 1.6E-12 131795 European Scott et al. (Nat Genet 2012) 0.39 0.02 0.00 6.66E-08 33230 
rs11558471 SLC30A8 No FGlu A/G 0.68 0.027 2.6E-11 45996 European Dupuis et al. (Nat Genet 2010) 0.64 0.02 0.00 2.09E-10 33231 
rs983309 PPP1R3B No FGlu T/G 0.12 0.026 6.3E-15 127470 European Scott et al. (Nat Genet 2012) - - - - - 
rs4841132 PPP1R3B 
 
FGluBMIadj A/G 0.1 0.027/0.030 7.6E-09 96496 European Manning et al. (Nat Genet 2012) 0.13 0.03 0.01 1.96E-07 33231 
rs2126259 PPP1R3B No FGlu T/C 0.11 0.51 6.3E-15 124740 European Scott et al. (Nat Genet 2012) 0.14 0.02 0.01 3.38E-06 33230 
rs16913693 IKBKAP No FGlu T/G 0.97 0.043 3.5E-11 125115 European Scott et al. (Nat Genet 2012) 0.96 0.04 0.01 7.46E-05 28667 
rs3829109 DNLZ No FGlu G/A 0.71 0.017 1.1E-10 115310 European Scott et al. (Nat Genet 2012) 0.68 0.01 0.00 1.24E-02 33229 
rs10811661 CDKN2B No FGlu T/C 0.82 0.024 5.6E-18 128488 European Scott et al. (Nat Genet 2012) - - - - - 
rs7034200 GLIS3 No FGlu A/C 0.49 0.014 1.0E-12 106250 European Dupuis et al. (Nat Genet 2010) 0.48 0.01 0.00 4.89E-04 33173 
rs10885122 ADRA2A No FGlu G/T 0.87 0.038 2.9E-16 118410 European Dupuis et al. (Nat Genet 2010) 0.87 0.02 0.01 7.89E-05 33230 
rs4506565 TCF7L2 No FGlu T/A 0.31 0.023 1.2E-08 46181 European Dupuis et al. (Nat Genet 2010) 0.26 0.02 0.00 9.85E-06 33230 
rs7903146 TCF7L2 No FGlu C/T 0.72 -0.022 2.7E-20 127477 European Scott et al. (Nat Genet 2012) 0.77 -0.02 0.00 4.31E-07 33231 
rs11605924 CRY2 No FGlu A/C 0.49 0.022 1.0E-14 116479 European Dupuis et al. (Nat Genet 2010) 0.52 0.02 0.01 3.46E-04 8772 
rs7944584 MADD No FGlu A/T 0.75 0.025 2.0E-18 118741 European Dupuis et al. (Nat Genet 2010) 0.77 0.03 0.00 2.62E-11 33231 
rs1483121 OR4S1 Yes FGluBMIadj G/A 0.86 0.021/0.015 1.6E-08 96496 European Manning et al. (Nat Genet 2012) 0.87 0.01 0.01 1.75E-02 28692 
rs174550 FADS1 No FGlu T/C 0.64 0.022 1.7E-15 118908 European Dupuis et al. (Nat Genet 2010) 0.62 0.02 0.00 3.37E-07 33230 
rs11603334 ARAP1 No FGluBMIadj G/A 0.83 0.022/0.030 2.4E-14 96496 European Manning et al. (Nat Genet 2012) 0.79 0.02 0.00 1.55E-08 33231 
rs11603334 ARAP1 No FGlu G/A 0.83 0.019 1.1E-11 128139 European Scott et al. (Nat Genet 2012) 0.79 0.02 0.00 1.55E-08 33231 
rs2166706 FAT3 - MTNR1B No FGlu G/A 
0.450-
0.462 0.05 2.1E-09 6776 South Asian Chambers et al. (Diabetes 2009) 0.40 0.06 0.00 5.48E-57 33231 
rs10830962 MTNR1B No FGlu G/C 0.4 0.12 5.0E-16 11616 European Kristiansson et al. (Circ Cardiovasc Genet,  2012) - - - - - 
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Fasting Glucose   Published WES + ExomeArray 
rsID Gene BMI PHENO Eff /Neff 
Effective 
Freq Effect P N Ancestry CITATION Freq Effect 
Std 
Error P N 
rs10830962 MTNR1B No FGlu C/G 0.531 0.041 4.8E-13 14081 EastAsian Go et al. (J Hum Genet 2013) - - - - - 
rs10830963 MTNR1B No FGlu G/C 0.205 0.048 3.7E-08 815 Hispanic Comuzzie et al. (PLoS One 2012) 0.31 0.09 0.00 2.79E-118 33230 
rs10830963 MTNR1B No FGlu G/C 0.3 0.079 5.8E-175 112844 European Dupuis et al. (Nat Genet 2010); Prokopenko et al. (Nat Genet,  2008) 0.31 0.09 0.00 2.79E-118 33230 
rs2657879 GLS2 Yes FGluBMIadj G/A 0.18 0.016 3.9E-08 123247 European Scott et al. (Nat Genet 2012) 0.18 0.00 0.00 1.87E-01 38339 
rs2074356 C12orf51 No FGlu T/C 0.199 -0.061 6.0E-14 14193 East Asian Go et al. (J Hum Genet 2013) - - - - - 
rs10747083 P2RX2 No FGlu A/G 0.66 0.013 7.6E-09 127111 European Scott et al. (Nat Genet 2012) 0.64 0.01 0.01 1.89E-02 16158 
rs11619319 PDX1 No FGlu G/A 0.23 0.02 1.3E-15 132996 European Scott et al. (Nat Genet 2012) 0.24 0.02 0.00 7.73E-06 33226 
rs2293941 PDX1 No FGluBMIadj A/G 0.22 0.019/0.016 5.3E-10 96496 European Manning et al. (Nat Genet 2012) - - - - - 
rs576674 KL No FGlu G/A 0.15 0.017 2.3E-08 131856 European Scott et al. (Nat Genet 2012) 0.14 0.02 0.01 1.48E-03 28601 
rs3783347 WARS No FGlu G/T 0.79 0.017 1.3E-10 132544 European Scott et al. (Nat Genet 2012) 0.78 0.01 0.00 1.01E-03 33231 
rs11071657 C2CD4B No FGlu A/G 0.63 0.021 3.6E-08 114454 European Dupuis et al. (Nat Genet 2010) 0.64 0.01 0.00 1.01E-03 33230 
rs2302593 GIPR No FGlu C/G 0.5 0.014 9.3E-10 116141 European Scott et al. (Nat Genet 2012) 0.53 -0.01 0.01 4.74E-01 5108 
rs6113722 FOXA2 No FGlu G/A 0.96 0.353 2.5E-11 123665 European Scott et al. (Nat Genet 2012) 0.96 0.02 0.01 1.12E-02 33231 
rs6048205 FOXA2 No FGluBMIadj A/G 0.95 0.040/0.029 1.6E-12 96496 European Manning et al. (Nat Genet 2012) - - - - - 
rs1209523 FOXA2 No FGlu T/C 
0.037-
0.391 - 2.2E-11 14853 
African 
American + 
European Xing et al. (Am J Hum Genet 2013) - - - - - 
rs6072275 TOP1 No FGlu A/G 0.16 0.016 1.7E-08 128616 European Scott et al. (Nat Genet 2012) 0.20 0.02 0.00 6.06E-05 33231 
	
Fasting Insulin   Published WES + ExomeArray 
rsID Gene BMI PHENO Eff /Neff 
Effective 
Freq Effect P N Ancestry CITATION Freq Effect 
Std 
Error P N 
rs2820436 LYPLAL1 
 
FIns C/A 0.67 0.015 4.4E-09 104044 European Scott et al. (Nat Genet 2012) - - - - - 
rs2785980 LYPLAL1 Yes FInsBMIadj T/C 0.67 0.016/0.017 2.0E-08 83116 European Manning et al. (Nat Genet 2012) 0.66 0.01 0.00 3.4E-02 17731 
rs4846565 LYPLAL1 
 
FInsBMIadj G/A 0.67 0.013 1.8E-09 99014 European Scott et al. (Nat Genet 2012) - - - - - 
rs7607980 GRB14 Yes FInsBMIadj T/C 0.88 0.023/0.039 4.3E-20 83116 European Manning et al. (Nat Genet 2012) 0.88 0.03 0.01 3.1E-09 34278 
rs1530559 YSK4 No FIns T/C 0.52 0.015 3.4E-08 107281 European Scott et al. (Nat Genet 2012) - - - - - 
rs10195252 GRB14 
 
FIns T/C 0.59 0.016 4.9E-10 99126 European Scott et al. (Nat Genet 2012) 0.60 0.02 0.00 3.0E-05 21680 
rs10195252 GRB14 Yes FInsBMIadj T/C 0.6 0.017 1.3E-16 98997 European Scott et al. (Nat Genet 2012) 0.60 0.02 0.00 3.0E-05 21680 
rs2943634 IRS1 Yes FInsBMIadj C/A 0.66 0.018/0.025 2.5E-14 83116 European Manning et al. (Nat Genet 2012) 0.66 0.03 0.00 7.7E-13 30816 
rs2943645 IRS1 
 
FInsBMIadj T/C 0.63 0.019 2.3E-19 99023 European Scott et al. (Nat Genet 2012) - - - - - 
rs2972143 IRS1 
 
FIns G/A 0.62 0.014 3.2E-08 99566 European Scott et al. (Nat Genet 2012) - - - - - 
rs780094 GCKR No FIns C/T 0.62 0.015 3.6E-20 96126 European Dupuis et al. (Nat Genet 2010) 0.63 0.02 0.00 6.3E-11 30825 
rs17036328 PPARG Yes FInsBMIadj T/C 0.86 0.021 3.6E-12 98497 European Scott et al. (Nat Genet 2012) - - - - - 
rs974801 TET2 
 
FInsBMIadj G/A 0.38 0.014 3.3E-11 103489 European Scott et al. (Nat Genet 2012) - - - - - 
rs9884482 TET2 No FIns C/T 0.39 0.017 1.4E-11 108420 European Scott et al. (Nat Genet 2012) 0.39 0.01 0.00 8.7E-03 26330 
rs4691380 PDGFC 
 
FInsBMIadj C/T 0.67 0.016/0.021 5.3E-09 83116 European Manning et al. (Nat Genet 2012) 0.71 0.01 0.00 2.3E-03 30825 
rs6822892 PDGFC Yes FInsBMIadj A/G 0.69 0.014 2.6E-10 103432 European Scott et al. (Nat Genet 2012) 0.70 0.01 0.01 3.3E-02 17280 
rs17046216 SC4MOL No FIns A/T 0.48 0.18 1.7E-08 1497 
African 
American Chen et. al (Hum Mol Genet 2012) - - - - - 
rs3822072 FAM13A Yes FInsBMIadj A/G 0.48 0.012 1.8E-08 99977 European Scott et al. (Nat Genet 2012) - - - - - 
rs4865796 ARL15 No FIns A/G 0.67 0.015 2.1E-08 100001 European Scott et al. (Nat Genet 2012) - - - - - 
rs4865796 ARL15 
 
FInsBMIadj A/G 0.67 0.015 2.2E-12 98314 European Scott et al. (Nat Genet 2012) - - - - - 
rs459193 
ANKRD55/MAP3
K1 Yes FInsBMIadj G/A 0.73 0.015 1.1E-12 103378 European Scott et al. (Nat Genet 2012) 0.71 0.02 0.00 1.5E-06 30825 
rs2745353 RSPO3 No FIns T/C 0.51 0.014 5.5E-09 104075 European Scott et al. (Nat Genet 2012) 0.52 0.01 0.00 3.7E-03 30825 
rs6912327 UHRF1BP1 
 
FInsBMIadj T/C 0.8 0.017 2.3E-08 80010 European Scott et al. (Nat Genet 2012) - - - - - 
rs4646949 UHRF1BP1 Yes FInsBMIadj T/G 0.75 0.014/0.020 3.7E-08 83116 European Manning et al. (Nat Genet 2012) 0.77 0.01 0.00 7.5E-02 30824 
rs1167800 HIP1 No FIns A/G 0.54 0.016 2.6E-09 90927 European Scott et al. (Nat Genet 2012) 0.55 0.01 0.00 7.1E-02 30825 
rs983309 PPP1R3B 
 
FInsBMIadj T/G 0.12 0.022 1.2E-12 99024 European Scott et al. (Nat Genet 2012) - - - - - 
rs983309 PPP1R3B 
 
FIns T/G 0.12 0.029 3.8E-14 103030 European Scott et al. (Nat Genet 2012) - - - - - 
rs4841132 PPP1R3B 
 
FInsBMIadj A/G 0.1 0.021/0.031 1.7E-10 83116 European Manning et al. (Nat Genet 2012) 0.13 0.02 0.01 1.4E-04 30825 
rs2126259 PPP1R3B Yes FInsBMIadj T/C 0.11 0.024 3.3E-13 99021 European Scott et al. (Nat Genet 2012) 0.14 0.02 0.01 2.2E-04 30824 
rs7903146 TCF7L2 No FIns C/T 0.72 0.018 6.1E-11 103037 European Scott et al. (Nat Genet 2012) 0.77 0.01 0.00 2.8E-03 30825 
rs7077836 TCERG1L No FIns T/C 0.12 0.28 7.5E-09 1497 
African 
American Chen et. al (Hum Mol Genet 2012) - - - - - 
rs35767 IGF1 No FIns G/A 0.85 0.028 3.3E-08 94590 European Dupuis et al. (Nat Genet 2010) 0.81 0.01 0.00 6.1E-04 30825 
rs1421085 FTO No FIns C/T 0.42 0.02 1.9E-15 104062 European Scott et al. (Nat Genet 2012) 0.41 0.00 0.00 5.7E-01 30825 
rs731839 PEPD Yes FInsBMIadj G/A 0.34 0.015 5.1E-12 103252 European Scott et al. (Nat Genet 2012) 0.34 0.02 0.00 6.7E-05 30825 
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Supplementary Table 2D: Significant and suggestive gene based association signals. Results for all data and mask combinations are shown for any gene that 
attains exome-wide significant (** P<2.5×10-6) or exome-wide suggestive levels (* P<2.5×10-5).  
 
Fasting Insulin   PTV+missense PTV+NSbroad PTV+NSstrict PTV-only 
Gene Ancestry 
MAC  
(No. vars) P value SKAT P value Burden 
MAC  













AKT2 AfrAm 1 0.67 0.67 1 0.67 0.67 - - - - - - 
19q13.1-q13.2 E.Asian 5 0.33 0.15 5 0.33 0.15 0 0.65 0.65 - - - 
 
Europ 31 0.53 0.31 31 0.53 0.31 - - - - - - 
 
Hisp 7 0.42 0.13 7 0.42 0.13 - - - - - - 
 
S.Asian 2 0.86 0.83 1 0.6 0.6 - - - - - - 
 
WES (all) 46(36) 0.6 0.051 45(33) 0.57 0.052 0(5) 0.65 0.65 - - - 
 
ExArray 398(4) 6.10E-07 3.60E-06 398(4) 6.10E-07 3.60E-06 - - - - - - 
 
WES (all) + ExArray 444 0.00056 7.30E-06 443 0.00048 7.50E-06 0 0.65 0.65 - - - 
NDUFAF1 AfrAm 15 0.25 0.92 7 0.29 0.24 2 0.35 0.29 - - - 
15q11.2-q21.3 E.Asian 12 0.4 0.96 6 0.62 0.51 4 0.54 0.4 - - - 
 
Europ 36 9.60E-05 4.10E-05 35 9.90E-05 0.0001 31 9.30E-05 9.30E-05 - - - 
 
Hisp 18 0.056 0.011 14 0.045 0.0058 5 0.033 0.011 - - - 
 
S.Asian 10 0.44 0.32 1 0.2 0.2 - - - - - - 
 
WES (all) 91(58) 6.10E-05 0.0001 63(38) 6.20E-05 9.20E-07 42(14) 7.60E-05 2.20E-06 0(2) 0 0 
 
ExArray 555(9) 0.02 0.094 535(6) 0.021 0.044 418(2) 0.017 0.018 - - - 
 
WES (all) + ExArray 646 1.50E-05 0.00019 598 1.60E-05 2.30E-06 460 1.50E-05 1.10E-06 - - - 
ALPK1 AfrAm 42 0.83 0.7 30 0.89 0.26 5 0.3 0.059 3 0.26 0.11 
4q25 E.Asian 82 0.85 0.26 55 0.63 0.4 32 0.85 0.84 23 0.68 0.69 
 
Europ 59 0.25 0.77 93 0.46 0.97 51 0.73 0.7 5 0.36 0.2 
 
Hisp 43 0.73 0.44 41 0.49 0.65 14 0.16 0.13 3 0.39 0.39 
 
S.Asian 26 0.036 6.50E-06 22 0.033 1.70E-05 14 0.24 0.011 4 0.16 0.017 
 
WES (all) 252(158) 0.65 0.062 241(105) 0.55 0.014 116(36) 0.7 0.071 38(16) 0.6 0.17 
 
ExArray 5514(26) 0.87 0.75 3237(17) 0.74 0.76 291(4) 0.91 0.83 - - - 
 
WES (all) + ExArray 5766 0.86 0.27 3478 0.71 0.15 407 0.91 0.36 38 0.6 0.17 
ZBTB10 AfrAm 2 0.56 0.37 2 0.56 0.37 - - - - - - 
8q13-q21.1 E.Asian 5 0.18 0.26 5 0.18 0.26 - - - - - - 
 
Europ 7 0.97 0.95 7 0.97 0.95 - - - - - - 
 
Hisp 20 0.82 0.64 18 0.74 0.53 2 0.92 0.92 - - - 
 
S.Asian 5 0.45 0.41 3 0.21 0.46 0 0.73 0.73 - - - 
 
WES (all) 39(44) 0.86 0.41 35(34) 0.76 0.39 2(4) 0.92 0.91 - - - 
 
ExArray 646(5) 7.40E-06 1.90E-05 646(5) 7.40E-06 1.90E-05 - - - - - - 
 
WES (all) + ExArray 685 0.011 0.0011 681 0.0051 0.00094 2 0.92 0.91 - - - 
PLCB3 AfrAm 15 0.0061 0.00012 11 0.0078 2.10E-05 5 0.0072 0.00056 1 0.0056 0.0056 
11q13 E.Asian 24 0.13 0.2 19 0.12 0.6 7 0.16 0.99 - - - 
 
Europ 77 0.59 0.86 65 0.57 0.84 3 0.074 0.093 1 0.9 0.9 
 
Hisp 36 0.23 0.62 32 0.19 0.54 2 0.86 0.59 - - - 
 
S.Asian 19 0.65 0.48 15 0.45 0.29 4 0.97 0.62 - - - 
 
WES (all) 173(121) 0.27 0.35 144(87) 0.23 0.16 21(27) 0.02 0.1 2(2) 0.024 0.043 
 
ExArray 730(12) 0.64 0.84 668(6) 0.67 0.82 8(1) 0.58 0.58 - - - 
 
WES (all) + ExArray 903 0.42 0.67 812 0.42 0.48 29 0.093 0.23 2 0.024 0.043 
              	
Fasting glucose  PTV+missense PTV+NSbroad PTV+NSstrict PTV-only 
Gene Ancestry 
MAC  
(No. vars) P value SKAT P value Burden 
MAC  













G6PC2 AfrAm 17 0.11 0.42 13 0.043 0.29 5 0.17 0.78 2 0.21 0.083 
2q24.3 E.Asian 26 0.26 0.1 21 0.2 0.022 4 0.11 0.034 3 0.18 0.18 
 
Europ 93 0.23 0.11 90 0.22 0.14 69 0.2 0.16 7 0.63 0.63 
 
Hisp 23 0.2 0.24 22 0.19 0.17 21 0.19 0.22 5 0.049 0.53 
 
S.Asian 11 0.059 0.053 9 0.046 0.02 8 0.049 0.047 - - - 
 
WES (all) 170(69) 0.12 0.0028 155(53) 0.1 0.00078 107(19) 0.11 0.01 17(8) 0.22 0.07 
 
ExArray 1174(15) 1.80E-13 4.10E-16 1129(12) 2.00E-13 1.20E-17 913(4) 3.60E-12 5.10E-13 71(1) 0.67 0.67 
 
WES (all) + ExArray 1344 1.30E-09 9.90E-15 1284 8.30E-10 9.60E-17 1020 5.40E-09 1.30E-11 88 0.41 0.23 
GIMAP8 AfrAm 24 0.49 0.28 19 0.35 0.38 3 0.04 0.055 1 0.0019 0.0019 
7q36.1 E.Asian 75 0.58 0.92 38 0.71 0.15 3 0.37 0.15 3 0.37 0.15 
 
Europ 18 0.95 0.54 12 0.75 0.53 4 0.54 0.56 1 0.13 0.13 
 
Hisp 24 0.35 0.88 22 0.3 0.85 6 0.077 0.068 4 0.048 0.048 
 
S.Asian 10 0.031 0.61 6 0.0096 0.28 3 0.011 0.0022 3 0.011 0.0022 
 
WES (all) 151(87) 0.6 0.43 97(52) 0.47 0.088 19(15) 0.012 0.00013 12(11) 0.0029 2.30E-06 
 
ExArray 240(14) 0.25 0.84 219(7) 0.25 0.77 17(2) 0.29 0.19 - - - 
 
WES (all) + ExArray 391 0.38 0.72 316 0.3 0.34 36 0.023 0.00065 12 0.0029 2.30E-06 
OR4S1 AfrAm 43 0.69 0.095 18 0.8 0.2 - - - - - - 
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Fasting glucose   PTV+missense   PTV+NSbroad   PTV+NSstrict  PTV-only 
Gene Ancestry 
MAC  
(No. vars) P value SKAT P value Burden 
MAC  













11p11.2 E.Asian 11 0.032 0.16 4 0.033 0.027 - - - - - - 
 
Europ 19 0.15 0.34 13 0.36 0.87 - - - - - - 
 
Hisp 22 0.21 0.87 15 0.1 0.53 1 0.56 0.56 1 0.56 0.56 
 
S.Asian 20 0.27 0.057 6 0.16 0.029 - - - - - - 
 
WES (all) 115(75) 0.15 0.0074 56(52) 0.16 0.023 1(3) 0.56 0.56 1(3) 0.56 0.56 
 
ExArray 201(8) 0.00051 3.70E-05 33(5) 0.075 0.036 - - - - - - 
 
WES (all) + ExArray 316 0.0011 3.10E-06 89 0.041 0.0036 1 0.56 0.56 1 0.56 0.56 
G6PC AfrAm 1 0.62 0.62 1 0.62 0.62 - - - - - - 
17q21 E.Asian 10 0.73 0.41 9 0.7 0.53 6 0.49 0.27 1 0.74 0.74 
 
Europ 47 0.48 0.62 46 0.47 0.52 6 0.048 0.98 1 0.33 0.33 
 
Hisp 16 0.075 0.052 16 0.075 0.052 14 0.088 0.2 12 0.084 0.057 
 
S.Asian 5 0.76 0.71 4 0.63 0.84 - - - - - - 
 
WES (all) 79(54) 0.38 0.51 76(48) 0.36 0.6 26(21) 0.063 0.14 14(5) 0.092 0.034 
 
ExArray 643(7) 1.90E-05 9.30E-06 643(7) 1.90E-05 9.30E-06 17(3) 0.072 0.077 3(1) 0.0056 0.0056 
 
WES (all) + ExArray 722 0.00086 0.0013 719 0.00076 0.0022 43 0.017 0.039 17 0.0031 0.001 
PIK3AP1 AfrAm 15 0.39 0.87 9 0.47 0.74 0 0.34 0.34 - - - 
10q24.1 E.Asian 22 0.42 0.19 10 0.074 0.12 3 0.18 0.36 - - - 
 
Europ 28 0.78 0.84 7 0.25 0.23 0 0.37 0.37 - - - 
 
Hisp 18 0.00018 0.0011 13 0.00049 1.70E-05 11 0.00045 1.40E-05 - - - 
 
S.Asian 11 0.92 0.8 4 0.85 0.3 3 0.8 0.41 - - - 
 
WES (all) 94(68) 0.019 0.054 43(42) 0.00059 0.017 17(15) 0.00048 0.005 - - - 
 
ExArray 204(9) 0.85 0.35 96(6) 0.57 0.27 35(2) 0.9 0.68 - - - 
 
WES (all) + ExArray 298 0.23 0.078 139 0.015 0.027 52 0.075 0.068 - - - 
ZNF44 AfrAm 9 0.0093 0.5 7 0.071 0.084 - - - - - - 
19p13.2 E.Asian 11 0.72 0.79 7 0.63 0.41 2 0.16 0.054 2 0.16 0.054 
 
Europ 68 0.002 0.0058 50 0.0024 0.02 3 0.41 0.41 3 0.41 0.41 
 
Hisp 14 7.50E-05 0.32 14 7.50E-05 0.32 4 1.40E-05 1.40E-05 4 1.40E-05 1.40E-05 
 
S.Asian 21 0.51 0.004 16 0.54 0.015 1 0.26 0.26 1 0.26 0.26 
 
WES (all) 123(80) 0.00044 0.6 94(56) 0.0002 0.94 10(9) 2.10E-05 0.0086 10(9) 2.10E-05 0.0086 
 
ExArray 570(7) 0.84 0.88 307(5) 0.77 0.52 - - - - - - 
 
WES (all) + ExArray 693 0.05 0.84 401 0.023 0.88 10 2.10E-05 0.0086 10 2.10E-05 0.0086 
OR13A1 AfrAm 71 0.073 0.046 70 0.069 0.072 67 0.06 0.068 62 0.25 0.3 
10q11.21 E.Asian 39 0.74 0.75 30 0.64 0.57 - - - - - - 
 
Europ 184 0.16 0.024 180 0.15 0.029 152 0.82 0.82 151 0.77 0.77 
 
Hisp 93 0.31 0.89 87 0.18 0.99 81 0.1 0.52 80 0.14 0.14 
 
S.Asian 24 0.17 0.13 22 0.14 0.13 16 0.15 0.53 15 0.18 0.18 
 
WES (all) 412(58) 0.16 0.89 390(40) 0.12 0.9 317(6) 0.3 0.57 309(2) 0.45 0.96 
 
ExArray 290(9) 4.30E-05 4.20E-05 257(5) 3.70E-05 1.50E-05 - - - - - - 
 
WES (all) + ExArray 702 0.00024 0.029 647 0.00013 0.021 317 0.3 0.57 309 0.45 0.96 
ANKH AfrAm 10 0.65 0.37 10 0.65 0.37 - - - - - - 
5p15.1 E.Asian 4 0.82 0.37 4 0.82 0.37 1 0.95 0.95 - - - 
 
Europ 22 0.16 0.95 16 0.24 0.4 - - - - - - 
 
Hisp 9 0.55 0.37 9 0.55 0.37 - - - - - - 
 
S.Asian 6 0.74 0.69 6 0.74 0.69 1 0.53 0.53 - - - 
 
WES (all) 51(46) 0.41 0.27 45(45) 0.61 0.082 2(11) 0.83 0.7 0(4) 0 0 
 
ExArray 371(5) 2.60E-05 0.016 202(4) 1.70E-05 5.70E-06 - - - - - - 
 
WES (all) + ExArray 422 0.0013 0.025 247 0.0031 2.20E-05 2 0.83 0.7 - - - 
	
MAP3K7CL AfrAm 13 0.065 0.052 3 0.2 0.8 - - - - - - 
21q22.3 E.Asian 0 0.91 0.91 0 0.91 0.91 - - - - - - 
 
Europ 3 0.38 0.23 2 0.55 0.62 - - - - - - 
 
Hisp 4 0.34 0.59 4 0.34 0.59 1 0.07 0.07 1 0.07 0.07 
 
S.Asian 3 0.92 0.94 1 0.83 0.83 1 0.83 0.83 1 0.83 0.83 
 
WES (all) 23(24) 0.11 0.1 10(19) 0.42 0.97 2(4) 0.18 0.15 2(3) 0.18 0.15 
 
ExArray 9(2) 1.90E-05 1.90E-05 8(1) 2.00E-05 2.00E-05 - - - - - - 
 
WES (all) + ExArray 32 7.60E-05 7.10E-05 18 0.0012 0.053 2 0.18 0.15 2 0.18 0.15 
CDC42BPA AfrAm 16 0.16 0.32 9 0.26 0.36 3 0.09 0.057 1 0.27 0.27 
1q42.11 E.Asian 48 0.041 0.17 38 0.043 0.08 6 0.0007 2.30E-05 - - - 
 
Europ 22 0.79 0.88 18 0.64 0.97 9 0.44 0.93 - - - 
 
Hisp 20 0.21 0.49 12 0.24 0.36 6 0.23 0.22 - - - 
 
S.Asian 23 0.61 0.75 22 0.61 0.92 3 0.12 0.36 - - - 
 
WES (all) 130(154) 0.078 0.57 100(124) 0.086 0.29 27(38) 0.0025 0.11 1(2) 0.27 0.27 
 
ExArray 111(13) 0.76 0.086 93(9) 0.77 0.24 17(4) 0.11 0.3 - - - 
 
WES (all) + ExArray 241 0.31 0.2 193 0.33 0.19 44 0.0022 0.11 1 0.27 0.27 
Page 81 of 91 Diabetes
SUPPLEMENTARY TABLES  Page 12 of 22
 
AfrAm: African American ancestry 
E.Asian: East asian ancestry 
Europ: European ancestry 
Hisp: Hispanic ancestry 
S.Asian: South Asican ancestry 
WES (all): Whole exome sequencing meta-analysis 
ExArray: Exome array meta-analysis 
WES (all) + ExArray: Whole exome sequencing and exome array meta-analysis 
Variant masks: 
PTV: containing only variants predicted to introduce a premature stop codon 
PTV+NS: containing variants in the PTV group and protein-altering variants with 
MAF<1% 
PTV+NSstrict: composed of variants in “PTV” and protein-altering variants predicted 
damaging by SIFT, LRT, MutationTaster, polyphen2 HDIV, and polyphen2 HVAR 
PTV+NSbroad: composed of “PTV+NSstrict” and NS variants with MAF<1% and 
predicted damaging by at least one prediction algorithm. 
 
Supplementary Table 2E: Replication of AKT2 p.Pro50Thr in independent Finnish cohorts and association results in the discovery and replication studies 
combined. 
    
Replication Analysis 
Combined Discovery and 
Replication Analysis 
Trait Location Gene Protein change MAC P N P N 
Fasting Insulin 19:40762860 AKT2 p.P50T 114 0.00054 5747 9.98E-10 25,316 
 




SUPPLEMENTARY TABLE 3  
Protein altering variation in AKT2. Displayed are all variants predicted to cause a nonsynonymous substitution or alter a splice site in 12,940 samples with whole 
exome sequencing data. Annotations were obtained using dbNSFP. 




MAF ExAC MAC MAC cases/ 
MAC 
controls 








Monogenic Functional domain 
- 40771156 p.I7V 1 Eur 5.69E-05 6 3/3 tolerated D D B,B,B B,B,B NA   PH domain 
rs387906659 40762959 E17K - 0 0 0/0 deleterious D D D,D,D D,D,D Thyroid; 
Breast 
hypoketotic hypoglycemia 
with hemihypertrophy (Arya 
2014, Hussain 2011) 
PH domain 
- 40762875 p.P45S - 8.23E-06 1 0/1 tolerated N N B,B,B B,B,B NA  PH domain 
rs184042322 40762860 p.P50T 4 Eur 1.01E-03 61 39/22 tolerated D D B,B,B B,B,B NA  PH domain 
- 40761140 p.N71S 1 Amr 1.98E-04 4 1/3 tolerated D D P,D,P,B P,P,B,B NA  PH domain 
- 40761132 p.V74F - 8.24E-06 1 0/1 tolerated D D B,B,B,B P,B,B,B NA  PH domain 
- 40761069 p.E95K - 4.94E-05 1 1/0 deleterious D D D,P,D,D D,B,P,P NA  PH domain 
- 40761059 splice - 8.24E-06 1 1/0 NA NA NA NA NA NA  PH domain 
- 40748581 p.R101W - 4.16E-05 1 0/1 deleterious N D B,B,B,B B,B,B,B NA  PH domain 
- 40748568 p.M105T - 8.29E-06 1 1/0 tolerated D D B,B,B,B B,B,B,B NA  PH domain 
rs141209878 40748535 p.G116A 1 Eur 2.64E-04 3 1/2 tolerated D N B,B,B,B B,B,B,B NA   
- 40748529 p.D118G - 8.26E-06 1 0/1 tolerated D D B,B,B,B B,B,B,B NA   
- 40748526 p.P119L - 8.26E-06 1 0/1 tolerated N D B,B,B,B B,B,B,B NA   
- 40748518 p.Y122H - 4.95E-05 4 2/2 tolerated N N B,B,B,B B,B,B,B NA   
- 40748517 p.Y122C 1 Eur 1.49E-04 4 2/2 tolerated N D B,B,B,B B,B,B,B NA   
- 40748480 p.E134D - 0 1 0/1 tolerated D D B,B,B,B B,B,B,B NA   
- 40748470 p.V138L - 8.25E-06 1 1/0 tolerated D D B,B,B,B B,B,B,B NA   
- 40747984 splice - 4.87E-04 5 3/2 NA NA NA NA NA NA   
- 40747892 p.R176C - 2.48E-05 1 0/1 deleterious D D D,P,D,D D,P,P,P NA  Protein kinase 
- 40747891 p.R176L - 1.65E-05 2 1/1 tolerated D D B,B,B,B B,B,B,B NA  Protein kinase 
- 40747846 p.K191R - 3.33E-05 1 1/0 tolerated NA NA NA NA NA  Protein kinase 
- 40747837 splice - 2.52E-05 3 1/2 NA NA NA NA NA NA  Protein kinase 
- 40746015 p.D192E - 8.24E-06 1 1/0 tolerated D D D,B,P,B D,B,P,B NA  Protein kinase 
rs35817154 40745968 p.R208K - 2.88E-04 4 2/2 tolerated D D B,B,B,B B,B,B,B NA Severe IR and acanthosis 
nigricans* (Tan 2007) 
Protein kinase 
- 40744879 p.A214V - 2.49E-05 1 1/0 tolerated D D B,B,B B,B,B Prostate  Protein kinase 
- 40744805 splice - 1.65E-05 1 1/0 NA NA NA NA NA NA  Protein kinase 
- 40744001 splice - 2.50E-04 2 1/1 NA NA NA NA NA NA  Protein kinase 
- 40743973 p.R245H - 2.85E-05 2 1/1 deleterious D D P,D,D B,P,D NA  Protein kinase 
- 40743956 p.R251W - 0 2 2/0 deleterious D D D,D,D D,D,D CCLE  Protein kinase 
- 40743953 p.A252T - 1.22E-05 2 1/1 tolerated D D B,B,B B,B,B NA  Protein kinase 
- 40743887 p.R274C - 1.75E-05 2 1/1 deleterious D D D,D,D D,D,D NA  Protein kinase 
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MAF ExAC MAC MAC cases/ 
MAC 
controls 








Monogenic Functional domain 
rs121434593 40743886 p.R274H - 0 0 0/0 deleterious D A D,D,D D,P,D NA severe insulin resistance and 
diabetes (George 2004) 
Protein kinase 
- 40743872 splice - 1.11E-04 6 4/2 NA NA NA NA NA NA  Protein kinase 
- 40742207 p.T306S - 1.40E-04 5 1/4 tolerated D D B,B B,B NA  Protein kinase 
glycosylation site 
- 40741992 p.Y327C - 0 1 1/0 deleterious D D D,D,D D,D,D NA  Protein kinase 
- 40741915 p.Q353E - 8.26E-06 1 0/1 tolerated D D B,B,B B,B,B NA  Protein kinase 
- 40741876 p.E366K - 2.49E-05 3 1/2 tolerated D D B,B,B B,B,B NA  Protein kinase 
- 40741270 splice - 6.70E-05 2 1/1 NA NA NA NA NA NA  Protein kinase 
- 40741222 p.M404T - 8.26E-06 1 0/1 tolerated D D P,P,B P,B,B NA  Protein kinase 
- 40741212 p.R407S - 0 1 0/1 tolerated D D B,B,B B,B,B NA  Protein kinase 
- 40741181 p.V418F - 8.25E-06 1 1/0 tolerated N D B,B,B B,B,B NA  AGC-kinase C-terminal 
- 40741176 p.Q419H - 8.25E-06 1 0/1 tolerated N D B,B,B B,B,B NA  AGC-kinase C-terminal 
- 40741058 splice - 9.90E-05 2 0/2 NA NA NA NA NA NA  AGC-kinase C-terminal 
- 40741026 p.T431M - 2.48E-05 1 1/0 deleterious D D B,P,B B,B,B NA  AGC-kinase C-terminal 
rs191069336 40739865 splice - 9.55E-05 2 1/1 NA NA NA NA NA NA  AGC-kinase C-terminal 
- 40739862 spice - 8.65E-06 1 1/0 NA NA NA NA NA NA  AGC-kinase C-terminal 
- 40739853 p.S458C - 1.71E-05 2 0/2 tolerated N D B,B B,B NA  AGC-kinase C-terminal 
rs142926499 40739826 p.R467W - 1.01E-04 1 0/1 deleterious D D D,D P,P NA T2D and partial 
lipodystrophy* (Tan 2007) 
AGC-kinase C-terminal 
SUPPLEMENTARY TABLE 4  
Association of AKT2 p.Pro50Thr with diabetes-related metabolic traits in Finnish Cohorts. 
Supplementary Table 4A: Association with quantitative metabolic traits. 
Trait Group Trait N MAF Effect (Std. Err) on inverse-
normalized trait residuals 
P Padjusted 
Anthropometric Traits Waist-hip ratio 31966 0.012 0.045 (0.0383) 0.24 1 
 Waist-hip ratio - females 12445 0.011 0.0822 (0.065) 0.21 1 
 Waist-hip ratio - males 19521 0.013 0.0299 (0.0473) 0.53 1 
 Waist circumference 31970 0.012 0.0354 (0.0384) 0.36 1 
 Waist circumference - females 12448 0.011 0.0741 (0.065) 0.25 1 
 Waist circumference - males 19522 0.013 0.0227 (0.0475) 0.63 1 
 Hip circumference 31972 0.012 -0.00851 (0.0384) 0.83 1 
 Hip circumference - females 12448 0.011 -0.0254 (0.0648) 0.70 1 
 Hip circumference - males 19524 0.013 -0.00317 (0.0476) 0.95 1 
 Body mass index 34597 0.012 -0.0978 (0.0371) 0.01 0.19 
 Height 34601 0.012 -0.105 (0.0373) 4.7E-03 0.11 
Lipid Traits HDL-C 36923 0.012 0.027 (0.0348) 0.44 1 
 LDL-C 31045 0.012 0.0604 (0.0372) 0.11 1 
 Total cholesterol 36939 0.012 0.0926 (0.0348) 0.01 0.18 
 Triglycerides 31303 0.012 -0.0418 (0.0371) 0.26 1 
 Adiponectin 10036 0.013 -0.0320 (0.0290) 0.27 1 
Glycemic Traits Fasting Glucose 22015 0.011 0.0163 (0.0468) 0.73 1 
 Fasting Insulin 21792 0.011 0.286 (0.0473) 1.5E-09 3.5E-08 
 2 hour Glucose 16715 0.0119 0.0717 (0.0952) 0.40 1 
 2 Hour Insulin 14150 0.0121 0.2337 (0.0435) 7.86E-08 1.8E-06 
 Matsuda index * 8566 0.012 -0.3448 (0.0709) 1.2E-06 2.8E-05 
Blood Pressure Traits Systolic blood pressure 31840 0.012 0.0115 (0.0384) 0.77 1 
 Diastolic blood pressure 31840 0.012 0.0705 (0.0384) 0.07 1 
 
N: sample size contributing to association 
MAF: minor allele frequency 
Effect (Std. Err): regression estimate of the additive genetic effect and standard error of the estimate 
P: P-value testing the significance of the association 
Padjusted: A Bonferroni P value correction for 23 tests was applied	
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Supplementary Table 4B: T2D and hypertension association analysis with AKT2 p.Pro50Thr. These analyses was performed in a staged meta-analysis modeling 
the approach taken in the discovery and replication of the FI association with AKT2 p.Pro50Thr, with the European exome sequence data, the Finnish exome chip 
cohorts and the Finnish replication cohorts. 
Outcome Adjustment 
Genotypes in Cases / 
Controls MAF N 
Odds Ratio  
(95% CI) P Padjusted 


















  Outcome: dichotomous outcome tested 
Adjustment: indicates if BMI was used as a covariate in addition to sex and age. 
MAF: minor allele frequency 
Odds Ratio (95% CI): odds ratio estimate for increased risk of outcome and 95% confidence interval of the estimate 
Padjusted: A Bonferroni P value correction for 23 tests was applied. 
 
Supplementary Table 4C: Statistics for differences in HbA1c, fasting glucose, and fasting insulin distributions in the sample sub-cohorts with the AKT2 P50T 
allele from the T2D-GENES whole exome sequencing data. Here, we provide genotype counts, median values of the scaled trait value, and tests difference in 
distributions using the non-parametric Kruskal-Wallis rank sum test and Monte Carlo permutation test. 
 
  Control Group  Type 2 Diabetes Group 
Trait Cohort AKT2 P50T Genotype 
counts: 0/0; 0/1; 1/1 
Median scaled trait 
value: 




Permutation Test P 
 
AKT2 P50T Genotype 
counts: 
0/0; 0/1; 1/1 
Median scaled trait value: 





Permutation Test P 
Percentile value for 
homozygous carrier 
(1/1) 





Botnia 220; 1; 0 -0.41; -0.33; NA 0.38 0.52  0; 0; 0     
FUSION 467; 9; 0 -0.32; -0.43; NA 0.12 0.12  0; 0; 0     
 METSIM 486; 12; 0 -0.28; -0.22; NA 0.016 0.071  465; 18; 1 0.41; 0.60; 4.6 0.06 0.002 99.8% 
Fasting 
Insulin 
Botnia 205; 1; 0 -0.35; -0.30; NA 0.82 0.91  0; 0; 0     
FUSION 464; 9; 0 1.1; 0.96; NA 0.86 0.46  0; 0; 0     
 METSIM 485; 12; 0 -0.49; -0.44; NA 0.32 0.56  465; 18; 1 -0.17; -0.29; 5.3 0.17 0.017 98.8% 
Genotype categories: 0/0 indicates the group of individuals who are homozygote for the reference allele at rs184042322 (C/C);  0/1 indicates the group of individuals who are 
heterozygote at rs184042322 (C/T); 1/1 indicates the group of individuals who are homozygote for the AKT2 p.Pro50Thr allele at rs184042322 (T/T). 
 
SUPPLEMENTARY TABLE 5  
Phenotype exploration of AKT2 p.Pro50Thr carriers electronic medical records. 
Phenotype exploration of AKT2 p.Pro50Thr carriers electronic medical records were queried in two cohorts for diseases plausibly related to AKT2. The genotype 
counts for the AKT2 p.Pro50Thr variant are displayed for individuals not coded for an outcome (Controls) and individuals coded for an outcome (Cases). * Other 
related phenotype outcome included Lipodystrophy (E88.1), Acanthosis nigricans (L83), and Malignant neoplasm of male breast (C50.*2). No cases were reported 
for these outcomes in both METSIM and FINRISK. ** ICD 10 codes are used to obtain diagnoses of the phenotype outcome from hospital discharge records or 
electronic health records. 
   
Genotype counts  (GG/TG/TT) 
Controls Cases 
Malignant neoplasm of digestive organs and peritoneum C15 – C26 
METSIM 8708/215/3 42/1/0 
FINRISK 8200/182/1 146/1/0 
Malignant neoplasm of genitourinary organs C55 – C68 METSIM 8620/213/3 130/3/0 FINRISK 8154/180/1 192/3/0 
Malignant neoplasm of female breast C50.*1 FINRISK 4167/87/0 70/1/0 
Ovaries, polycystic E28.2 FINRISK 4236/88/0 1/0/0 
Cyst of ovary, follicular N83.0 FINRISK 4233/88/0 4/0/0 
ICD = International Classification of Diseases 
OR = Odds ratio 
95% CI = 95% Confidence interval 
METSIM = Metabolic Syndrome in Men Study 
FINRISK = The National FINRISK Study
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SUPPLEMENTARY TABLE 6  
Aggregate test of variants in monogenic gene sets and in the Insulin Receptor Signaling Pathway. 
 
Supplementary Table 6A: List of the genes in the monogenic gene sets and the Insulin Receptor Signaling Pathway. 
Chr Location Gene 










1 1p12 SLC16A1/MCT1 hyperinsulinsim 1 1 1 0 
1 1p21 S1PR1 
 
0 0 0 1 
1 1p22 BCL10 
 
0 0 0 1 
1 1p31 LEPR 
 
1 0 0 0 
1 1p32 TAL1 
 
0 0 0 1 
1 1p32-p31 JUN 
 
0 0 0 1 
1 1p34 PTPRF 
 
0 0 0 1 
1 1p34 YBX1 
 
0 0 0 1 
1 1p34 ZMPSTE24 
 
1 1 1 0 
1 1p34.1 PIK3R3 
 
0 0 0 1 
1 1p36.11 SFN 
 
0 0 0 1 
1 1p36.2 MTOR 
 
0 0 0 1 
1 1p36.2 PIK3CD 
 
0 0 0 1 
1 1p36.21 CASP9 
 
0 0 0 1 
1 1p36.33 SKI 
 
0 0 0 1 
1 1q21 CLK2 
 
0 0 0 1 
1 1q21 MCL1 
 
0 0 0 1 
1 1q21 SHC1 
 
0 0 0 1 
1 1q21 THEM4 
 
0 0 0 1 
1 1q22 DAP3 
 
0 0 0 1 
1 1q22 LMNA 
 
1 1 1 0 
1 1q23.3 SLC19A2 NDM 1 0 0 0 
1 1q25 NCF2 
 
0 0 0 1 
1 1q25.2-q25.3 PTGS2 
 
0 0 0 1 
1 1q32 PIK3C2B 
 
0 0 0 1 
2 2p12 EIF2AK3 NDM 1 1 0 0 
2 2p13 ALMS1 syndromic 1 1 1 0 
2 2p13 HK2 
 
0 0 0 1 
2 2p16.1 CCDC88A 
 
0 0 0 1 
2 2p21 RHOQ 
 
0 0 0 1 
2 2p23.3 POMC 
 
1 0 0 0 
2 2p25 KLF11 MODY7 1 0 0 0 
2 2q12.3 LIMS1 
 
0 0 0 1 
2 2q31.1 BBS5 
 
1 0 0 0 
2 2q31.1 C2ORF37/DCAF17 1 0 0                  0 
2 2q32 NEUROD1 MODY6 NDM 1 1 1 0 
2 2q32.2 STAT1 
 
0 0 0 1 
2 2q34 PIKFYVE 
 
0 0 0 1 
2 2q36 IRS1 
 
0 0 0 1 
3 3p21 CTNNB1 
 
0 0 0 1 
3 3p21.3 USP4 
 
0 0 0 1 
3 3p25 PPARG 
 
1 1 1 0 
3 3p25 RAF1 
 
0 0 0 1 
3 3p25.3 CIDEC 
 
1 0 0 0 
3 3q11.2 ARL6 
 
1 0 0 0 
3 3q13.3 GSK3B 
 
0 0 0 1 
3 3q21 NCK1 
 
0 0 0 1 
3 3q22.1 TOPBP1 
 
0 0 0 1 
3 3q22.3 PIK3CB 
 
0 0 0 1 
3 3q26.1-q26.2 SLC2A2/GLUT2 NDM 1 1 1 0 
3 3q26.3 PIK3CA/PI3K 
 
1 1 1 1 
4 4p15.1 PPARGC1A 
 
0 0 0 1 
4 4p16.1 WFS1 NDM 1 1 1 0 
4 4p16.3 HTT 
 
0 0 0 1 
4 4q22-q26 HADH hyperinsulinsim 1 1 1 0 
4 4q23 EIF4E 
 
0 0 0 1 
4 4q24 CISD2 (WFS2) 
 
1 1 1 0 
4 4q25 SEC24B 
 
0 0 0 1 
4 4q27 BBS12 
 
1 0 0 0 
Chr Location Gene 










4 4q27 BBS7 
 
1 0 0 0 
4 4q31.21 GAB1 
 
0 0 0 1 
4 4q34 CASP3 
 
0 0 0 1 
4 4q35.1 SORBS2 
 
0 0 0 1 
5 5p12 PRKAA1 
 
0 0 0 1 
5 5p15.33 TERT 
 
0 0 0 1 
5 5q11.1 ISL1 
 
1 0 0 0 
5 5q13.1 PIK3R1 
 
1 1 1 1 
5 5q13.3 RASA1 
 
0 0 0 1 
5 5q15-q21 PCSK1 
 
1 0 0 0 
5 5q31 SMAD5 
 
0 0 0 1 
5 5q32 SPINK1/PST1 
 
1 0 0 0 
5 5q33 HAND1 
 
0 0 0 1 
5 5q35.1 NPM1 
 
0 0 0 1 
6 6p21 RUNX2 
 
0 0 0 1 
6 6p21.1 SRF 
 
0 0 0 1 
6 6p21.2 CDKN1A 
 
0 0 0 1 
6 6p21.31 POU5F1 
 
0 0 0 1 
6 6p22.1 ZFP57 NDM 1 0 0 0 
6 6p25 FOXC1 
 
0 0 0 1 
6 6q21 FOXO3 
 
0 0 0 1 
6 6q21 FYN 
 
0 0 0 1 
6 6q22.1 RFX6 NDM 1 1 1 0 
6 6q22.31 GJA1 
 
0 0 0 1 
6 6q22.33 MAP3K5 
 
0 0 0 1 
6 6q23 SGK1 
 
0 0 0 1 
6 6q24-q25 PLAGL1 NDM 1 0 0 0 
6 6q24.2 HYMAI NDM 1 0 0 0 
6 6q25.1 ESR1 
 
0 0 0 1 
6 6q26 IGF2R 
 
0 0 0 1 
6 6q27 MLLT4 
 
0 0 0 1 
7 7p12 EGFR 
 
0 0 0 1 
7 7p12.2 GRB10 
 
0 0 0 1 
7 7p14 BBS9 
 
1 0 0 0 
7 7p15.3-p15.1 GCK MODY2 NDM 1 1 1 0 
7 7p21.2 TWIST1 
 
0 0 0 1 
7 7p22 RAC1 
 
0 0 0 1 
7 7q11.23 NCF1 
 
0 0 0 1 
7 7q22 DLX5 
 
0 0 0 1 
7 7q22 SH2B2 
 
0 0 0 1 
7 7q22-q31.1 SRPK2 
 
0 0 0 1 
7 7q22.1 COPS6 
 
0 0 0 1 
7 7q22.3 PIK3CG 
 
0 0 0 1 
7 7q31.1 CAV1 
 
1 1 1 0 
7 7q31.1 PPP1R3 
 
1 1 1 0 
7 7q31.2 CFTR 
 
1 0 0 0 
7 7q31.3 LEP 
 
1 0 0 0 
7 7q32 PAX4 MODY9 1 0 0 0 
7 7q34 BRAF 
 
0 0 0 1 
7 7q34 PRSS1 
 
1 0 0 0 
7 7q36 MNX1 NDM 1 1 1 0 
7 7q36 NOS3 
 
0 0 0 1 
7 7q36 RHEB 
 
0 0 0 1 
8 8p11 KAT6A 
 
0 0 0 1 
8 8p12 EIF4EBP1 
 
0 0 0 1 
8 8p12 WRN/RECQL2 
 
1 1 0 0 
8 8p21.1 PTK2B 
 
0 0 0 1 
8 8p22-p21 DPYSL2 
 
0 0 0 1 
8 8p23-p22 BLK MODY11 1 0 0 0 
8 8p23.1-p22 GATA4 NDM 1 1 1 0 
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Chr Location Gene 










8 8q22.2 STK3 
 
0 0 0 1 
8 8q23.1 YWHAZ 
 
0 0 0 1 
8 8q24.3 NDRG1 
 
0 0 0 1 
8 8q24.3 PTK2 
 
0 0 0 1 
9 9p21 RPS6 
 
0 0 0 1 
9 9p24.2 GLIS3 NDM 1 1 1 0 
9 9q33.1 TRIM32/BBS11 
 
1 0 0 0 
9 9q33.3 MAPKAP1 
 
0 0 0 1 
9 9q34 TSC1 
 
0 0 0 1 
9 9q34.3 AGPAT2 
 
1 0 0 0 
9 9q34.3 CEL MODY8 1 1 0 0 
9 9q34.3 RAPGEF1 
 
0 0 0 1 
10 10p11.23 BMI1 
 
0 0 0 1 
10 10p11.23 MAP3K8 
 
0 0 0 1 
10 10p12.2 PTF1A NDM 1 1 1 0 
10 10q11.22 MAPK8 
 
0 0 0 1 
10 10q21.3 NEUROG3 NDM 1 1 1 0 
10 10q21.3 SIRT1 
 
1 0 0 0 
10 10q23.3 GLUD1 hyperinsulinsim 1 1 1 0 
10 10q23.3 PTEN 
 
1 1 1 1 
10 10q24-q25 CHUK 
 
0 0 0 1 
11 11p11.2 MAPK8IP1 
 
0 0 0 1 
11 11p13 PAX6 NDM 1 0 0 0 
11 11p15 ARFIP2 
 
0 0 0 1 
11 11p15.1 ABCC8 MODY NDM 1 1 1 0 
11 11p15.1 KCNJ11 MODY NDM 1 1 1 0 
11 11p15.1 PDE3B 
 
0 0 0 1 
11 11p15.4 ILK 
 
0 0 0 1 
11 11p15.5 CDKN1C 
 
0 0 0 1 
11 11p15.5 INS MODY10 NDM 1 1 1 0 
11 11p15.5-p14 PIK3C2A 
 
0 0 0 1 
11 11q13 BBS1 
 
1 0 0 0 
11 11q13 BSCL2 
 
1 1 1 0 
11 11q13 CCND1 
 
0 0 0 1 
11 11q13 RELA 
 
0 0 0 1 
11 11q13 UCP2 hyperinsulinsim 1 1 1 0 
11 11q13 YAP1 
 
0 0 0 1 
11 11q13.1 BAD 
 
0 0 0 1 
11 11q13.1-q13.3 MAP3K11 
 
0 0 0 1 
11 11q23.3 CBL 
 
0 0 0 1 
11 11q24.2 CHEK1 
 
0 0 0 1 
12 12p12 PIK3C2G 
 
0 0 0 1 
12 12p13.1-p12 CDKN1B 
 
0 0 0 1 
12 12p13.31 NANOG 
 
0 0 0 1 
12 12q12-q14 PRKAG1 
 
0 0 0 1 
12 12q13 NR4A1 
 
0 0 0 1 
12 12q13.1 SP1 
 
0 0 0 1 
12 12q14.3-q15 MDM2 
 
0 0 0 1 
12 12q21.2 BBS10 
 
1 0 0 0 
12 12q21.32 CEP290 
 
1 0 0 0 
12 12q23.2 IGF1 
 
0 0 0 1 
12 12q24 PTPN11 
 
0 0 0 1 
12 12q24.1-q24.3 PRKAB1 
 
0 0 0 1 
12 12q24.2 HNF1A MODY3 1 1 0 0 
12 12q24.31 PXN 
 
0 0 0 1 
12 12q24.33 CHFR 
 
0 0 0 1 
13 13q12.1 PDX1/IPF1 MODY4 NDM 1 1 1 0 
13 13q13.1 STARD13 
 
0 0 0 1 
13 13q14.1 FOXO1 
 
0 0 0 1 
13 13q14.2 RB1 
 
0 0 0 1 
13 13q22.2 TBC1D4 
 
0 0 0 1 
13 13q34 IRS2 
 
0 0 0 1 
14 14q11.2 NDRG2 
 
0 0 0 1 
14 14q12 LTB4R2 
 
0 0 0 1 
14 14q13 NFKBIA 
 
0 0 0 1 
14 14q23.2 HIF1A 
 
0 0 0 1 
14 14q24 SRSF5 
 
0 0 0 1 
14 14q24.3 FOS 
 
0 0 0 1 
14 14q31.3 TTC8/BBS8 
 
1 0 0 0 
14 14q32.32 AKT1 
 
0 0 0 1 
15 15q NEDD4 
 
0 0 0 1 
Chr Location Gene 










15 15q21 MYO5A 
 
0 0 0 1 
15 15q21.2 USP8 
 
0 0 0 1 
15 15q22.3-q23 BBS4 
 
1 0 0 0 
15 15q22.33 SMAD3 
 
0 0 0 1 
15 15q24.1 EDC3 
 
0 0 0 1 
15 15q26 PLIN 
 
1 1 1 0 
15 15q26.3 IGF1R 
 
0 0 0 1 
16 16p11.2 SH2B1 
 
1 0 0 0 
16 16p11.2 STX4 
 
0 0 0 1 
16 16p13.3 TSC2 
 
0 0 0 1 
16 16q21 BBS2 
 
1 0 0 0 
17 17p11.2 SREBF1 
 
0 0 0 1 
17 17p12 MAP2K4 
 
0 0 0 1 
17 17p13 SLC2A4 
 
0 0 0 1 
17 17p13.1 PIK3R5 
 
0 0 0 1 
17 17p13.1 PIK3R6 
 
0 0 0 1 
17 17p13.1 TP53 
 
0 0 0 1 
17 17p13.1 VAMP2 
 
0 0 0 1 
17 17p13.3 YWHAE 
 
0 0 0 1 
17 17q12 HNF1B MODY5 NDM 1 1 1 0 
17 17q21 BRCA1 
 
0 0 0 1 
17 17q21.1 MAPT 
 
0 0 0 1 
17 17q21.2 ACLY 
 
0 0 0 1 
17 17q21.2 PTRF 
 
1 1 1 0 
17 17q21.31 STAT3 
 
0 0 0 1 
17 17q22 MKS1 
 
1 0 0 0 
17 17q22 SRSF1 
 
0 0 0 1 
17 17q22 STXBP4 
 
0 0 0 1 
17 17q23.1 RPS6KB1 
 
0 0 0 1 
17 17q24-q25 GRB2 
 
0 0 0 1 
17 17q25.3 RPTOR 
 
0 0 0 1 
17 17q25.3 SOCS3 
 
0 0 0 1 
18 18q11.1-q11.2 GATA6 NDM 1 1 1 0 
18 18q12 IER3IP1 NDM 1 0 0 0 
18 18q21.3 BCL2 
 
0 0 0 1 
18 18q22 MC4R 
 
1 0 0 0 
19 19p13.11 GDF15 
 
0 0 0 1 
19 19p13.2 CDC37 
 
0 0 0 1 
19 19p13.3 STK11 
 
0 0 0 1 
19 19p13.3 TRIP10 
 
0 0 0 1 
19 19p13.3-p13.2 INSR 
 
1 1 1 1 
19 19q13.1-q13.2 AKT2 
 
1 1 1 1 
19 19q13.12 NFKBID 
 
0 0 0 1 
19 19q13.2 GSK3A 
 
0 0 0 1 
19 19q13.2 LIPE 
 
0 0 0 1 
19 19q13.2-q13.4 PIK3R2 
 
0 0 0 1 
19 19q13.3 DMPK 
 
1 0 0 0 
19 19q13.3 POLD1 
 
1 1 1 0 
19 19q13.3-q13.4 BAX 
 
0 0 0 1 
19 19q13.3-q13.4 IRF3 
 
0 0 0 1 
19 19q13.33 AKT1S1 
 
0 0 0 1 
20 20p12 MKKS 
 
1 0 0 0 
20 20q11.2-q13.2 STK4 
 
0 0 0 1 
20 20q11.21 BCL2L1 
 
0 0 0 1 
20 20q12-q13 SRC 
 
0 0 0 1 
20 20q13.1-q13.2 PTPN1 
 
0 0 0 1 
20 20q13.12 HNF4A MODY1 1 1 1 0 
20 20q13.2 SGK2 
 
0 0 0 1 
20 20q13.31 RBM38 
 
0 0 0 1 
20 20q13.33 DNAJC5 
 
0 0 0 1 
21 21q22.3 AIRE 
 
1 0 0 0 
21 21q22.3 PCNT 
 
1 0 0 0 
23 Xp11.23 FOXP3 NDM 1 0 0 0 
NA NA C8orf44-SGK3/SGK3 0 0 0 1 
X Xp11.2 ELK1 
 
0 0 0 1 
X Xq13.1 FOXO4 
 
0 0 0 1 
X Xq22.3 IRS4 
 
0 0 0 1 
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Supplementary Table 6B: Global test of monogenic genes from exome chip analysis. Aggregate tests of rare variants based on functional annotation were 
performed using exome array variants in all the genes in each gene set. We performed conditional analyses to understand the variants contributing to the 
significant association signals. 
Trait Gene set Test PTV PTV+NSstrict PTV+NSbroad PTV+Missense 
Fasting Insulin All Monogenic SKAT 0.275 0.494 0.014* 0.028 
BURDEN 0.972 0.012 0.00024*** 0.019 
Monogenic Insulin SKAT 0.173 0.618 0.002* 0.011 
BURDEN 0.136 0.147 0.001* 0.01 
Insulin Receptor Signaling 
Pathway 
SKAT 0.361901 0.826451 0.011 0.00066**** 
BURDEN 0.595991 0.800962 0.278479 0.072434 
       
Fasting Glucose All Monogenic SKAT 0.073 0.078 0.635 0.712 
BURDEN 0.00697** 0.131 0.041 0.375 
Monogenic Glucose SKAT 0.073 0.026 0.224 0.189 
BURDEN 0.0098** 0.431 0.051 0.346 
        
* After conditioning on ATK2 p.Pro50Thr, the global test P values for the Monogenic gene set was P=0.38 (SKAT). For the Monogenic Insulin gene set, the conditional P values were 
P = 0.02 (SKAT) and  P = 0.017 (BURDEN).  
** After conditioning on BSCL2 p.Q271*, the global test was P = 0.019 (BURDEN) for the Monogenic gene set and P = 0.039 (BURDEN) for the Monogenic Glucose gene set.  
*** Conditional analysis of this test is presented in Supplementary Table 6C.  
**** After conditioning on AKT2 p.Pro50Thr, the global test P values for the Insulin Receptor Signaling Pathway was P=0.01. 
 
Supplementary Table 6C: Global test of monogenic genes from exome sequencing analysis. 
Trait Gene set Test PTV PTV+NSstrict PTV+NSbroad PTV+NS 
Fasting Insulin 
Monogenic SKAT 0.25 0.15 0.15 0.48 
 BURDEN 0.91 0.2 0.87 0.55 Monogenic Insulin SKAT 0.44 0.39 0.49 0.71 
 BURDEN 0.95 0.31 0.05 0.62 
 Insulin Receptor Signaling Pathway 
SKAT 0.52 0.04 0.26 0.69 
 BURDEN 0.61 0.04 0.79 0.12 Fasting Glucose Monogenic SKAT 0.49 0.93 0.82 0.6 
  BURDEN 0.86 0.1 0.92 0.83 
 Monogenic Glucose SKAT 0.22 0.74 0.52 0.49 
  BURDEN 0.97 0.5 0.96 0.33 
Variant masks: 
PTV: containing only variants predicted to introduce a premature stop codon 
PTV+NS: containing variants in the PTV group and protein-altering variants with MAF<1% 
PTV+NSstrict: composed of variants in “PTV” and protein-altering variants predicted damaging by SIFT, LRT, MutationTaster, polyphen2 HDIV, and polyphen2 HVAR 
PTV+NSbroad: composed of “PTV+NSstrict” and NS variants with MAF<1% and predicted damaging by at least one prediction algorithm. 
 
Supplementary Table 6D: Sequential conditional analysis of the exome chip global BURDEN test with the monogenic all gene set for FI with PTV + NSstrict + 
Nsbroad variants. Variants that contributed the most to the association, as reported by RAREMETALS v.4.7, were added to the model sequentially. Single variant 
association results of these variants are provided in Supplementary Table 7B.  
Location rsID REF ALT Gene Protein change 
Global Test  
P value after conditioning 
No conditioning      0.00024 19:40762860 rs184042322 G T AKT2 p.P50T 0.0017 
7:117282582 rs11971167 G A CFTR p.D1270N 0.0029 
19:7125518 rs1799816 C T INSR p.V1012M 0.0087 
1:40756572 rs41268053 G A ZMPSTE24 p.R369Q 0.0089 
6:29641139 rs199589695 G A ZFP57 p.R178H 0.0098 
7:117171169 rs78756941 G T CFTR Splice donor 0.0089 
21:47831307 rs201709021 G A PCNT p.E1785K 0.0104 
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Supplementary Table 6E: Association results of the variants contributing to the exome chip global burden test association of the “Monogenic” genes for FI level. 
Location rsID REF ALT Gene Protein change Effect Allele;  Effect allele frequency 
Effect  
(Standard error) BF P N 
19:40762860 rs184042322 G T AKT2 p.P50T T; 0.011 0.112 (0.023) 5.4 2.1×10-7 28118 
7:117282582 rs11971167 G A CFTR p.D1270N A; 0.008 0.143 (0.048) 1.7 1.5×10-3 9898 
19:7125518 rs1799816 C T INSR p.V1012M T; 0.01 0.065 (0.02) 1.1 5.4×10-3 32685 
1:40756572 * rs41268053 G A ZMPSTE24 p.R369Q - - - 7.1×10-3 ** - 
6:29641139 * rs199589695 G A ZFP57 p.R178H - - - 7.2×10-3 ** - 
7:117171169 * rs78756941 G T CFTR Splice donor T; 0.001 -0.426 (0.161) 1 9.7×10-3 4136 
21:47831307 * rs201709021 G A PCNT p.E1785K - - - 7.9×10-3 ** - 
 
* Single variant association tests were not performed because variant did not meet the inclusion criteria (MAC > 5 within each cohort).  
** P values from the RAREMETALS v.4.7 software. 
BF: log10( Bayes factor) for association 
P: P value for association test 
N: Total Sample size contributing to analysis 
 
SUPPLEMENTARY TABLE 7  
Gene-based and single-variant association results from genes highlighted in the enrichment analyses.  
 
Supplementary Table 7A: Gene based results of the monogenic genes or insulin receptor signaling genes exhibiting enrichment of association signals. 
Fasting insulin  PTV+missense PTV+NSbroad PTV+NSstrict PTV-only 
Gene Ancestry MAC (No. 
vars) 
P value SKAT P value Burden MAC (No. 
vars) 










AKT2 AfrAm 1 0.67 0.67 1 0.67 0.67 - - - 3 0.043 0.52 
19q13.1-q13.2 E.Asian 5 0.33 0.15 5 0.33 0.15 <1 0.65 0.65 1 0.95 0.95 
 
Europ 31 0.53 0.31 31 0.53 0.31 - - - 3 0.12 0.12 
 
Hisp 7 0.42 0.13 7 0.42 0.13 - - - 2 0.55 0.88 
 
S.Asian 2 0.86 0.83 1 0.6 0.6 - - - - - - 
 
WES (all) 46(36) 0.6 0.051 45(33) 0.57 0.052 <1(5) 0.65 0.65 9(14) 0.083 0.52 
 
ExArray 398(4) 6.10E-07 3.60E-06 398(4) 6.10E-07 3.60E-06 - - - 5(2) 0.63 0.99 
 
WES (all) + ExArray 444 0.00056 7.30E-06 443 0.00048 7.50E-06 <1 0.65 0.65 14 0.23 0.96 
INSR AfrAm 29 0.43 0.98 20 0.29 0.79 1 0.75 0.75 1 0.75 0.75 
19p13.3-p13.2 E.Asian 29 0.015 0.29 24 0.02 0.095 - - - - - - 
 
Europ 42 0.46 0.76 35 0.42 0.89 1 0.73 0.73 - - - 
 
Hisp 7 0.48 0.68 6 0.66 0.26 - - - - - - 
 
S.Asian 16 0.39 0.029 5 0.14 0.021 - - - - - - 
 
WES (all) 123(127) 0.17 0.62 90(96) 0.12 0.99 2(9) 0.9 0.64 1(4) 0.75 0.75 
 
ExArray 767(10) 0.0066 0.035 667(6) 0.0074 0.033 - - - - - - 
 
WES (all) + ExArray 890 0.0074 0.14 757 0.0055 0.61 2 0.9 0.64 1 0.75 0.75 
ZMPSTE24 AfrAm 1 0.28 0.28 1 0.28 0.28 1 0.28 0.28 1 0.28 0.28 
1p34 E.Asian 6 0.62 0.86 6 0.62 0.86 4 0.83 0.79 - - - 
 
Europ 10 0.35 0.65 9 0.54 0.84 6 0.54 0.53 5 0.42 0.52 
 
Hisp 8 0.75 0.49 8 0.75 0.49 5 0.53 0.87 4 0.49 0.74 
 
S.Asian 8 0.072 0.94 8 0.072 0.94 1 0.18 0.18 - - - 
 
WES (all) 33(51) 0.23 0.82 32(46) 0.3 0.56 17(22) 0.73 0.62 10(9) 0.54 0.74 
 
ExArray 8(2) 0.011 0.078 8(2) 0.011 0.078 - - - - - - 
 
WES (all) + ExArray 41 0.016 0.36 40 0.024 0.18 17 0.73 0.62 10 0.54 0.74 
CFTR AfrAm 37 0.39 0.5 43 0.34 0.4 30 0.2 0.19 2 0.16 0.16 
7q31.2 E.Asian 99 0.45 0.76 67 0.25 0.43 20 0.32 0.045 1 0.55 0.55 
 
Europ 179 0.27 0.26 109 0.17 0.7 52 0.35 0.41 7 0.98 0.57 
 
Hisp 107 0.015 0.66 74 0.0096 0.043 42 0.0073 0.074 - - - 
 
S.Asian 50 0.0021 0.92 41 0.0016 0.36 23 0.0039 0.13 2 0.23 0.8 
 
WES (all) 474(248) 0.031 0.36 335(216) 0.012 0.11 168(100) 0.011 0.027 12(27) 0.76 0.48 
 
ExArray 3410(54) 0.58 0.82 3851(50) 0.53 0.31 2140(25) 0.27 0.049 28(7) 0.076 0.34 
 
WES (all) + ExArray 3884 0.12 0.65 4186 0.063 0.11 2308 0.021 0.0057 40 0.3 0.38 
ZFP57 AfrAm 30 0.45 0.74 5 1 0.93 - - - - - - 
6p22.1 E.Asian 74 0.58 0.42 1 0.21 0.21 - - - - - - 
 
Europ 11 0.49 0.4 - - - - - - - - - 
 
Hisp 20 1 1 - - - - - - - - - 
 
S.Asian 6 0.15 0.24 4 0.093 0.093 - - - - - - 
 
WES (all) 141(55) 0.77 0.76 10(17) 0.27 0.59 - - - - - - 
 
ExArray 243(10) 0.65 0.41 4(1) 0.0077 0.0077 - - - - - - 
 
WES (all) + ExArray 384 0.78 0.63 14 0.016 0.061 - - - - - - 
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Fasting insulin  PTV+missense PTV+NSbroad PTV+NSstrict PTV-only 
Gene Ancestry MAC (No. 
vars) 
P value SKAT P value Burden MAC (No. 
vars) 










PCNT AfrAm 129 0.31 0.34 36 0.28 0.057 3 0.043 0.52 - - - 
21q22.3 E.Asian 252 0.51 0.85 92 0.64 0.61 1 0.95 0.95 - - - 
 
Europ 174 0.043 0.61 75 0.16 0.11 3 0.12 0.12 - - - 
 
Hisp 110 0.32 0.87 32 0.53 0.36 2 0.55 0.88 - - - 
 
S.Asian 40 0.99 0.54 18 0.88 0.52 - - - - - - 
 
WES (all) 706(531) 0.14 0.94 254(230) 0.4 0.16 9(14) 0.083 0.52 - - - 
 
ExArray 3805(86) 0.58 0.65 2205(39) 0.88 0.98 5(2) 0.63 0.99 - - - 
 
WES (all) + ExArray 4511 0.26 0.91 2459 0.75 0.75 14 0.23 0.96 - - - 
PTGS2 Afr. Amer. 2 0.74 0.74 - - - - - - - - - 
1q25.2-q25.3 E.Asian 23 0.042 0.0062 4 0.27 0.29 - - - - - - 
 
European 13 0.0024 0.0043 7 0.72 0.49 1 0.41 0.41 - - - 
 
Hispanic 6 0.29 0.39 - - - - - - - - - 
 
S.Asian 2 0.43 0.43 2 0.43 0.43 2 0.43 0.43 - - - 
 
all sequencing 46(31) 0.0041 0.00011 13(21) 0.64 0.16 3(5) 0.51 0.26 - - - 
 
ExArray 200(5) 0.71 0.28 110(2) 0.61 0.57 - - - - - - 
 
WES (all) + ExArray 246 0.069 0.0013 123 0.68 0.28 3 0.51 0.26 - - - 
              	 Fasting glucose  PTV+missense PTV+NSbroad PTV+NSstrict PTV-only 
Gene Ancestry 
MAC  
(No. vars) P value SKAT P value Burden 
MAC  




SKAT P value Burden 
MAC  
(No. vars) P value SKAT 
P value 
Burden 
BSCL2 AfrAm 10 0.77 0.46 4 0.66 0.48 - - - - - - 
11q13 E.Asian 26 0.15 0.16 23 0.17 0.18 2 0.026 0.026 2 0.026 0.026 
 
Europ 38 0.00072 0.00034 4 0.88 0.63 - - - - - - 
 
Hisp 29 0.49 0.58 14 0.77 0.88 <1 0.41 0.41 <1 0.41 0.41 
 
S.Asian 12 0.6 0.16 8 0.36 0.058 1 0.9 0.9 1 0.9 0.9 
 
WES (all) 116(60) 0.0013 0.048 53(36) 0.4 0.74 3(5) 0.049 0.24 3(5) 0.049 0.24 
 
ExArray 574(13) 0.08 0.022 288(9) 0.021 0.0043 102(2) 0.033 0.0067 102(2) 0.033 0.0067 
 
WES (all) + ExArray 690 0.00088 0.0046 341 0.051 0.081 105 0.0068 0.012 105 0.0068 0.012 
CAV1 AfrAm 2 0.14 0.05 2 0.14 0.05 1 0.095 0.095 - - - 
7q31.1 E.Asian 5 0.027 0.23 5 0.027 0.23 4 0.022 0.1 - - - 
 
Europ 9 0.17 0.0065 6 0.13 0.018 3 0.17 0.064 2 0.36 0.36 
 
Hisp 11 0.098 0.1 11 0.098 0.1 - - - - - - 
 
S.Asian 5 0.69 0.36 2 0.92 0.68 1 0.79 0.79 - - - 
 
WES (all) 32(18) 0.032 0.00017 26(16) 0.025 0.00065 9(8) 0.019 0.0051 2(1) 0.36 0.36 
 
ExArray 77(4) 0.31 0.35 77(4) 0.31 0.35 - - - - - - 
 
WES (all) + ExArray 109 0.049 0.0025 103 0.041 0.0055 9 0.019 0.0051 2 0.36 0.36 
	
MAC (No. vars): Minor allele count (number of variants in the test) 
Variant masks: 
PTV: containing only variants predicted to introduce a premature stop codon 
PTV+NS: containing variants in the PTV group and protein-altering variants with MAF<1% 
PTV+NSstrict: composed of variants in “PTV” and protein-altering variants predicted damaging by SIFT, LRT, MutationTaster, polyphen2 HDIV, and polyphen2 HVAR 
PTV+NSbroad: composed of “PTV+NSstrict” and NS variants with MAF<1% and predicted damaging by at least one prediction algorithm. 
 
Supplementary Table 7B: Single variant association results with FG levels from the monogenic genes exhibiting enrichment of association signals. 




Gene Protein change Inverse Normalized Effect  (Standard error, Effect Allele, Effect allele frequency) 
Untransformed Effect 
(Standard Error) BF P N 
Monogenic - PTV 11:62458267 rs149907021 G A BSCL2 p.Q271* 1.621 (0.39; A; 0.001) 0.844 (0.185) 3.3 3.3E-05 4513 
Monogenic - PTV + Nsstrict 11:62458267 rs149907021 G A BSCL2 p.Q271* 1.621 (0.39; A; 0.001) 0.844 (0.185) 3.3 3.3E-05 4513 7:33545217 rs61764068 A T BBS9 p.E753V -0.576 (0.19; A; 0.998) -0.27 (0.086) 1.6 2.4E-03 8754 
Monogenic - PTV + Nsstrict + 
Nsbroad 
11:62458267 rs149907021 G A BSCL2 p.Q271* 1.621 (0.39; A; 0.001) 0.844 (0.185) 3.3 3.3E-05 4513 
2:73786157 rs34398445 G C ALMS1 p.K3423N 0.673 (0.188; C; 0.018) 0.221 (0.065) 2.3 3.4E-04 5935 
3:170715865 rs140138702 G C SLC2A2 p.L468V 0.641 (0.197; C; 0.012) 0.267 (0.081) 1.7 1.2E-03 1104 
7:33545217 rs61764068 A T BBS9 p.E753V -0.576 (0.19; A; 0.998) -0.27 (0.086) 1.6 2.4E-03 8754 
11:66287196 rs35520756 G A BBS1 p.E234K 0.275 (0.095; A; 0.102) 0.086 (0.032) 1.4 3.8E-03 1352 
Monogenic glucose - 
PTV+Nsstrict+Nsbroad 
11:62458267 rs149907021 G A BSCL2 p.Q271* 1.621 (0.39; A; 0.001) 0.844 (0.185) 3.3 3.3E-05 4513 
2:73786157 rs34398445 G C ALMS1 p.K3423N 0.673 (0.188; C; 0.018) 0.221 (0.065) 2.3 3.4E-04 5935 
3:170715865 rs140138702 G C SLC2A2 p.L468V 0.641 (0.197; C; 0.012) 0.267 (0.081) 1.7 1.2E-03 1104 
Monogenic glucose - 
PTV+Missense 
11:62458267 rs149907021 G A BSCL2 p.Q271* 1.621 (0.39; A; 0.001) 0.844 (0.185) 3.3 3.3E-05 4513 
2:73786157 rs34398445 G C ALMS1 p.K3423N 0.673 (0.188; C; 0.018) 0.221 (0.065) 2.3 3.4E-04 5935 
3:170715865 rs140138702 G C SLC2A2 p.L468V 0.641 (0.197; C; 0.012) 0.267 (0.081) 1.7 1.2E-03 1104 
9:4286344 rs113754532 T C GLIS3 p.I28V 0.418 (0.144; T; 0.998) 0.213 (0.071) 1.2 3.6E-03 19883 
2:73677876 var_2_73677876 G A ALMS1 p.V1407I -0.949 (0.357; A; 0.001) -0.44 (0.169) 1.2 7.8E-03 4513 
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BF: log10( Bayes factor) for association 
P: P value for association test 
N: Total Sample size contributing to analysis 
 
SUPPLEMENTARY TABLE 8  
GTEx tissue differential expression of AKT2 compared to AKT1 and 
AKT3. Listed are  the tissues from the GTEx project pilot phase release 
where AKT2 expression was assessed. 
Tissue abbreviation * Tissue description ** N P (AKT2 > AKT1) P (AKT2 > AKT3) 
ADPSBQ Adipose - Subcutaneous 94 1 5.08×10-15 
ADPVSC Adipose - Visceral (Omentum) 19 1 2.74×10-3 
ADRNLG Adrenal Gland 12 1 5.37E-10 
ARTAORT Artery - Aorta 24 1 0.03 
ARTCRN Artery - Coronary 9 1 0.8 
ARTTBL Artery - Tibial 112 1 1 
BREAST Breast - Mammary Tissue 27 1 2.12×10-6 
BRNACC Brain - Anterior cingulate cortex (BA24) 17 1 1 
BRNAMY Brain - Amygdala 23 1 1 
BRNCDT Brain - Caudate (basal ganglia) 36 1 0.12 
BRNCHA # Brain - Cerebellum 30 3.04×10-7 8.94×10-17 
BRNCHB # Brain - Cerebellar Hemisphere 24 6.60×10-4 2.41×10-9 
BRNCTXA Brain - Cortex 23 1 1 
BRNCTXB Brain - Frontal Cortex (BA9) 24 1 1 
BRNHPP Brain - Hippocampus 24 1 0.99 
BRNHPT Brain - Hypothalamus 23 1 0.99 
BRNNCC Brain - Nucleus accumbens (basal ganglia) 28 1 2.15×10-3 
BRNPTM Brain - Putamen (basal ganglia) 20 1 0.02 
BRNSNG Brain - Substantia nigra 25 1 0.67 
BRNSPC Brain - Spinal cord (cervical c-1) 16 1 0.16 
CLNTRN Colon - Transverse 12 1 2.24×10-5 
ESPMCS Esophagus - Mucosa 18 1 3.13×10-12 
ESPMSL Esophagus - Muscularis 20 1 3.39×10-3 
FIBRBLS Cells - Transformed fibroblasts 14 1 1.78×10-4 
HRTAA Heart - Atrial Appendage 25 1 1.45×10-9 
HRTLV Heart - Left Ventricle 83 1 9.20×10-53 
Tissue abbreviation * Tissue description ** N P (AKT2 > AKT1) P (AKT2 > AKT3) 
KDNCTX Kidney - Cortex 3 0.71 0.11 
LCL Cells - EBV-transformed lymphocytes 39 1 1.74×10-25 
LIVER Liver 5 0.97 6.56×10-4 
LUNG Lung 119 1 5.24×10-25 
MSCLSK # Muscle - Skeletal 138 1.47×10-19 7.76×10-91 
NERVET Nerve - Tibial 88 1 3.19×10-17 
OVARY Ovary 6 0.53 4.03×10-4 
PNCREAS Pancreas 19 1 1.19×10-16 
PRSTTE Prostate 9 1 2.38×10-3 
PTTARY # Pituitary 13 0.03 8.55×10-11 
SKINNS Skin - Not Sun Exposed (Suprapubic) 23 1 1.05×10-14 
SKINS Skin - Sun Exposed (Lower leg) 96 1 1.99×10-51 
STMACH Stomach 12 1 3.64×10-4 
TESTIS Testis 14 0.84 2.87×10-9 
THYROID Thyroid 105 0.13 7.22×10-51 
UTERUS Uterus 7 0.99 0.02 
VAGINA Vagina 6 0.99 1.09×10-3 
WHLBLD Whole Blood 156 1 1.43×10-101 
 
N = sample size per tissue; P(AKT2 > AKT1) = P value for the test of expression in 
AKT2 compared to AKT1; P(AKT2 > AKT3) =  P value for the test of expression in 
AKT2 compared to AKT3. * The tissue abbreviation used in Fig. S13 and Fig. S14. ** 
The corresponding tissue description. *** The one-sided paired t-test P-values for the 
comparison of AKT2 expression with AKT1 and AKT3. # The tissues where AKT2 
expression is significantly (P < 0.05) higher than both AKT1 and AKT3 expression. 
BRNCHA/BRNCHB and BRNCTXA/BRNCTXB are sampled from the same regions, 
cerebellum and cortex, respectively, but in separate collections.    
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SUPPLEMENTARY TABLE 9  
Expression analyses in adipose tissue in the METSIM, EuroBATS and GTEx studies.  
Supplementary Table 9A: The associations of the two eSNPs discovered in METSIM (rs8104727) and EuroBATS (rs11880261) with AKT2 transcript levels. 
Results are presented for all the three cohorts queried (METSIM, EuroBATS and GTEx). The eSNPs are in linkage disequilibrium: R2 = 0.847 and D' = 0.92 in 
1000 Genomes European population samples and R2 = 1 and D' = 1 in 1000 Genomes Finnish population samples.  
 
GeneID Cohort Tissue N SNP SNP origin Effect allele Other allele EAF Beta effect SE P-value (SNP-AKT2) 
AKT2 GTEx Adipose Subcutaneous 94 rs11880261 EuroBATS eSNP T C 0.25 0.186 0.103 7.56E-02 
AKT2 EuroBATS Adipose 720 rs11880261 EuroBATS eSNP T C NA 0.206 0.037 2.27E-08 
AKT2 METSIM Adipose 770 rs8104727 METSIM eSNP T C 0.35312 0.4026 0.05214 3.595E-14 
AKT2 METSIM Adipose 770 rs11880261 EuroBATS eSNP T C 0.35239 0.3983 0.05219 6.882E-14 
 
Supplementary Table 9B: Associations of the AKT2 eSNPs with FI are displayed for the METSIM and EuroBATS studies.  
GeneID Cohort N SNP SNP origin Effect allele Other allele Adjustment Effect SE P-value (eSNP-FI) 
AKT2 METSIM 10081 rs8104727 METSIM eSNP T C Age, BMI -0.016 0.01523 0.2857 
AKT2 METSIM 10081 rs11880261 EuroBATS eSNP T C Age, BMI -0.017 0.01527 0.2661 
AKT2 EuroBATS 710 rs11880261 EuroBATS eSNP T C Age, BMI -0.015 0.0555131 0.7842 
AKT2 METSIM 10081 rs8104727 METSIM eSNP T C Age -0.00088 0.01523 0.9541 
AKT2 METSIM 10081 rs11880261 EuroBATS eSNP T C Age -0.0011 0.01527 0.9436 
AKT2 EuroBATS 710 rs11880261 EuroBATS eSNP T C Age -0.0094 0.05497855 0.8649 
 
Supplementary Table 9C: Associations of AKT2 expression with FI are shown for the METSIM and EuroBATS studies.  
GeneID Cohort N Adjustment Effect SE P-value (AKT2-FI) 
AKT2 METSIM 770 Age, BMI -0.33 0.07 0.00000949 
AKT2 METSIM 770 Age -0.42 0.06 3.293E-11 
AKT2 EuroBATS 710 Age, BMI -0.05 0.11 6.28E-04 
AKT2 EuroBATS 710 Age -0.04 0.01 1.14E-03 
 
Supplementary Table 9D: The association between AKT2 expression and age was queried in adipose tissue in the METSIM, EuroBATS and GTEx cohorts.  
GeneID Study Tissue N ChiSq (age) P-value (age) Effect (age) 
AKT2 METSIM Adipose 770 8.46 0.00362 0.02 
AKT2 EuroBATS Adipose 720 0.143 0.71 0.001 
AKT2 GTEx  Adipose Subcutaneous 89 3.49 0.06 -0.02 
 
Supplementary Table 9E: The association between AKT2 expression and BMI was queried in adipose tissue in the METSIM, EuroBATS and GTEx cohorts. 
GeneID Study Tissue N ChiSq (BMI) P-value (BMI) Effect (BMI) 
AKT2 METSIM Adipose 770 28.772 8.143E-08 -0.06 
AKT2 EuroBATS Adipose 720 120.07 6.10E-28 -0.07 
AKT2 GTEx  Adipose Subcutaneous 89 0.30 0.58 -0.01 
 
	  
Beta effect: The effect estimate for the effect allele 
SE: Standard error for the effect estimate 
P-value (SNP-AKT2): The P-value for the SNP-expression association 
Study: Study in which the association was studied  
Adjustment: The covariate adjustment for fasting insulin 
P-value (eSNP-FI): The P-value for the SNP-fasting insulin association 
P-value (AKT2-FI): The P-value for the gene-fasting insulin association 
ChiSq (age): Chi squared test statistic for the expression-age association 
P-value (age): P-value for the SNP-expression association 
NA: The data was not available 
GeneID: The name of the gene investigated 
Cohort: The cohort the association was studied in  
Tissue: The tissue the expression data is from 
N: The sample size in analysis 
SNP: The rsID of the SNP for which the association is shown 
SNP origin: The cohort where the SNP was most associated with AKT2 expression 
Effect allele and Other allele: The effect and non-effect alleles of the SNP 
EAF: The frequency of the effect allele 
 
Effect (age): Effect estimate for the age in the model 
ChiSq (BMI): Chi squared test statistic for the expression-BMI association 
P-value (BMI): P-value for the SNP-expression association 
Effect (BMI): Effect estimate for the BMI in the model 
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SUPPLEMENTARY TABLE 10  
Mendelian randomization analysis to assess the causality of AKT2 expression for fasting insulin (FI) levels.  
 
The results from the meta-analysis of the EuroBATS and METSIM data and for the instrumental variable (IV) estimator are shown for the EuroBATs eSNPs 
(rs11880261) additionally separated by whether BMI adjustment was used for SNP-FI and AKT2-FI analyses. 
 
 
No BMI adjustment BMI adjusted 
Association N Effect SE P-value P-value for difference Effect SE P-value P-value for difference 
SNP-AKT2 1490 0.270 0.030 1.89E-19 
 
0.270 0.030 1.89E-19 
 SNP-FI 10791 -0.002 0.014 9.13E-01 
 
-0.017 0.014 2.44E-01 
 AKT2-FI 1480 -0.050 0.011 4.39E-06 
 
-0.064 0.013 5.95E-07 
 IV 
 
-0.006 0.054 9.13E-01 0.41 -0.063 0.054 2.48E-01 0.99 
 
Association: The pair of traits tested or the instrumental variable (IV) 
N: The sample size in meta-analysis 
Effect: The effect estimate in the association 
SE: Standard error 
P-value: The P-value for the association 
P-value for difference: The P-value for the difference between the IV estimator and the AKT2-FI estimate 
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